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ABSTRACT 
p53 is a tumour suppressor protein that is stabilised and activated by DNA damage. DN:-\ 
damage-induced p53 is able to bring about either cell cycle arrest or apoptosis by the 
induction of p53-responsive genes such as mdm2 and p21 waf-I. Mdm2 regulates p53 
function by blocking the transcriptional transactivation domain of p53 and also by 
targeting p53 for degradation via an ubiquitin-mediated pathway. Increases in the levels 
and activity of p53 are brought about by post-translational modifications. The most widely 
studied modification ofp53 is phosphorylation, mediated by several DNA damage-
activated kinases. Poly(ADP-Ribose) Polymerase-l (PARP-l) is also a DNA damage-
activated enzyme which covalently modifies several target proteins by poly(ADP-
ribosylation). It is well established that PARP-I plays a key role in DNA base excision 
repair. More recently, several studies have implicated PARP-I in the regulation of p53 
function in response to DNA damage, although the nature of this relationship has been 
controversial. 
This study aimed to clarify and investigate further the role of P ARP-I in p53 regulation 
using PARP-I proficient and PARP-I deficient mouse embryonic fibroblasts (MEFs) as 
well as a novel potent PARP-I inhibitor (AGI4361; Ki < 6nM). In this study, both 
primary and immortalised P ARP-l MEFs were used. Initial experiments revealed a 
tendency for P ARP-l +1+ MEFs to develop p53 mutations during immortalisation. 
Interestingly. PARP-I-1- MEFs retained wild-type p53, suggesting that the absence of 
P ARP-l bypasses the requirement for p53 to be mutated during the immortalisation of 
MEFs. As these cells could not be used to analyse p53 responses, experiments were 
perfonned on primary PARP-l \lEFs. HoweH~r. the primary PARP-l- - \lEFs were f()und 
to grow very slowly compared to their P ARP-1 proficient counterparts. Interestingly. 
treatment of primary PARP-1+1+ MEFs with AG14361 had a similar effect on cellular 
growth. This growth inhibition in the absence of P ARP-1 was only evident in primary and 
not immortalised cells. It was therefore decided to stably transfect immortalised PARP-l--
MEFs, expressing wild-type p53, with a plasmid construct containing PARP-l to produce 
an isogenic cell line pair. These cells have been used, together with a human colorectal 
carcinoma cell line (HCT -116) and the potent P ARP-1 inhibitor AG 14361 to analyse the 
p53 response to different DNA damaging agents. In response to ionising radiation and 
ultra violet radiation, the absence ofPARP-1 did not alter the induction or activity of p53. 
In response to the alkylating agent temozolomide, treatment of PARP-l proficient MEFs 
with AG 14361 potentiated the increase in p53 protein levels without affecting the 
transcriptional transactivation activity ofp53, possibly due to an impaired repair of the 
DNA damage and hence increased signalling to p53 due to the persistence of DNA strand 
breaks. However, similar results were not obtained in the absence of P ARP-1 protein 
(P ARP-1-1- MEFs) or in HCT -116 cells treated with AG 14361 The data presented do not 
support the hypothesis that P ARP-1 is directly involved in the DNA damage induced 
regulation ofp53. There may, however, be an altered p53 response in the absence of 
P ARP-l when cells are treated with particular DNA damaging agents, due to an impaired 
DNA repair pathway. 
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1.1 GENERAL INTRODUCTION 
The division of cells normally occurs in a highly ordered and controlled manner. This 
growth involves a stage during which the DNA of the cell is replicated in order for the cell 
to divide into two. As the DNA of a cell is replicated and one copy passed on to a 
daughter cell, it is essential that the integrity of the DNA be maintained. If the DNA does 
become damaged, this can lead to mutations to genes which can ultimately lead to cell 
death, or in the case of multicellular organisms, the formation of a cancerous cell. Several 
mechanisms exist to ensure that errors do not occur during DNA replication. In addition 
to errors occurring during replication, DNA damage can occur as a result of many 
exogenous factors such as ionising radiation, ultra-violet light, various classes of chemicals 
and even certain viruses. Again, cells possess mechanisms to counteract the effect of these 
agents. It is these mechanisms that are the focus of my research. 
1.1.1 The cell cycle 
The eukaryotic cell cycle is divided into four sections, as can be seen in the diagram below 
(figure 1.1). During S phase, synthesis of new DNA occurs. G 1 (gap 1) and G2 (gap 2) 
are gaps of time during which the cell prepares itself for the next stage in the cycle. 
Mitosis is the phase during which the cell actually divides into two. There are two points 
at which this cycle is regulated:- the G liS phase junction and the G2/M junction. Cells 
that are not cycling are said to be quiescent and in a phase known as GO. Stimulation of 
cells in this state to enter the cell cycle is provided by growth factors. Subsequent 
progression of a cell through the cycle is dependent upon a range of cell cycle control 
proteins, including cyclins and cyclin-dependent kinases. 
2 
G2 
(G p2) 
S phase 
(DNA svntttesis) 
(m< is) 
Figure 1.1 Diagram summarising the eukaryotic cell cycle 
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cease 
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The activity of the kinases is dependent upon their binding to a specific cyclin (Solomon et 
al. , 1990) and as such the kinases are known as cyclin dependent kinases (Cdks). To date, 
six Cdks have been implicated in the cell cycle, and at least thirteen cyclins. The levels of 
particular Cdk-cyclin complexes oscillate throughout the cycle, with different complexes 
phosphorylating different target proteins dependent upon the stage in the cell cycle. For 
example, initial stimulation of a quiescent cell by the Ras-Raf-MAPK pathway results in 
the expression of cyclin D 1 (Aktas et al. , 1997), which complexes with cdk4 or cdk6. The 
principal targets of these activated kinases are the retinoblastoma protein (Rb) (Kato et ai. , 
1993), which functions to bind and negatively regulate a transcription factor called E2F 
(Kovesdi et al., 1997). E2F is a transcription factor (part of a family), which is required 
for progression of the cell through the G I-S phase transition and will be discu sed in more 
d tail in a lat r ction. In addition two other Rb famil member ha e been id ntifi d a 
fth y linDl / dk4/6complex,nam 1 pl07andp130.bothof\\hichar gr \\1h 
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inhibitory proteins It should be noted that cyclins D2 and D3 have also been identified 
(Sherr et al., 1995) and the presence of at least one cyclin D is necessary for the 
completion of G 1. 
In mid-late G 1, cyclin E is expressed, which complexes with Cdk2. The activity of this 
complex is necessary for entry into S-phase and also DNA replication (Koff et al., 1992). 
This cyclin-Cdk complex also targets phosphorylation ofRb, but at a different site to the 
previously described cyclin-Cdk complex. It is likely that phosphorylation of Rb at several 
sites is necessary for the full inactivation of the protein. This will release and fully activate 
E2F, allowing transcription of genes required for G 1 to S phase progression. 
Cyclin A is expressed at the G I-S phase boundary and also complexes with Cdk2 (Elledge 
et at., 1992). The activity of this complex is required for S phase transition and control of 
DNA replication (Heuvel and Harlow, 1993). One known substrate of the cyclin A-Cdk2 
complex is Cdc6, which is required for the initiation of DNA synthesis. Upon 
phosphorylation, Cdc6 is exported from the nucleus, possibly to prevent re-replication of 
DNA (Petersen et al., 1999). In addition, this complex phosphorylates HIRA (histone cell 
cycle regulation defective homologue A), a protein involved in the repression of histone 
gene transcription. Phosphorylation abolishes its repressor activity leading to increased 
histone transcription. 
The final cyclin-Cdk complex to be discussed is cyclin B l-Cdk 1, which is expressed in 
late S and G2 phases. Despite being expressed, the kinase remains inactive until late G2 
when the activity is required for entry into mitosis (Nurse, 1990). This complex 
phosphory lates several kinds of lamins, leading to the breakdown of the nuclear envelope, 
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obviously an essential event in mitosis. Other essential events include condensation of the 
chromosomes, possibly via phosphorylation of his tones and reorganisation of the 
cytoskeleton. In addition the cyclin B1-Cdk1 complex phosphorylates the TFIIH subunit 
of RNA polymerase II resulting in the global inhibition of transcription and translation that 
occurs during mitosis (Long et aI., 1998). 
In conclusion, this section has briefly described the cyclins and kinases that are involved 
during each stage of the cell cycle. In addition, some of the targets of the kinases have 
been highlighted along with the likely relevance to that particular stage in the cell cycle. 
Efficient progression of the cell cycle is dependent upon regulation of both components of 
the complex. The factors involved in the regulation of cyclins and Cdks will be discussed 
in the following section. 
1.1.2 Regulation of the cell cycle 
There are several different mechanisms involved in the regulation of Cdk activity. All of 
these mechanisms are carefully orchestrated such that the cell is able to efficiently 
complete a cell cycle and also prepare itself for further proliferation. The regulatory 
mechanisms to be discussed in this section are phosphorylation, the inhibition of Cdk 
activity and the degradation of both components of the complex at specific points during 
the cycle. 
Although stated earlier that the binding of a particular Cdk to a cyclin results in activation 
of the kinase, it should be noted that this only results in partial activation. An additional 
phosphory lation event is required for full activation of the kinase. This phosphory lation 
occurs at a site on the Cdks proximal to the ATP binding site and induces a conformational 
5 
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change such that ATP is able to enter and bind the active site more readily (Jeffrey et al., 
1995). For each of the Cdks discussed, the phosphorylation occurs on a conserved 
threonine residue and is performed by Cdk-activating kinase (CAK). CAK is actual! a 
complex itself, composed of Cdk7 and cyelin H. The phosphate group is subsequently 
removed by a phosphatase called KAP (kinase associated phosphatase; Hannon et at. , 
1994). 
~dk4/6~ ~ 
cc::::::::::==~ 
c.c::::=:::::::::::::::>-
c:c:::::::::::::::::>-
Cdc25A 
T '" 
Cip/Kip CAK 
T 
CiplKip 
/ 
Weel 
Mytl 
~ Cdc25B/C 
CAK 
Figure 1.2 Diagram ummari ing the regulation of cyctins and Cdks 
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As well as being stimulatory, phosphorylation of Cdks can also have a negative regulatory 
effect (Morgan, 1995). For all of the Cdks discussed this inhibitory phosphoI)'lation 
occurs near the N-terminal and involves a tyrosine residue. Cdkl and Cdk2 also have a 
second threonine residue that is phosphorylated. The kinases responsible for the two 
phosphorylation events on Cdkl and 2 have been identified as Wee 1 and Myt!. which are 
bi-functional kinases, capable of phosphorylating both tyrosine and threonine residues 
(Parker et aI., 1992; Mueller et ai., 1995). The kinases responsible for the stimulatory or 
inhibitory phosphorylation of Cdks are themselves subject to regulatory signals. Therefore 
the regulation of Cdks via phosphorylation is a highly complex but well-controlled process 
that results in the activation or repression of a particular kinase at the relevant point in the 
cell cycle, allowing the cycle to be completed efficiently. 
A second mechanism by which Cdks are inhibited is by protein inhibition. To date seven 
Cdk inhibitors have been identified and have been assigned to one of two families. The 
Ink4 family consists of p 15, P 16, P 18 and p 19 and bind monomeric Cdks, before complex 
formation (Serrano et aI., 1993; Hirai et aI., 1995). Binding of a specific inhibitor to a Cdk 
is believed to prevent complex formation with the relevant cyclin and hence the Cdk will 
remain inactive. The second family of Cdk inhibitors is termed the CiplKip family (Sherr 
and Roberts, 1995) and consists of p21, p27 and p57. These proteins bind to preformed 
cyclin-Cdk complexes and inhibit kinase activity, possible by inducing a conformational 
change in the Cdk or preventing binding of ATP to the active site. The Cancer Research 
Unit in Newcastle is currently developing and testing Cdk inhibitors with the aim of using 
them in cancer therapy. In theory, the tumour cells will then lack a kinase activity required 
for efficient cell cycle progression and hence the tumour cells will not be able to divide, 
7 
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The final regulatory mechanism to be discussed is degradation. Degradation of cell cycle 
components is performed by two complexes, the Skp-Cullin-F-box (SCF) complex and the 
anaphase promoting complex (APC). Both complexes utilise the ubiquitin-proteosome 
pathway and act as E3 ligases for the degradation of target proteins. SCF acts late in G 1. 
through S phase and in early G2, whereas APC is active at the end of G2 and mediates the 
transition through mitosis. The purpose of these degradation pathways is to remove the 
kinases or cyclins that have been induced or activated during the cell cycle. This allows 
the cell to 'reset' itself such that it can perform further rounds of cellular proliferation. 
1.1.3 Cell cycle arrest 
The previous sections have provided a brief overview of the cell cycle and highlighted 
some of the components required for this process. The principal aim of the cycle is to 
replicate the genome of a cell followed by division of the cell and DNA to form two 
daughter cells. Obviously in such a process it is essential that the integrity of the DNA be 
maintained to prevent mutations occurring. The accumulation of a variety of mutations 
over time can lead to the formation of a cancerous cell. If the DNA of a cell does become 
damaged, there are mechanisms allowing the cell cycle to be halted, allowing efficient 
repair of the DNA before resumption of the cell cycle. The cycle is actually controlled at 
two different stages; at the G 1 IS phase boundary and the G21M phase boundary, both of 
which are known as cell cycle checkpoints. 
During the G l-S phase transition, proteins necessary for DNA and deoxyribonucleotide 
synthesis are induced. A family of transcription factors, together called E2F, have been 
identified as being essential to this process. Binding of RB to E2F prevents E2F acting as 
a transcription factor. This inhibition can be alleviated by phosphorylation of RB, 
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breaking up the complex and freeing E2F. This phosphory lation can be performed by 
cyclin-CDK complexes, specifically cyclin D-Cdk4/6 and cyclin E-Cdk2. The G liS phase 
checkpoint is mediated by a Cdk inhibitor called p21 waf-\, which binds to and inhibits the 
catalytic activity of the kinases involved in E2F activation. Inhibition of the kinases 
described earlier will result in Rb remaining in a hypophosphorylated state and hence will 
remain bound to E2F. This will in turn prevent transcription of genes necessary for 
progression to the next stage of the cell cycle. It should be noted that the expression of 
p21 waf-\ is mediated by p53, a DNA damage-inducible tumour suppressor protein, the 
regulation of which will be discussed in a later section (Section 1.2). The importance of 
the G 1 IS phase checkpoint is highlighted by the fact that virtually all tumour cells have lost 
the ability to undergo G 1 arrest. In the majority of tumours, the lack of G 1 arrest is 
attributed to functional inactivation of p53, the most common mechanism being mutation 
of the p53 gene. 
The mechanisms behind the G2/M checkpoint are less well understood but are not believed 
to involve either p21 waf-\ or p53, as p53 mutant cells are capable of inducing a G2 arrest in 
response to DNA damage (Kastan et al., 1991). As described earlier, cyclins A and B, 
along with Cdc2 are required for the transition from G2 into mitosis. Inhibitory 
phosphorylation of this Cdk on amino acid residues Thr14 and Tyr15 is thought to bring 
about cell cycle arrest at the G2/M checkpoint. The latter phosphorylation site is highly 
conserved, with identical regulation found in fission yeast (Nurse, 1990). In addition, 
mutation of this site to a non-phosphorylatable residue results in abrogation of the G2 
arrest (Blasina et aI., 1997). The kinase responsible for this phosphorylation event has 
been identified as Wee 1. The increased phosphory lation of Thr 15 is potentiated by 
inactivation of the Cdc25 phosphatase, which targets the same residue. It should be noted 
9 
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that Wee 1 is activated by another protein kinase, Chld. This kinase is initially activated in 
response to genotoxic stress thus providing a link between DNA damage and cell cycle 
arrest at the G21M checkpoint. 
1.1.4 Cancer, tumour suppressor genes and oncogenes 
As described above cellular proliferation occurs via the cell cycle, which can be halted at 
one of two checkpoints in response to DNA damage. A disruption in the regulation of the 
cell cycle such that the cycle can no longer be suppressed or stopped leads to the formation 
of a cancerous cell. Such disruptions are caused by mutations to particular genes. Various 
chemicals, ionising radiation (IR), ultra violet light (UV) and environmental factors (e.g. 
chemicals inhaled due to smoking) can bring about these mutations. Cancerous cells are 
typified by their genomic instability, which is likely to promote a greater mutation rate in 
these cells, allowing them to evolve (Lengauer et al., 1998). 
A group of genes commonly mutated in cancers are oncogenes. These are mutated or 
abnormally expressed forms of normal cellular genes that induce or maintain the 
uncontrolled cellular proliferation associated with cancer, an example of which is the ras 
oncogene. Ras is a G-protein that normally cycles from an inactive state to an active state 
by changing the bound GDP to GTP. When in the active state, ras relays growth-
promoting signals to the cell. Mutation of ras prevents the release of GTP from the protein 
and hence the protein is permanently active and cells continually grow and divide. 
Oncogenes can be carried by retroviruses (for example v-src) or may be produced due to 
mutation (as for ros described above). A second group of genes commonly mutated are 
tumour suppressor genes. Non-mutated tumour suppressor genes function to suppress cell 
growth and division (therefore they have an opposite effect to cellular proto-oncogenes). 
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This group includes the previously discussed RB gene, mutation of which pre ents the 
regulation of E2F (Section 1.1.3). If, through mutation, Rb is unable to bind E2F this will 
lead to cell cycle progression, even in the presence of DNA damage resulting in the 
accumulation of more genetic alterations. A second tumour suppressor gene p53 is found 
to be mutated in around 50% of cancers. p53 is a transcription factor that brings about c 11 
cycle arrest or apoptosis by activating a variety of genes, the details of which will be 
explained below. 
1.2 P53 - tumour suppressor 
P53 is the product of a tumour suppressor gene (reviewed in Ryan et al. , 2001 and Colman 
et al., 2000) and is the most common target for genetic alterations in cancer, with around 
50% of tumours possessing mutations in the p53 gene. It accumulates and is activated in 
response to DNA damage and subsequently functions as a transcription factor stimulating 
transcription of various genes. These genes produce proteins that are involved 
predominantly in cell cycle arrest or the apoptotic pathway, depending upon the extent of 
DNA damage. The use of mouse model systems (Attardi & Jacks, 1999) and various 
mutant cell lines has led to a clearer elucidation of p53 function in the last decade. 
1.2.1 The structure of pS3 
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P53 is a nuclear phosphoprotein consisting of 393 amino acids and has been described as 
having five conserved domains (figure 1.3). The N-terminal consists of a transcriptional 
transactivation domain, necessary for the interaction of p53 with the components of the 
transcriptional machinery. Amino acids F 19, L22 and W23 have been shown to be 
essential for transcriptional activation by p53 in vivo (Lin et al., 1994). These amino acids 
bind to two subunits of transcription factor lID in vitro (Lu & Levine, 1995; Thut et al., 
1995). The central domain ofp53 consists of the sequence-specific DNA-binding domain. 
Native p53 is in the form of a tetramer (actually a dimer of a dimer). The amino acids 
necessary for this oligomerisation are residues 324-355, within the C-terminaL which form 
two a-helices and two ~-sheets. The four a-helices come together to form a four-helix 
bundle, aided by hydrophobic interactions. The oligomerisation domain also contains a 
nuclear localisation signal (NLS). Finally, the C-terminus contains a domain that regulates 
the latent form ofp53. Deletion of this domain, phosphorylation at S378 by protein kinase 
C or S392 by casein kinase II or binding of antibody PAb421, all activate site-specific 
DNA binding by the central domain ofp53 (Hupp and Lane, 1994). 
In a normal cycling cell, p53 is in an inactive form, bound to its negative regulator, Mdm2 
(a product of a murine double minute gene, see Section 1.3). The importance of this 
interaction is highlighted by the fact that mdm2 knockout mice die at the embryotic stage 
due to uncontrolled p53 activity (Jones et al., 1995). The mice can be rescued by 
additionally knocking out the p53 gene. In response to DNA damaging agents, this p53-
Mdm2 complex is disrupted resulting in p53 activation followed by cell cycle arrest or 
apoptosis. 
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1.2.2 Activation of p53 
In response to DNA damage, p53 levels increase due to increased stability and hence 
increased half-life of the protein. In addition, p53 transcriptional transacti ation acti ity 
increases, resulting in the increased expression of p53 target genes. Both of these effects 
are brought about by post-translational modifications of the p53 protein. p53 has been 
reported to be subject to several post-translational modifications such as phosphorylation 
acetylation and sumoylation (see figure 1.4). With particular relevance to this study, p53 
has also been shown to be a target for poly(ADP-ribosyl)ation, catalysed by the enzyme 
poly(ADP-ribose) polymerase-1 (PARP-1), although this is by no means a universal 
observation (see Section 1.4.6). 
S6 S9 SI5 TI8 S20 S33 S37 S46 T55 T81 S315 392 
TAD DBD REG 
~----------- -----------,/ y-
p300 
Pr,AF ---1.~ K320 K373 K382 
t t 
Figure 1.4 Schematic diagram showing the post-translational modifications of p53 
The phosphorylation sites reported to date are shown in blue circles and the acetylation sites are shown in red 
hexagons . TAD = transcriptional activation domain; DBD = DNA binding domain and REG = regulatory 
domain. Mdm2 binds the N-terrninal of p53, within the main cluster of putative phosphorylation sites 
The initial step in p53 activation is the alleviation of the inhibition imposed by the binding 
of Mdm2. Mdm2 blocks the transcriptional transactivation domain of p53 and also targ t 
p53 for degradation th d tail of which will be discus ed in a later section ction 1.3 .2 . 
It i th pr c of pho phory lation that ha been mo t wid ly implicat d in di rupting th 
p53-Mdm2 mpl x and thu th ti ation of p53 Martin z el al., 1997' M k, 19 4). 
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The use of phosphorylation site-specific antibodies has led to the identification of several 
phosphorylation sites within the N-tenninus ofp53. To date eight N-tenninal 
phosphorylation sites have been identified, consisting ofserines 6, 9,15.20,33,37 and 47 
as well as threonine 18. In addition two C-tenninal phosphorylation sites have been 
identified, serines 315 and 392. It should be noted that phosphorylation at certain sites has 
only been observed in response to particular DNA damaging agents. For example, Ser37 is 
phosphorylated in response to UV, but not IR. As well as different phosphorylation sites 
being identified, different kinases have been shown to be responsible for these 
phosphorylations. Among the kinases implicated in the activation of p53 are the ataxia 
telangiectasia mutated kinase (A TM), the AT related kinase (A TR), checkpoint kinase 2 
(Chk2) and casein kinase 1 (CKl) (Delia et aI., 2000; Banin et aI., 1998; Hirao et al., 
2000). These kinases have been identified by knocking out, down-regulating or 
constitutively activating the kinase in question and analysing the stabilisation (and/or 
phosphorylation) ofp53 in response to DNA damage. As yet, no specific site or 
combinations of sites have been identified as being solely responsible for the activation of 
p53. 
Attempts to identify important residues have involved substituting specific serine residues 
by alanine residues. Studies involving substitution of many of the serine residues resulted 
in no major defect in p53 stabilisation in response to DNA damage (Ashcroft et al., 1999; 
Blattner et al., 1999), suggesting that p53 stabilisation is not dependent upon 
phosphorylation. However, this suggestion may be flawed as one group failed to analyse 
p53 containing a Ser20 substitution (Ashcroft et aI., 1999) and the other reported a partial 
stabilisation when all N-tenninal serines were substituted (Blattner et aL 1999). although 
this latter group did not follow up their analysis by examining single-site mutants. Another 
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study (Chehab et al., 1999) has proposed that phosphorylation of Ser20 brings about p53 
stabilisation. This was based upon findings that substitution of Ser20 with Ala or Asp 
completely abrogates p53 stabilisation after exposure to IR or UV radiation. Furthermore. 
A TM and the related kinase ATR cannot directly phosphorylate p53 on Ser20. However. it 
is believed that one or the other is required for p53 stabilisation in response to IR or UV. 
Therefore, the authors (Chehab et aI., 1999) proposed that ATM or ATR are required to 
phosphorylate and activate another kinase in response to DNA damage. The checkpoint 
kinases Chkl and Chk2 have subsequently been identified as phosphorylating Ser20 (Shieh 
et al., 2000; Chehab et al., 2000) downstream of ATRIATM. 
Several studies have also identified Ser15 as being important in p53 activation in response 
to DNA damage (Appella et al., 2001; Canman et al., 1998). This residue is 
phosphorylated in an ATM-dependent manner in response to IR, leading to a disruption of 
the p53-Mdm2 complex. This will obviously increase the stability of p53 and lead to the 
induction in protein levels observed in response to IR. It should be noted that ATM-
deficient cells show delayed p53 induction in response to IR (Delia et al., 2000) but show 
an intact p53 response to UV. This further highlights the previously mentioned 
observation that some p53 phosphorylation sites are DNA damage-specific. Serine 15 has 
also been identified as a DNA-PK target, in vitro (Lees-Miller et al., 1992; Shieh et al., 
1997~ Silicano et al., 1997). A subsequent study showed that cells lacking DNA-PK 
possess a transcriptionally inactive p53, with p53 being unable to bind DNA and therefore 
unable to activate transcription of target genes and bring about cell cycle arrest (Woo et a/., 
1998). This study suggested that sites phosphorylated by DNA-PK may be vital in the 
activation of p53. However, these results could be described in one of the two cell lines 
studied by the presence of a mutation in the DBD of p53. Several subsequent studies ha\'~ 
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contradicted the findings of Woo et al., 1998, with p53 induction being shown to be 
independent ofDNA-PK activity (Jimenez et al., 1999; Burma et al., 1999; Jhappan et al., 
2000). 
The experimental data summarised above highlights the number of phosphorylation sites 
present on p53. However, to date Ser15 and Ser20 have been identified as perhaps the 
most important residues in p53 activation. As the sites are within the Mdm2-binding site 
ofp53, the likely result is disruption of the p53-Mdm2 complex, possibly involving a 
conformational change ofp53, or steric hindrance in formation of the complex. Full 
activation of p5 3 is likely to involve a combination of the identified phosphory lation sites. 
In addition, dephosphorylation by particular phosphatases is likely to play an important 
role in p53 regulation as phosphate groups must be removed to allow reassembly of the 
p53-Mdm2 complex. As yet, the phosphatases responsible for this activity have not been 
identified. 
A second post-translational modification involved in the activation of p53 is acetylation. 
This reaction is performed by the CREB binding protein (CBP)/p300 and p300/CBP 
associated factor (PCAF). Antibody studies have identified target residues within the C-
terminal ofp53; Lys320 (PCAF), Lys373 (p300 and PCAF) and Lys382 (P300), with the 
observed effect of acetylation being increased DNA binding of p53 (Liu et al., 1999). In 
vitro, p300 has actually been shown to bind to the N-terminal ofp53, with residues 
between Leu22 and Phe54 being critical for this interaction (Scolnick et al., 1997). In 
response to DNA damage (both IR and UV; Ito et al., 2001), p53 and p300 colocalize to 
the nucleus in a stable DNA binding complex (Lill et al., 1997). The mechanism behind 
the formation of nuclear aggregates of p300 and p53 is unclear. However, a recent study 
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identified a second nuclear export signal within the N-terminal of p53 (Zhang and Xiong. 
2001), coinciding with the p300-binding motif. It is therefore possible that in response to 
DNA damage, p300 binds to p53, concealing this nuclear export signal, resulting in nuclear 
retention and accumulation ofp53. Subsequent acetylation of the previously described C-
terminal residues results in increased transcription ofp53 target genes. To further 
highlight the complex nature of p53 activation, acetylation can be influenced by 
phosphory lation of particular residues. Ser 15 phosphorylation increases the binding of 
p300 to p53 but is not an absolute requirement for acetylation to occur (Lambert et a/. , 
1998). 
The data summarised thus far suggests that p300 and acetylation of p53 results in nuclear 
retention and increased DNA binding of the protein. Both of these observations would be 
consistent with a positive role for acetylation in p53 activation. However, there is also data 
suggesting a negative regulatory role for acetylation. Kawai et ai., 2001, suggest that the 
initial acetylation of p53 results in the previously described effects. However, upon 
induction of Mdm2, the authors propose that Mdm2 becomes a target for acety lation. This 
modification results in stabilisation of Mdm2 and a subsequent increase in the half-life of 
the protein. The ability of Mdm2 to target p53 for degradation (see Section 1.3.2) is thus 
augmented and p53 levels begin to decrease. This model is consistent with the transient 
nature of the increase in p53 levels that are observed in response to DNA damage, thus 
allowing the cell to resume DNA replication and re-enter the cell cycle. It is likely that 
further mechanisms such as dephosphorylation of critical p53 residues are also involved in 
the reduction of p53 levels usually observed 6-24 hours after DNA damage. 
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1.2.3 P53 and the cell cycle 
The cell cycle has been described in Section 1.1.1. If DNA is damaged, it is essential that 
cells harbouring this damage are not allowed to progress through the cell cycle which 
would result in the copying of a damaged template, leading to mutations in the newly 
synthesised DNA. 
DNA 
DAMAGE 
SIGNALLING ~ (ATM, ATR) 
o t ""~ .................. ..;:bax,fas-R promoter 
p53 1 ~ 
Cell cycle 
arrest 
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Feedback 
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Figure 1.5 Diagram summarising the major functions of p53 
Bax, fas-R 
Apoptosis 
P53 is activated in response to DNA damage (see figure 1.5) and is essential for slowing or 
halting the cell cycle to allow the efficient repair of this damage by repair enzym . Thi i 
illu trat d by th u c ptibility of p53 kn ckout mice to tumour formation (D n how reI 
I., 1992). p53 111 diat tran ription f ral g n , th pr duct of whi h ar able t 
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bring about cell cycle arrest (Kuerbitz et al., 1992) at the G liS phase checkpoint. Perhaps 
one of the most important genes activated by p53 is wafl (El DeifY et al., 1993). This gene 
produces a small Cdk inhibitor called p21 waf] and brings about cell cycle arrest at the G liS 
phase junction. It is believed that this protein binds to cyclin-CDK complexes (in 
particular Cdk2/cyclin E), inhibiting the kinase activity (Dulic et al., 1994). This prevents 
phosphorylation of the RB-E2F complex; hence E2F is not released and cell cycle 
progression does not occur. Li et ai, 1994, proposed a role for p53 in cell cycle arrest at 
G2/M. This was based on the observation that p21 waf] can associate with cyclin A and 
cyclin B complexes, which are involved in the later stages of the cell cycle (Li et al., 
1994). However, several more recent studies have concluded that p53 is not involved in 
the regulation of this particular checkpoint (Kastan et al., 1991; Taylor and Stark, 2001; 
Koniaras et al., 2001). 
1.2.4 P53 and Apoptosis 
In addition to cell cycle arrest, p53 has another role to play in maintaining the integrity of 
the genome. In incidences where the DNA damage cannot be repaired, depending on the 
cell type and level of DNA damage, the cell is directed to die via a process called 
apoptosis. Apoptosis can be stimulated by several factors including withdrawal of 
essential stimuli, IR and other types of DNA damage and activation of a variety of cellular 
receptors. The response itself is characterised by the activation of a particular family of 
proteolytic enzymes called caspases, which then activate further caspases via cleavage 
(Saikumar et al., 1999; Wolf and Green, 1999). Events downstream of catalytic cleavage 
include nuclear condensation and fragmentation of the DNA (Enari et al., 1998; Martin & 
Green, 1995). In most cases, the initial stimuli converge on a common pathway, as 
suggested by the ability of Bcl-2 to inhibit apoptosis. Apoptosis can occur via both p53-
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dependent and p53-independent mechanisms. For the purposes of this thesis I will focus on 
the p53-dependent mechanism. The exact processes involved have not yet been elucidated. 
However, several genes with an apoptotic function have been shown to be p53-inducible. 
As described previously, p53-dependent cell death is mediated by caspases. These 
caspases are activated by the release of apoptogenic factors, such as cytochrome c from the 
mitochondria. Permeabilisation of the mitochondrial membrane allows the release of 
cytochrome c and is controlled by the pro- or anti- apoptotic members of the bcl-2 family. 
It is believed that p53 signalling to the pro-apoptotic Bax protein initiates the release of 
cytochrome c from mitochondria. Release of cytochrome c allows the formation of the 
apoptosome, consisting of the adaptor protein, Apaf-1 and caspase nine, which is activated 
upon recruitment to the complex. This caspase in turn cleaves and activates caspase-3 and 
-7 leading to the execution of cell death (Zou et al, 1997; Li et al, 1997; Saleh et al., 
1999; Hu et al, 1999). The process described above is known as intrinsic apoptosis. A 
second pathway exists, called extrinsic apoptosis, which relies upon the stimulation of 
cellular receptors known as death receptors. There are several members of the death 
receptor family including CD95, Fas, TRAIL and DR5. Ligation of the receptors by their 
respective ligands results in formation of the death inducing signalling complex (DISC) 
composed of the adaptor protein FADD and caspase-8. Subsequent activation of this 
caspase sets in motion the cascade of caspase activation observed in intrinsic apoptosis. 
It should be noted that the membrane expression of several of the death receptors 
mentioned earlier can be regulated by p53 (reviewed in Vousden and Lu, 2002). For 
instance, DR5, a member of the TNFR family has been identified as a possible participant 
in the p53-dependent apoptotic pathway (Sheikh et al., 1998; Wu et al., 1997). The Fas 
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gene has also been shown to contain a p53 binding consensus sequence. The same study 
showed that certain chemotherapeutic drugs up-regulate Fas only in the presence of wild 
type p53 (Muller et al., 1997). Fas and TNF-Rl both contain a loosely conserved (-28%) 
region near the C-terminus, which has been called the death domain. It is this domain that 
interacts with intracellular proteins to initiate the apoptotic pathway. An important step in 
the apoptotic pathway is the release of reactive oxygen species (ROS), which are powerful 
activators of both mitochondrial damage and apoptosis (Johnson et al., 1996~ Lotem et al.. 
1996). Several genes can bring about the release of such species, including p53-induced 
genes (PIGs). One such gene, PIG3, was shown to contain p53-binding sites in its 
promoter (Polyak et al., 1997). 
This section on p53 has described the factors involved in the activation of p53 in response 
to DNA damage. It is clear that several factors are involved, including phosphorylation 
and acety lation, with both modifications occurring on several residues. Less is known 
about how these modifications are reversed although this is undoubtedly a very important 
step in the overall regulation ofp53. This section has also described some of the 
downstream effects of p53 activation, that is cell cycle arrest and apoptosis. The fact that 
p53 is able to induce such vital cellular processes as these, highlights how important it is to 
deduce the processes involved in the regulation ofp53. Fundamental to the regulation of 
p53 and hence to these downstream effects is the negative regulation imposed by Mdm2. 
Mentioned only briefly in this section, the details involved in how Mdm2 interacts with 
p53 and the consequence of this interaction will be discussed in the following section 
(Section 1.3). In addition, the regulation of Mdm2 itself by another tumour suppressor 
protein, p14ARI will be discussed in terms of the implications on p53 activity. 
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1.3 Mdm2 
Murine double minute 2 (MDM2) is a proto-oncogene that was fIrst disco ered as the gene 
responsible for the spontaneous transformation of an immortalised murine cell line called 
BALB/c 3T3 (Fakharzadeh et al. , 1991). The MDM2 gene is approximately 25-kb in size 
and can give rise to Mdm2 polypeptide of varying size due to alternative splicing of the 
mRNA transcript (Olson et al., 1993; Sigalas et al. , 1996; Haines et al. , 1994). In addition 
the MDM2 gene has two different promoters, termed PI and P2, which can initiate 
transcription at different transcriptional start sites (Barak et al. , 1994). Despite the 
presence of several different sized Mdm2 polypeptides, resulting from alternative splicing 
and post-translational cleavage, it is unclear whether they perform individual functions or 
whether their functions overlap. 
1.3.1 The structure of Mdm2 
The largest form of human Mdm2 spans 491 amino acids and contains several domains, 
which are conserved. The N-terminal region of the protein is necessary for binding to p53 
and mediates the best-characterised function of Mdm2, the binding to and inhibition of p5 3 
(fIgure l. 6). 
p53-binding NLS NES Acidic ZF Ring finger 
19 102 181 200 223 274 305-322 438 478 491 
Figuroe 1.6 The domain tructure of Mdm2 . . . 
NL = nuclear loca li ation ignal, NE == nuclear e port signal and ZF == ZinC finger domain 
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In addition, the N-terminal region has been implicated in binding to the transcription factor 
E2F 1 (Martin et al 1995). The next conserved regions in the Mdm2 sequence are 
responsible for the shuttling of Mdm2 between the nucleus and the cytoplasm (Roth et al., 
1998b), with the nuclear localisation signal and the nuclear export signal being adjacent to 
each other in the sequence. It is believed that shuttling from the nucleus to the cytoplasm 
is necessary for the efficient regulation of p53 function. The centre of the protein contains 
a highly acidic region responsible for the interaction of Mdm2 with the ribosomal protein 
L5 and 5S ribosomal RNA. The remaining conserved regions are a zinc finger domain, a 
caspase-3 cleavage site, three putative DNA-dependent protein kinase (DNA-PK) 
phosphorylation sites and finally two zinc fingers in a ring conformation at the C-terminus. 
This C-terminus is also thought to be involved in regulating p53 levels by acting as a 
ubiquitin ligase leading to the degradation of p53 (Honda et al., 1997), which will be 
discussed in more detail later. 
1.3.2 The regulation of p53 by Mdm2 
Expression ofMdm2 is induced in response to activated p53 (Barak et aI., 1993). The 
induction in response to p53 is not an immediate one, with at least an hour needed before 
Mdm2 levels begin to rise. The MDM2 gene contains two tandem p53-binding sites. 
Binding ofp53 slightly increases the rate of transcription from the PI promoter of the 
MDM2 gene but leads to a large increase in transcription from the P2 promoter. Therefore, 
in response to DNA damage, p53-dependent transcription of Mdm2 is initiated primarily 
from the P2 promoter site. The production of these different Mdm2 transcripts at different 
rates may be significant to the function or regulation of the Mdm2 protein. It should be 
noted that the two promoter sites are conserved in the human and mouse Mdm2 genes, 
perhaps indicating the importance of having two distinct promoter sites. 
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Once produced, Mdm2 binds p53, as illustrated by the fact that the two proteins can be 
coimmunoprecipitated (Chen et ai., 1993b) (figure 1.7). The binding involves the insertion 
of an amphipathic a-helix of two and a half turns from p53 into the cleft of Mdm2. The 
formation of the a-helix structure is induced as the two proteins come close together. Van 
der Waals interactions form between the a-helix of p53 and several hydrophobic and 
aromatic amino acids in the cleft of Mdm2. Mutational analysis has revealed amino acid 
residues D68, C77, 058 and V75 ofMdm2 as being critical for the formation of the 
complex (Freedman et ai., 1997). 
Figure 1.7 The p53-Mdm2 complex 
The panel shows Phel9, Trp23 and Leu26 ofp53 inserted into a deep cleft ofMdm2. 
Chen et al (1995) showed that the expression of the N-terminal domain of Mdm2 could 
block the activity of p53 in both cell culture and also in an in vitro transcription assay 
(Chen et al., 1995). The basis for this inhibition was, until recently thought to be 
mediated primarily by the binding of Mdm2 to the same region of p53 necessary to contact 
ari u protein in 01 d in transcription. Without these interaction . p53 is unable t 
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initiate transcription (Li et al., 1993; Lu & Levine, 1995; Thut et al., 1995). Mdm2 can be 
thought of as acting rather like a competitive enzyme inhibitor, with Mdm2 competing 
with various components of the transcription machinery for binding to a particular site on 
the p53 protein. 
Recent evidence has suggested a second mechanism by which Mdm2 inhibits p53 activity. 
Roth et al (1998) demonstrated that human Mdm2 contains a nuclear export signal (NES). 
When mutated in this region, the mutant hdm2 demonstrated an enhanced inhibition of 
p53, as demonstrated by a reduction in the expression of a p53-dependent reporter gene 
(Roth et al., 1998a). In addition, immunoblotting analysis of cells transfected to express 
p53 and hdm2 (either wild type or NES mutant) showed no change in p53 levels when the 
mutant hdm2 was expressed. This was in total contrast to the near disappearance ofp53 
upon expression of the wild type hdm2. Roth et al (1998) also showed that prior treatment 
of cells with a proteosome inhibitor (N-carbobenzoxy-Ieucyl-Ieucyl-Ieucinal) abolished the 
ability of either wild type or mutant hdm2 to reduce the amount of cellular p53. These 
findings indicate that hdm2 nuclear export is necessary for the proteosome-mediated 
degradation ofp53. Honda et al (1997) suggested that Mdm2 may function as an E3 
ubiquitin ligase for p53, with Mdm2 binding to p53 and then ubiquitinating p53 and itself. 
Mutagenesis studies have demonstrated that the conserved residue Cys464 on Mdm2 is 
necessary for both transferring ubiquitin to p53 (Honda et ai., 1997) and for mediating p53 
degradation in cultured cells (Kubbatat et ai., 1999). Ubiquitinated proteins are then 
directed towards the 26S proteasome where they are degraded. 
From what has been discussed, it is clear that an autoregulatory feedback loop is operating 
to regulate the k\'l~ls of p53 in the cell. However, it is also necessary to regulate the loop 
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itself such that p53 levels are able to rise at the appropriate time. Under normal 
circumstances a basal level of both Mdm2 and p53 is present in cells, mostly in the form of 
a complex. In this situation p53 is unstable and thus has a short half-life of approximately 
20 minutes. However, in response to DNA damage, p53 levels rise (on average 2-6 hours 
after DNA damage) due to increased stability ofp53. In order for this rise to occur, it is 
necessary to alleviate the inhibition imposed upon p53 by Mdm2. The most obvious way 
to achieve this is to disrupt the interactions between the two proteins. 
1.3.3 The role of Mdm2 phosphorylation in p53 activation 
Evidence exists that the p53-Mdm2 complex can be disrupted by phosphorylation of p53 at 
Ser 15 after y-irradiation (Shieh et aI., 1997). This phosphorylation is performed by a 
kinase called ATM. A recent study (Khosravi et al., 1999) has also shown that this kinase 
can phosphorylate Mdm2 after treatment of cells with IR or radiomimetic chemicals. 
However, in this study the expression of mutant p53 (with Ser 15 substituted by Ala) in 
p53-null and p53/ ATM-null backgrounds did not prevent ATM-dependent stabilisation of 
p53. This showed that phosphorylation ofSer 15 alone cannot account for the stabilisation 
ofp53. Further studies showed that treatment of cells with IR produced a faster migrating 
form of Mdm2, a change that occurred well before p53 induction (Khosravi et al., 1999). 
This change was subsequently shown to be due to ATM-dependent phosphorylation of 
Mdm2. A more recent study using site directed mutagenesis (Maya et al., 2001) 
demonstrated that Ser395 of Mdm2 is a target for ATM dependent phosphorylation. 
Furthermore, this study showed that phosphorylation of this residue resulted in nuclear 
accumulation of p53. It is therefore apparent that A TM may act on both members of the 
p53-Mdm2 complex so as to stabilise p53. 
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A second method by which p53 could be stabilised in response to DNA damage is by the 
destabilisation of Mdm2. Evidence shows that Mdm2 levels decrease rapidly after 
exposure to UV in a p53-independent manner, before the induction ofp53 (Wu & Levine, 
1997). This destabilisation of Mdm2 would give rise to an increase in p53 levels such that 
p53 can promote transcription of proteins involved in cell cycle arrest, allowing repair of 
any damaged DNA. A similar effect in terms of Mdm2 down-regulation has also been 
observed in response to hypoxia and several DNA damaging chemotherapeutic agents 
(Ashcroft et aI., 2000; Alarcon et aI., 1999). The principal mechanism for the decrease in 
Mdm2 levels was a reduction in the expression of the Mdm2 gene. However, some studies 
have suggested that the observed decrease in Mdm2 levels is due to an inability of the 
antibody used in Western blot analysis to recognise a particular epitope. For example, 
Toledo et ai, 2000, demonstrated that Mdm2 is rapidly phosphorylated in response to DNA 
damage in an ATM-dependent-manner. If a particular antibody (SMP 14, recognising 
amino acid resdues 154-167) is used to detect Mdm2 then there is an apparent decrease in 
Mdm2 levels. However, if a different antibody (AB-l), with a different epitope site, is 
used then Mdm2 levels do not decrease. The authors suggest that the initial antibody used 
recognises an epitope containing a phosphorylation site and hence the antibody is unable to 
recognise the modified Mdm2 upon Western blot analysis. The same study also showed 
no change in Mdrn2 mRNA levels and no change in the rate of Mdrn2 protein degradation. 
Despite this apparently conflicting set of data, there is a growing body of evidence 
suggesting that Mdrn2 is a target for phosphorylation, with the likely outcome being the 
acti vation of p5 3. 
It should be noted that a p53-binding protein with homology to Mdm2 has been identified 
(Shvarts ('/ al., 1996). This protein is called mdrnX and is able to bind p53 and prevent 
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p53 transactivation (Jackson & Berberich, 2000). However, it does not possess the Mdm2 
properties of being able to facilitate nuclear export or bring about p53 degradation. 
Expression of mdrnX can reverse Mdm2-induced degradation whilst maintaining inhibition 
of p53 transactivation. The authors (Jackson & Berberich, 2000) propose that this 
represents a mechanism whereby undamaged cells can retain a nuclear pool of p53. 
It should be noted that mdmx null mice are embryonic lethal (Parant et al., 2001), as are 
Mdm2 null mice. In addition, they can also be rescued by additionally knocking out or 
mutating p53. 
1.3.4 The regulation of Mdm2 by p14ARF 
P 14 ARF is the product of a tumour suppressor gene (p 19ARF in mice) that functions to 
negatively regulate the activity of Mdm2 (Pomerantz et al., 1998). Inhibition of Mdm2 
results in the activation ofp53 and subsequent cell cycle arrest, hence p14ARF is only 
tumour suppressive in the presence of wild type p53. The mechanism by which p14ARF 
activates p53 has been the focus of intensive research in the last 4 years. Presently, p14ARF 
is believed to act via two mechanisms. Firstly, Honda and Yasuda, 1999 demonstrated that 
binding ofp14ARF to Mdm2 abolished the E3 ligase activity ofMdm2 hence protecting p53 
from ubiquitin-mediated degradation. Protein localisation studies have also revealed that 
Mdm2 is sequestered in the nucleus in response to p 14 ARF activation (Tao and Levine, 
1999; Weber et al., 1999). This is a likely consequence ofp14ARF binding to Mdm2 and 
concealing the NES. This will in tum prevent the shuttling of Mdm2 into the cytoplasm, 
which is an essential step in the regulation of p53, as ubiquitin-mediated degradation only 
occurs in the cytoplasm. Both of the mechanisms described will have the effect of 
activating p53. 
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1.3.5 The oncogenic properties of Mdm2 
Thus far only overexpression ofMdm2 and subsequent binding to p53 has been discussed 
in relation to the oncogenic properties of Mdm2. However, there is evidence for 
alternative oncogenic mechanisms of Mdm2. For instance, the transfection of NIH 3T3 
cells with any of five alternatively spliced forms of Mdm2 (designated a-e), which all lack 
part of the p53-binding domain, generated transformed foci at a high frequency (Sigalas et 
al., 1996). In addition, in the same study the alternatively spliced Mdm2 variants were 
found more frequently in poorly differentiated and late-stage tumours. Only splice variant 
e retained normal p53 binding, therefore the increased transforming capacity of the other 
four splice variants cannot be attributed to a p53-dependent effect. 
It is also of note that Mdm2 is thought to be able to bind to both the transcription factor 
E2F (Martin et al., 1995) and the retinoblastoma protein, RB (Xiao et al., 1995). E2F 
functions to drive the cell cycle through S-phase, with RB functioning to negatively 
regulate this activity. Mdm2 has been shown to activate an E2F reporter gene and as such 
may playa role in progression through the cell cycle. This could possibly represent a p53-
independent mechanism by which Mdm2 can be oncogenic. It should be noted that E2F 
and RB bind to the N-terminal domain of Mdm2. As all of the Mdm2 splice variants 
contain N-terminal deletions (in particular variants a-d with large deletions), it is unlikely 
that they are still able to bind either E2F or RB. The potential role of these splice variants 
in the formation of certain cancers is currently unknown. 
A high percentage of tun lOurS (around 50%) retain wild type p53 activity. Jones et al 
(1995) found that knocking out the Mdm2 gene in mice resulted in early embryonic 
lethality. This lethality could be prevented by additionally knocking out the p53 gene. 
29 
Chapter 1 - Introduction 
Therefore, removing Mdm2 activity from cells expressing wild type p53 results in death of 
those cells (Jones et at., 1995). This offers a potential target for the treatment of tumours 
expressing wild type p53. One such strategy of 'removing' Mdm2 activity is to block the 
binding of Mdm2 to p53. Proof of principle that such approaches may be effective has 
been provided by the introduction of a synthetic peptide modelled to bind the p53-binding 
site of Mdm2 (Bottger et at., 1997). Alternatively, microinjection of a monoclonal 
antibody raised against the p53-binding site of Mdm2 can be used to block complex 
formation (Chen et at., 1993a). However, such molecules do not enter cells easily, if at all 
and therefore are not suitable for therapy. Future directions include the design of smaller 
molecules able to achieve the same effect. Other potential treatments for tumours with wild 
type p53 include stabilising p53 by blocking the nucleo-cytoplasmic shuttling of Mdm2. 
This can be achieved by transfecting target cells with NLS-rex, an inhibitor of nuclear 
protein export. 
Previous sections have aimed to highlight the importance of the tumour suppressor protein 
p53 in the regulation of genomic stability. By inducing cell cycle arrest or apoptosis, p53 
allows repair of DNA damage or removal of a highly damaged cell by apoptosis before 
mutations are propagated. Therefore the mechanisms involved in the activation of p53 are 
vital for maintaining normal cellular function. Thus far phosphorylation, acetylation and 
regulation by Mdm2 have all been described as regulatory mechanisms. However, data 
exists in the literature suggesting a further regulatory function performed by the DNA 
damage-inducible enzyme poly(ADP-ribose) polymerase-1 (PARP-l). As will be 
described in the following sections PARP-l is involved in DNA repair and has been 
reported to post-translationally modify a variety of nuclear proteins, including p53. 
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1.4 Poly(ADP-Ribose) Polymerase-l 
P ARP-1 is a nuclear enzyme involved in the detection of DNA strand breaks (for re lews 
see (D'Amours et al. , 1999; Oliver et al. , 1999). The occurrence of such breaks results in 
the rapid activation of PARP-1 and the subsequent poly(ADP-ribosyl)ation of se era I 
nuclear proteins (Althaus & Richter, 1987). The reaction involves the transfer of the ADP-
ribose moeity from NAD+ to target proteins and occurs in three steps. The reaction is 
initiated by the mono-ADPribosylation of target proteins, followed by elongation and 
branching. Target proteins identified in vitro include several involved in chromatin 
structure, DNA metabolism and cell cycle control, for example, DNA polymerases a and 0 
and DNA ligases I and II (Yoshihara et al. , 1985 and Ohashi et al. , 1986). Observations 
made in vitro should be interpreted with caution as these proteins may not be targets for 
poly(ADP-ribosyl)ation under physiological conditions. The major acceptors of 
poly(ADP-ribose) identified in vivo are histones and PARP-1 itself (Ogata et al. , 1981 ; 
Adamietz and Rudolph, 1984). The result ofpoly(ADP-ribosyl)ation differs depending 
upon the protein involved. The effect on proteins with a particular relevance to this study 
will be discussed later. 
1.4.1 Structure ofPARP-l 
1 
DNA binding 
domain 
FT FTT NT,s 
Auto 
modification 
372 
Figure 1.8 ch ma tic diagram howing the domain structure of P RP-l 
Catalytic 
domain 
859 908 1014 
FI and FII repr ent th zin fi n r of PARP- J; NL = Nuclear locali at ion signal and A = Acti\e it 
31 
Chapter 1 - Introduction 
Human PARP-1 consists of 1,014 amino acids and contains three major structural domains 
(Alkhatib et al., 1987; Kurosaki et al., 1987) (see fig 1.8). The N-terminal of the protein 
comprises the DNA binding domain (DBD), which contains two zinc fingers, termed FI 
and FII (Mazen et aI., 1989) and a high proportion of basic amino acids (believed to be 
involved in the enzyme's interaction with DNA). Unlike the vast majority of zinc fingers 
in proteins, those of P ARP-1 do not recognise specific DNA sequences, rather they 
recognise altered structures such as strand breaks (both single stranded and double stranded 
breaks). It is this strand break recognition which activates PARP-l, with activity being 
increased up to 500-fold (Wielckens et aI., 1983). DNA protection experiments have 
suggested that P ARP-1 binds DNA strand breaks in the form of a dimer, with seven 
nucleotides either side of a single strand break being protected from nucleolytic digestion 
(Gradwohl et aI., 1990; Menissier de Murcia et aI., 1989). 
The central region of P ARP-1, located between amino acid residues 374 and 525 
comprises the automodification domain. P ARP-I binds tightly to DNA strand breaks, is 
rapidly activated and poly(ADP-ribosyl)ates other DNA-bound proteins as well as itself. 
This poly(ADP-ribosyl)ation results in the addition of many ADP-ribose (ADPr) units, 
carrying negative charge, to the target protein. The effect of this automodification upon 
P ARP-1 is the dissociation of the enzyme from the DNA strands as a result of the opposing 
negative charges of the DNA strand and PARP-l. The chain length of the ADPr polymers 
can be up to 200 units. The chain attached to PARP-1 and other targeted proteins is 
removed by the action of an enzyme called poly(ADP-ribose) glycohydrolase (PARG; 
Miwa and Sugimura, 1971) thus allowing the proteins to re-bind to DNA. The catabolism 
of the polymers is very rapid, with the average half-life of polymers produced in response 
to DNA damage being less than 1 minute (Wielckens el aI., 1983). The automodification 
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domain prevents the permanent activation of P ARP-l when it encounters DNA strand 
breaks and thus plays a vital regulatory role and may be important in allowing other repair 
enzymes to access the strand break. 
The C-terminal domain of P ARP-l consists of residues 526-1014 and comprises the 
catalytic domain of the enzyme (Kurosaki et aI., 1987), involved in the nick-binding 
poly(ADP ribose) synthesis. As described earlier, P ARP-l binds DNA strand breaks as a 
dimer and is subsequently automodified. The observation that the ADPr polymers are 
elongated at their distal extremity suggests that the automodification is intermolecular, 
with one half of the dimer targeting the other half during catalysis (Alvarez-Gonzalez, 
1988). The catalytic reaction involves the transfer of the ADP-ribose moiety from NAD+ 
to target proteins via the y-carboxy groups of glutamic acid residues (Riquelme et aI., 1979 
and Burzio et aI., 1979). The polymer is then elongated and branched, with the individual 
residues being joined by glycosidic bonds (see figure l.9). As described above, the 
polymer is degraded by PARG, an enzyme possessing both endo and exoglycosidase 
activity that hydrolyses the glycosidic bonds between ADPr units. The most proximal 
ADP-ribose unit is removed by an enzyme called ADP-ribosyl protein lyase. This step 
appears to be the rate-limiting step in ADPr metabolism (Wielckens et aI., 1982). 
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1.4.2 The activation of P ARP-l 
The product of poly(ADP-ribosyl)ation was initially identified as a homopolymer of 
riboadenylate units (Chambon et al., 1963). However, this possibility was excluded by the 
finding that the polymer contained 2 mol of ribose and 2 mol of phosphate per mol of 
adenine. In addition, it was discovered that the synthesis of this polymer required NAD+ 
as a precursor, suggesting that the polymer was in fact a homopolymer of ADP-ribose units 
generated via NAD+ hydrolysis (Chambon et ai., 1963; Chambon et ai., 1966, Sugimura et 
ai., 1967). This requirement for NAD+ has been demonstrated in many studies, with 
poly(ADP-ribosyl)ation now accepted as the main factor in cellular NAD+ catabolism 
(Wielckens et ai., 1983 and Schraufstatter et al., 1986). A direct link between PARP-l and 
DNA damage was provided by the observation that a wide range of DNA damaging 
agents, including various alkylating agents and IR caused an intracellular decrease in 
NAD+ levels in a dose-dependent manner. 
In addition to requiring NAD+, PARP-l activity is dependent upon the presence of DNA 
ends. Benjamin and Gill, 1980, performed a study to identify what DNA structures are 
capable of activating P ARP-l. This study used a P ARP permeabilised cell assay 
(described in Section 2.9) to assay PARP-l activity in the presence of various DNA 
substrates. For example, comparisons were made between single and double-stranded 
DNA by heating and cooling the DNA. This revealed that PARP-l activity was increased 
much more in the presence of double stranded DNA. In addition, the E. coli plasmid, 
pBR322 was used as a substrate, in a double stranded supercoiled state and also after 
digestion with certain restriction enzymes. Use of these enzymes allowed the generation of 
substrates with a known number of specific strand breaks (for example, single or double 
stranded breaks could be generated). The results generated clearly showed a lack of 
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PARP-I activation, even at high concentrations, when closed circle or supercoiled plasmid 
DNA was used, presumably due to a lack of DNA ends. In contrast, digestion of the 
plasmid DNA with agents inducing single or double stranded breaks resulted in a marked 
increase in P ARP-I activity, highlighting the absolute requirement of DNA strand breaks 
for P ARP-l activation. The finding that P ARP-l requires DNA strand breaks for 
activation led to the hypothesis that PARP-l functions in repair of this damage. Numerous 
studies have been performed investigating the role of P ARP-l in the repair, some of which 
will be described in the following section (1.4.3). 
As described previously in this section, PARP-l activation causes a decrease in the 
intracellular levels ofNAD+ (reviewed in d' Amours et at., 1999). In response to certain 
damaging agents, at high doses, the level ofNAD+ can drop to approximately 10% of its 
normal level (Skidmore et al., 1979 and Rankin et al., 1980). As a consequence of this, the 
levels of ATP within cells also drops, as the synthesis of one molecule ofNAD+ requires at 
least two molecules of A TP (depending upon the particular synthetic pathway used). In 
addition, a decrease in NAD+ levels inhibits glyceraldehydes-3-phosphate dehydrogenase 
activity, which is required to resynthesise ATP during glycolysis (Goodwin et at., 1978). 
Therefore, activation of PARP-l by high doses of IR brings about a reduction in the 
cellular levels of A TP. This ATP depletion has been shown to bring about a switch in the 
mode of cell death in response to DNA damage, from apoptosis to necrosis (Eguchi et at., 
1997 and Leist et at., 1997). This is due to the absolute requirement of ATP for the 
efficient execution of apoptosis. Necrotic death is characterised by cell lysis and the 
release of inflammatory factors which cause damage to neighbouring cells (reviewed in 
Szabo. 1998). This is in contrast to apoptotic cell death, which is localised to the particular 
damaged cell(s). The death of cells \'ia necrosis is responsible for the pathological 
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complications associated with ischemia and with some forms of diabetes. Therefore, a 
major area of research is currently involved in the development of PARP-1 inhibitors, 
which may be used in patients who have suffered ischaemia. The aim is to inhibit P ARP-l 
and prevent the intracellular depletion ofNAD+ and hence protect cells from switching to 
the necrotic mode of cell death. Interestingly, studies with P ARP-1 deficient mice show 
that these animals are protected from post-ischaemia damage compared to the PARP-1 
proficient animals (Szabo et al., 1996 and Masutani et aI., 1999). It should be noted that 
PARP-1 proficient cells appear to have evolved a mechanism to prevent massive depletion 
ofNAD+ during cell death. For example, once a cell is commited to apoptosis, PARP-1 is 
rapidly cleaved and inactivated by caspase-3 (Lazebnik et at., 1994). This cleavage 
separates the DBD of PARP-1 from the catalytic domain and hence the catalytic activity 
can no longer be activated by DNA strand breaks. A characteristic of apoptotic cell death 
is chromosomal degradation, which would obviously generate many DNA ends. Under 
normal circumstances, these ends would massively activate PARP-1 and possibly cause a 
switch from apoptosis to necrosis. Therefore, cleavage of P ARP-1 early in apoptosis 
prevents this from occurring thus preventing cells undergoing necrotic cell death, which 
can result in damage to neighbouring healthy cells. 
1.4.3 PARP-l and DNA repair 
An initial role for PARP-1 in DNA repair was proposed by Durkacz et at., 1980, who 
showed that the repair of damage induced by the monofunctional alkylating agent, 
dimethyl sulphate, was significantly slowed in the presence of a PARP-1 inhibitor, 3-
aminobenzamide (3-AB). In the last decade, many genetic and biochemical studies have 
been performed involving PARP-l to try and clarify the role it performs in DNA repair. 
The principal aim of these studies was to remove PARP-l protein and/or activity from 
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whole animals or various cell types and observe the response to various DNA damaging 
agents. Several techniques have been used to remove P ARP-l from the system being 
studied. These include a dominant-negative strategy involving the overexpression of the 
DBD of PARP-l (Kupper et al., 1995) such that it binds to DNA breaks in competition 
with the native PARP-l and hence poly(ADP-ribosyl)ation does not occur. Other methods 
include the use ofPARP-l inhibitors (e.g. Boulton et a/., 1995; Griffm et al., 1995) 
expression of an antisense RNA construct and knocking out the P ARP-l gene (e.g. de 
Murcia et al., 1997; Masutani et al., 1999; Wang et al., 1995). 
Before describing the putative role of PARP-l in DNA repair, some of the pathways 
involved in the process of DNA repair will be discussed. This is particularly relevant to 
this study as a variety of DNA damaging agents have been used, which in turn produce 
different forms of DNA damage. A description of the forms of damage and their repair 
will be provided below. 
1.4.3.1 Base excision repair 
Base excision repair (BER) involves the repair of damage induced by oxidative, alkylating 
and other DNA damaging agents (McCullough et al., 99). Figure 1.10 summarises this 
repair pathway. Damage induced includes the formation of covalent bonds between, for 
example, an alkylating agent and the base. Common lesions include 3-methyladenine and 
8-hydroxyguanine. Enzymes called DNA glycosylases diffuse along the minor groove of 
the DNA. They are able to recognise specific types of damaged nucleotide and excise the 
altered base via cleavage of the glycosidic bond between the base and deoxyribose. 
Human cells possess many glycosylases, with each one being capable of recognising and 
removing a particular modi tied base. At this stage the backbone of the DNA helix remains 
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intact. An apurinic (AP) endonuclease then nicks the damaged DNA strand upstream of 
the abasic site to produce a 3' OR. This produces a single stranded DNA break (shown in 
figure 1.9), which may be important in the activation ofPARP-l and other DNA damage 
response proteins to be discussed later. The gap in the DNA is ultimately filled by the 
extension of the 3' OR, by a DNA polymerase followed by excision of the abasic site. The 
repair process is completed by the ligation of the DNA ends. 
Base damage 
• 
AP endonuclease 
• 
Figure 1.10 Diagram showing the formation of a SSB during BER 
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1.4.3.2 Nucleotide excision repair 
A second repair pathway, called nucleotide excision repair (NER) serves to remove a 
whole oligonucleotide at sites containing damaged base(s), which result in alteration of the 
normal helical structure of the DNA. A multiprotein complex is responsible for 
recognition of such sites, followed by incision of the DNA strand, displacement of the 
oligonucleotide and finally filling of the gap by DNA polymerisation and ligation (Muller 
et aI., 98). The repair complex contains several XP proteins, identified as being defective 
in the human condition xeroderma pigmentosum, characterised by a sensitivity to UV light. 
An important type of damage repaired by NER are the pyrimidine dimers caused by 
exposure of cells to UV radiation. Interestingly, ADP-ribose polymer formation has been 
detected in permeabilised cells treated with UV. Studies have also shown a UV dose-
dependent decrease in NAD+ levels that can be inhibited by the PARP inhibitor 3-
aminobenzamide (Jacobson et aI., 1983; Fujiwara et aI., 1983). This synthesis of ADP-
ribose polymer is dependent upon the incision of the damaged DNA strand that occurs as 
part ofNER thus generating a strand break. Lymphocytes from normal individuals show 
an increase in ADP-ribose polymer after UV. However, lymphocytes from individuals 
with Xeroderma pigmentosum, where the incision step ofNER is deficient, do not show 
such an increase in ADP-ribose polymer (Berger et aI., 1980; Fujiwara et aI., 1983 ). 
Although several studies have shown an apparent P ARP-I activation after UV radiation, it 
should be noted that studies analysing the actual repair of UV -induced DNA damage have 
found no difference in DNA repair or cell survival in the presence or absence of PARP-1 
(James and Lehmann, 1982; Jacobson et aI., 1983; Collins, 1985; Wang et aI., 1995). 
1.4.3.3 Double strand break repair 
The final form of DNA damage to be discussed is double strand breaks (DSBs) which 
result from exposure to ionising radiation. Ionising radiation is a form of DNA damage 
40 
Chapter 1 - Introduction 
that induces both single and double stranded DNA breaks. In addition, free radicals 
(reactive oxygen species, for example, hydroxyl radicals and hydrogen peroxide) are 
produced, which can chemically modify DNA bases via oxidation e.g. 8-hydroxyguanine, 
which is repaired by BER, as are thymine glycols, produced by oxidation of a thymine 
base and 8-hydroxyguanine. The most cytotoxic lesions induced by IR are considered to 
be DSBs. If repaired inefficiently, this type of break frequently leads to mutations, in 
particular chromosomal translocations (Richardson and Jasin, 2000) or apoptosis (Rich et 
al., 2000). As such it is important to the normal (i.e. non mutated) survival of the cell that 
DSBs are recognised and repaired as efficiently as possible. Two pathways are involved in 
the repair of DSBs, homologous recombination (HR) and non-homologous end-joining 
(NHEJ), with the latter being the predominant pathway in mammalian cells (Chu, 1997). 
During HR (reviewed in Jackson, 2002), the damaged chromosome aligns with and 
retrieves genetic information from an undamaged DNA molecule with which it shares 
sequence homology. In humans, a set of proteins termed the 'RAD50' group have been 
described, which are extensively involved in HR (Wood et al., 2001). Briefly, a complex 
containing Rad50 resects one strand of the DSB in the 5' to 3' direction. The resultant 3' 
single stranded DNA tail is then bound by Rad51, which interacts with an undamaged 
DNA template and locates a homologous region on the undamaged chromosome. Rad51 
then catalyses strand invasion by the single-stranded DNA into the undamaged DNA 
duplex resulting in displacement of one of the strands. The 3 'terminus of the damaged 
DNA is then extended by a DNA polymerase, using the undamaged strand of DNA as a 
template. Upon completion. the DNA crossovers (Holliday junctions) are cleaved and 
ligated to yield two intact DNA molecules. 
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Efficient recognition and repair ofDSBs by NHEJ (reviewed in Jackson, 2002) is 
dependent upon a heterodimeric protein called Ku, consisting of 70 and 86kDa subunits. 
Biochemical studies have revealed that Ku binds to DSBs in a non-sequence-dependent 
manner (Dynan and Yoo et aI., 1998). Binding of Ku leads to recruitment and activation 
of a catalytic subunit, the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) to 
form a trimeric complex. The catalytic subunit shares C-terminal sequence homology with 
two previously discussed DNA damage response kinases, A TR and ATM. Ku also recruits 
XRCC4 and DNA ligase IV to the DSB, with the latter bringing about direct ligation of the 
DNA ends. Prior to this ligation it is likely that the ends of the DNA require processing by 
nucleases. In addition to the recruitment of a DNA ligase to the site of damage, it is 
possible that the DNA-PK complex performs other functions. For example, binding of Ku 
to the DSB may protect the DNA ends from further damage initiated by nucleases. 
Alternatively, the recruitment of the bulky DNA-PK complex and subsequent 
phosphory lation of nearby proteins may decondense chromatin structure, aiding the access 
of other DNA damage response proteins to the site of damage. 
Although a precise role for P ARP-l in HR or NHEJ has not been described, several studies 
discussed below have shown that the lack of PARP-l leads to hypersensitivity in response 
to IR. It is possible that a subset of breaks produced by IR (distinct from DSBs) are reliant 
upon PARP-l for repair (Durkacz et aI., 1980). As described earlier in this section, certain 
lesions induced by IR e.g. thymine glycols and 8-hydroxyguanine are repaired by the BER 
pathway. Therefore, persistence of these breaks due to lack of PARP-l may be sufficient 
to sensitise cells to IR. Alternatively, PARP-l may have a direct role to play in the cellular 
response to IR. For example, PARP-l has been shown to bind to double strand breaks and 
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therefore may perform a protective role, preventing further damage to the DNA ends by 
nuc1eases. 
The types of DNA damage mostly responsible for the activation of P ARP-l in vivo are 
SSBs. This type of damage is usually repaired by the base excision repair pathway (BER) 
and this is the type of repair with which P ARP-l has been implicated. Satoh and Lindahl 
(1992) demonstrated that the repair of SSBs in a cell-free BER assay is dependent upon the 
presence ofNAD+, the substrate of P ARP-l (Satoh & Lindahl, 1992). Furthermore, 
inhibition of poly(ADP-ribosyl)ation in this assay resulted in a decreased repair of SSBs. 
In addition, inhibitor studies have shown that the base recognition and excision steps of 
BER are not influenced by P ARP-l. Shall, 1984, showed that the formation of DNA 
breaks during BER was not affected by treatment with a P ARP-l inhibitor but that the 
subsequent re-joining of the break was retarded. As might be expected, this suggests that 
PARP-l is not required until a strand break has been generated by the repair process, to 
which PARP-l can bind and become activated .. In addition, this and other studies indicate 
that P ARP-l is not absolutely required for BER. Rather P ARP-l appears to increase the 
efficiency of BER such that the strand breaks are repaired more quickly in the presence of 
PARP-l. 
Studies of PARP-l-deficient animals or cell lines initially suggested that P ARP-l was not 
involved in base excision repair. For example, it was reported that mice inactivated in both 
PARP-l alleles were able to repair and transcribe alkylated plasm ids introduced into cells 
derived from the mice (Wang et aI., 1995), suggesting that PARP-l is not involved in the 
repair of alkylation damage. However, it may be that the plasmid is repaired but the actual 
kinetics are slower in the absence of P ARP-l. Therefore, depending upon the time scale 
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for repair, the role ofPARP-1 in BER in this particular assay may have been missed. In 
addition, the plasmid DNA used in these studies is not in the same state as normal cellular 
DNA, as the plasmid is not tightly coiled around histone proteins. 
Subsequent studies have led to the consensus of opinion that P ARP-1 deficient mice are 
hypersensitive to monofunctional alkylating agents and IR. Whole body exposure of the 
mice to IR (8Gy) or treatment with the alkylating agents MNNG, MNU (75mglKg) or 
MMS (1 OOJ!M) led to far greater death in the P ARP-1 knockout animals compared to the 
PARP-1 proficient counterparts (de Murcia et aI., 1997; Masutani et aI., 1999; Wang et al., 
1997). Examination of P ARP-1-1- mice after 8Gy IR treatment revealed that the mice died 
due to acute radiation toxicity to the small intestine (de Murcia et aI., 1997). Similar 
results have been obtained in cells derived from these mice, where colony forming assays 
after IR exposure or alkylating agent treatment have shown a marked decrease in colony 
formation (and hence cell survival) in the PARP-rl- MEFs compared to PARP-1+1+ MEFs. 
It should be noted that the alkylating agents used are potent PARP-1 activators in wild type 
mice. In addition DNA damage induced by MNU treatment and y-irradiation of PARP-I-1-
mice led to an increase in sister chromatid exchange (SeE) indicative of the genetic 
instability caused by the suppression ofpoly(ADP-ribosyl)ation reactions (de Murcia et al., 
1997). 
Although it is now widely accepted that P ARP-1 plays a role in BER, it is not clear as to 
what that role might be. Several theories exist, each of which is supported by different 
lines of evidence. It may be that PARP-1 has overlapping roles involving aspects of each 
of the proposed mechanisms. One proposed mechanism is based on the very rapid binding 
of PARP-l to DNA strand breaks. It has been suggested that P ARP-1 subsequently 
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recruits several other DNA-damage repair proteins to the site leading to the initiation of 
repair. Supporting evidence includes the identification of a BER complex consisting of 
PARP-l, XRCC 1, DNA ligase III and DNA polymerase ~ (Caldecott et al.. 1996; Kubota 
et ai., 1996; Masson et ai., 1998). Central to this complex is the putative scaffold protein, 
XRCC 1, upon which the other components of the complex bind. P ARP-l was first found 
to bind XRCC 1 via a yeast two hybrid screen (Masson et ai., 1998), where human PARP-l 
cDNA was fused to the LexA-encoding DNA binding domain and used as bait to screen a 
HeLa cell cDNA library fused with the activation domain of Ga14. This screen identified 
XRCC 1 as a factor to which P ARP-l binds. Subsequent in vivo experiments using 
glutathione S-transferase (GST)-tagged fusion proteins showed that the interaction was via 
the BRCT domains of the respective proteins. Interestingly, the association of P ARP-l 
with XRCC 1 was found to dramatically decrease the catalytic activity of P ARP-l, without 
affecting the nick-binding function of this enzyme. This finding would be consistent with 
the recruitment model as one would not expect a complex to form in the vicinity of 
automodified P ARP-l due to electrostatic repulsion and also steric hindrance. Therefore, 
to allow the complex to form, the activity of P ARP-l is down-regulated, possibly before 
being switched on again, by an as yet unidentified mechanism, to allow dissociation of the 
enzyme from the DNA and repair of the SSB. 
Another possible mechanism is based on the structure of chromatin. In this state the DNA 
of the cell is tightly wound around histone molecules into a very compact structure. DNA 
damage may allow access of PARP-l to the site of damage. Poly(ADP-ribosyl)ation of 
nearby histones (Kreimeyer el ai., 1984) may decondense the DNA (Althaus, 1992), 
allowing access to the bulky complexes associated with the repair of DNA (see figure 
1.11). This model of 'histone shuttling' was based on initial studies by Althaus and 
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colleagues who demonstrated that poly-ADPr turnover renders DNA susceptible to 
nuclease digestion when core histones are incubated with the DNA. In addition, 
degradation of the ADPr polymer by P ARG abolishes the nucleolytic digestion of the 
DNA. These observations were described in terms of a relaxation of chromatin structure 
due to modification of his tones by ADPr polymer. This negatively charged polymer 
results in dissociation of his tones from DNA due to electrostatic repulsion causing 
localised relaxation of the chromatin structure and hence nucleolytic digestion of the DNA 
in this assay. Degradation of the polymer by P ARG would prevent any electrostatic 
repulsion between the histones and DNA and hence the chromatin structure would remain 
intact and the DNA would be protected from nucleolytic digestion. 
Further evidence for this proposed mechanism is the observation that the repair of damage 
in non-transcribed regions of the genome requires P ARP-l activity, whereas repair of 
transcribed regions does not require PARP-l activity (Ray et al., 1996). In transcribed 
regions of the genome, the DNA is already in a relaxed state to allow efficient gene 
transcription by RNA polymerase. Therefore, ADP-(ribosyl)ation is perhaps not required 
to decondense the DNA. However, in non-transcribed regions, where the DNA is tightly 
coiled around histones, P ARP-I activity may be necessary to decondense the DNA and 
allow access of other repair enzymes to the site of damage. In P ARP-I-deficient mice 
treated with alkylating agents or y-radiation, despite the presence of DNA damage, the 
DNA would remain in a highly condensed state. Therefore these mice exhibit 
hypersensitivity to the DNA-damaging agents mentioned due to the persistence of 
unrepaired DNA (de Murcia et aI., 1997; Wang et aI., 1997) and subsequent induction of 
cell death. 
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A further mechanism by which P ARP-1 may mediate DNA repair is via a signalling 
pathway. PARP-1 activation is an immediate response to DNA damage, resulting in a 
rapid modification of several proteins at the site of damage (including histones and P ARP-
1 itself). The formation of ADP-ribose polymers may act as the initiating step in a 
signalling cascade resulting in the activation of downstream effectors involved in co-
ordinating the cellular response to DNA damage. Supporting this model are studies 
suggesting a functional relationship between P ARP-1 and p53, the details of which will be 
discussed in Section 1.4.6. In addition, PARP-1 has been shown to be capable of 
activating a DNA damage response kinase (DNA-PK; Ruscetti et aI., 1998), which has 
been implicated in the phosphorylation of p53 during the cellular response to DNA damage 
(Woo et a/., 1998). As well as being involved in the repair of SSBs it should be noted that 
PARP-1 has also been implicated in DSB repair (Weinfeld et aI., 1997 and Boulton et aI., 
1999), although less data is currently available concerning PARP-1 's involvement in this 
process. 
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1.4.4 PARP-l inhibitors 
PARP-l inhibitors are being developed (see fig 1.12) in the hope that they may eventually 
be used to potentiate the effects of current chemotherapeutic or radiotherapeutic treatments 
leading to increased cell death and tumour regression. The most widely used inhibitor in 
the literature is 3-aminobenzamide (3-AB, developed by Purnell and Whish), which was 
first used in the late 1970s and was shown to prevent the drop in NAD+ levels associated 
with PARP-l activation. It was shown by Durkacz et aI., 1980, that 3-AB was able to 
inhibit the repair of DNA damage (specifically, SSBs) induced by the monofunctional 
alkylating agent dimethyl sulphate. In addition, a proportion of breaks induced by IR 
treatment were also shown to be repaired less efficiently in the presence of 3-AB. The 
same PARP-l inhibitor was also shown to have no effect on the repair of UV -induced 
damage (James et aI., 1982). Taken together, these results suggest that PARP-l is 
involved in the repair of specific DNA lesions (in particular single strand breaks). As 
might be expected, a decrease in DNA repair in 3-AB treated cells correlated with a 
decreased cell survival after DNA damage (Durkacz et al., 1980 and Nduka et aI., 1980). 
Objections have been raised regarding the specificity of inhibitors such as 3-AB and hence 
the validity of the conclusions derived from studies using these inhibitors. However, as 
has been described in Section 1.4.3, all major conclusions derived using PARP-l inhibitors 
have since been validated in P ARP-l knockout mice. In addition, as will be described later 
in this section, much more potent P ARP-l inhibitors have recently been developed and 
again results confirm initial studies using 3-AB. 
Treatment of tumours with the majority of current chemotherapeutic agents or radiotherapy 
aims to damage the DNA of the cancer cells resulting in cell death. Therefore, it may be of 
therapeutic benefit to be able to potentiate the effects of chemo- or radio-therapy within 
49 
Chapter 1 - Introduction 
tumour cells. Treatment of tumour cells with an inhibitor of a DNA repair pathway would 
be expected to achieve such an objective. Therefore, there is a great deal; of interest in 
developing potent P ARP-1 inhibitors that can be used for this purpose. The Cancer 
Research Unit in Newcastle has developed and tested a variety of novel inhibitors. Initial 
pre-clinical studies have characterised several potent P ARP-1 inhibitors (Griffin, 1996; 
Griffin et aI., 1995; Suto et al., 1991). Boulton et a/1995 demonstrated that the PARP-1 
inhibitor 8-hydroxy-2-methylquinazolin-4-one (NUl 025) potentiated the cytotoxicity of 
the monofunctional alkylating agent temozolomide, correlating with an inhibition of SSB 
repair. This study showed both a decrease in clonogenic survival and an increase in DNA 
strand breaks when the cell cultures were incubated with NUl 025 at 300J.lM prior to, and 
following exposure to ionising radiation and temozolomide. It is of note that both of the 
DNA damaging agents used in this study (i.e. temozolomide and IR) are currently used in 
the treatment of certain cancers, therefore any potentiation observed in the presence of a 
potent P ARP-1 inhibitor may be therapeutically beneficial to these patients. The P ARP-1 
inhibitor used in this study, AG 14361 (k i < 6nM, made in a collaboration between the 
Cancer Research Unit and Pfizer GRD, CA) is approximately 1000-fold more potent than 
3-AB (ki = 5.7J.lM) and has also been tested within the Cancer Research Unit. Figure 1.12 
shows the structures of the P ARP-1 inhibitors discussed above. 
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Unpublished data (Cancer Research Unit) has shown that treatment of a range of PARP-l 
proficient human tumour cells with OAJ.!M AG 14361 resulted in a large potentiation of IR-
and temozolomide induced damage (Drug Development Group, Cancer Research Unit), 
associated with a decrease in cell survival. Also, in response to IR, P ARP-l +1+ MEFs 
treated with OAJ..1M AG14361 showed a dose dependent decrease in cell survival, as 
measured by clonogenic survival assays. At a dose of 6Gy IR, cell survival had decreased 
by 50% in the inhibitor-treated P ARP-l +1+ MEFs. In the same experiment, P ARP-I-I-
MEFs were shown to be much more sensitive to IR treatment than the P ARP-l +1+ MEFs. 
Approximately 90% of PARP-l +1+ MEFs were killed at a dose of5Gy, whereas a dose of 
only I.5Gy was required to kill the same number of PARP-I-I- MEFs. It should be noted 
that the treatment of P ARP-I-I- MEFs with OAJ.!M AG 14361 did not potentiate the effects 
of IR in these cells. This concentration of OAJ.!M AG 14361 should be compared to the 
concentration of 3mM 3-AB used in the study of Durkacz et al., 1980 to highlight the 
potency of these new inhibitors. In addition, local studies in nude mice have shown that 
treatment with AG] 4361 results in significant regression of human tumour xenografts in 
response to IR. temozolomide and irinotecan (w1published data). It should be noted that 
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P ARP-l inhibitors may also be useful in reducing the harmful side effects of current cancer 
treatments, caused by damage to non-cancerous cells. As well as being used in the 
treatment of cancers P ARP-l inhibitors may be useful in the treatment of ischaemia and 
certain types of diabetes, as described in Section 1.4.2. 
1.4.5 Additional functions of P ARP-l 
The previous section (Section 1.4.4) has described the requirement for PARP-l in cell 
survival after certain types of DNA damage. In addition, a variety of models have been 
proposed for the precise function ofPARP-l in the repair of these DNA lesions. These 
models have been based on evidence spanning back initially to the 1980s. However, 
additional functions of P ARP-l have been described, for example P ARP-l has been 
implicated in the control of cellular transcription and also in the regulation of the 
transcription factor NF-KB (reviewed in Chiarugi, 2002 and Shall and de Murcia, 2000). 
A role for P ARP-l in transcriptional control was initially proposed based on the 
identification of PARP-l as a factor that could increase the specificity of initiation of RNA 
polymerase II (Matsui et al., 1980; Slattery et at., 1983). Subsequent studies have 
produced a body of evidence showing that P ARP-l can have stimulatory or inhibitory 
effects on transcription, dependent upon the cell type, the gene being transcribed and the 
transcription factors involved (Ziegler and Oei, 2001). For example, PARP-l was found to 
stimulate transcription in human cell extracts, but only if the P ARP-l remained 
catalytically inactive by excluding NAD+ from the assay. Consistent with this finding is 
the identification of P ARP-l as a binding partner to a variety of transcription factors, 
including Oct-I, TEF-l and AP-2 (Nie et aI., 1998; Butler et aI., 1999 and Kannan et aI., 
1999). Addition of NAD+ to the previously described assay resulted in silencing of RNA 
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polymerase II-dependent transcription due to protein modification by poly(ADP-ribose). 
During the formation of ADPr, P ARP-1 is likely to become automodified and hence 
binding to the previously described transcription factors (Oct-I, TEF 1 and AP-2) will be 
abolished. In addition, several other transcription factors have been identified as targets 
for poly(ADP-ribosyl)ation, including the TATA-binding protein and Yin Yang 1, with the 
likely result of dissociation of these proteins from transcription complexes or DNA 
promoter sequences hence the inhibition of transcription. 
The precise role of P ARP-1 in transcriptional control is likely to be complex, with P ARP-1 
able to bind DNA itself, bind to various transcription factors and also to poly(ADP-
ribosyl)ate several transcription factors. One model for the role of PARP-1 has been 
proposed by Ziegler and Oei, 2001, who proposed that the functions of PARP-1 in DNA 
repair and transcription are combined in response to genotoxic stress. They suggested that 
upon exposure to DNA damage, P ARP-1 rapidly binds to the DNA strand lesions (such as 
SSBs). As a consequence of this binding PARP-1 is catalytically activated and 
automodifies itself. This has recently been shown to increase the rate of ongoing 
transcription elongation (Vispe et aI., 2000). At the same time, PARP-1 targets various 
transcription factors for poly(ADP-ribosyl)ation, preventing the binding of these factors to 
promoter sites and hence preventing the initiation of transcription. It is obviously 
beneficial to prevent transcription of potentially damaged areas of the genome. Having 
shut down transcription, PARP-I is able to perform its role in DNA repair, possibly by 
relaxing the localised chromatin structure and allowing access of repair enzymes to the 
lesion. After repair, the ADPr bound to PARP-1 and transcription factors is removed by 
P ARG, allowing the cell to resume normal physiological processes. 
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Studies involving the use of P ARP-l inhibitors have implicated P ARP-l in the innate 
immune response under certain circumstances. For example, exposure of bone marrow 
macrophages to lipopolysaccharide (LPS) induces nitric oxide formation, which can be 
blocked by treatment of cells with the PARP-l inhibitor 3AB (Hauschildt et al., 1991). 
Nitric oxide is generated by the product of the inducible nitric oxide synthase gene (iNOS). 
Subsequent studies have revealed that the inhibition of PARP-l brought about an inhibition 
in transcription of the iNOS gene, mediated by the transcription factor NF-KB (Le Page et 
aI., 1998). This study demonstrated clearly that the ability ofNF-KB to function as a 
transcription activator of the iNOS gene was impaired in the absence of P ARP-1. The 
transcription factor NF-KB is vital to many cellular processes, including DNA damage and 
repair and immune responses and is activated by a wide variety of agents, for example, IR, 
UV, tumour necrosis factor-a (TNF-a) and various mitogens. Once activated, NF-KB 
induces the expression of several immune response genes and is also crucial in preventing 
the initiation of apoptosis (reviewed in Foo and Nolan, 1999). As such an understanding 
of the regulation of this protein could prove very useful in deciphering the steps involved 
in various cellular pathways and also the treatment of certain diseases. 
Studies involving P ARP-1 knockout cells have further highlighted the functional 
relationship between PARP-l and NF-KB. PARP-rl- cells exhibited greater sensitivity to 
TNF -a cytotoxicity compared to P ARP-1 +1+ cells, a difference which was attributed to an 
inability to induce NF-KB expression in the absence ofPARP-1 (Oliver et aI., 1999). 
Identical results were obtained after exposure of cells to hydrogen peroxide. This same 
study also demonstrated impaired NF-KB function in PARP-1 knockout mice, where these 
animals \\Crc protected against the whole animal toxicity of LPS, again attributed to an 
inability to induce NF-KB and hence reduced expression iNOS and nitric oxide. Although 
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there is clear evidence supporting a role for PARP-l in the expression ofNF-KB, the exact 
mechanisms involved are not clear, although PARP-l has been detected in a stable nuclear 
complex bound to both the p65 and p50 subunits ofNF-KB (Hassa and Hottinger, 1999). 
The fact that PARP-l is able to induce the expression of the transcription factor NF-KB 
supports the hypothesis that P ARP-l is able to influence transcription of various genes. As 
described in this section P ARP-l has been shown to have both positive and negative 
effects on the rate of transcription, putatively by binding to or ADP-ribosylating a variety 
of transcription factors. The following section discusses in detail the potential role of 
PARP-l in the regulation of another transcription factor, p53, which has turned out to be a 
controversial area of research. It is this regulation that is the focus of this thesis. 
1.4.6 PARP-l and p53 
PARP-l is activated immediately in response to DNA damage and has been implicated in 
signalling to several molecules, perhaps most significantly, p53. The effect ofPARP-l 
upon p53 is an area of research where a lot of contradiction still exists. Several groups 
have reported an altered p53 induction in P ARP-l-deficient cells, whereas others have 
reported an unchanged p53 induction. However for a lot of the studies, different cell lines 
were used as well as different DNA-damaging agents. 
For example Menissier-de Murcia et al. 1997 demonstrated an accumulation of p53 after 
treatment of PARP-1 knockout cells (splenocytes disrupted in exon 4) with an alkylating 
agent whereas p53 induction did not occur in the PARP-l +/+ cells (de Murcia et al., 1997). 
It is perhaps surprising that the PARP-1 proficient cell line showed no evidence of a p53 
induction in response to DNA damage. This result is in accordance with Lu and Lane 
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(1993) who demonstrated an increased p53 induction after x-ray irradiation of mouse 
prostate cells treated with 3-AB, a PARP-l inhibitor (Lu & Lane, 1993). These results 
were explained in terms of a persistence of DNA strand breaks in the absence of P ARP-l 
activity due to inefficient repair of the DNA. It was hypothesised that these breaks would 
relay greater activation signals to p53 and hence an increased response was observed. A 
recent study using the aforementioned de Murcia knockout cells demonstrated a 
differential requirement for P ARP-l in the p53 response to different DNA damaging 
agents (Valenzuela et aI., 2002). More precisely, primary PARP-I-I- MEFs showed a 
reduced p53 induction after exposure to ionising radiation but showed an increased p53 
induction after treatment with an alkylating agent compared to P ARP-l +1+ MEFs. The 
authors proposed that the observed response to IR was due to impaired activation of A TM 
in the P ARP-l knockout cells, leading to the observed decrease in p53 Serl5 
phosphorylation and hence a decrease in p53 activation. In response to the alkylating 
agent, a greater p53 response was observed in the PARP-l knockout MEFs, possibly due to 
inefficient BER and hence persistence of strand breaks. A second set of P ARP-l knockout 
MEFs disrupted in exon 2 (Wang et aI., 1995) showed a reduced induction but normal 
activation and function of p53 in response to adriamycin and IR (Agarwal et ai., 1997). 
The authors proposed that the accumulation of p53 can occur via P ARP-l dependent and 
P ARP-l independent pathways but that the activation of p53 is predominantly independent 
of PARP-l. The final set of PARP-l knockout MEFs are disrupted in exon 1 of the P ARP-
1 locus. These cells exhibit identical p53 responses (both induction and activity) to the 
PARP-l wild type counterparts after treatment with 80y IR (Masutani et ai., 1999). 
Simbulan-Rosenthal et ai. (1998a) used the expression of P ARP-l antisense RNA to 
remove PARP-l activity from cells (Burkitt's Lymphoma A0876). In response to ionising 
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radiation, the absence of P ARP-1 activity led to a prolonged p53 response but with the 
magnitude of the response being unaffected compared to P ARP-l proficient cells. This 
study is in accordance with Lu and Lane, 1993 and de Murcia et ai., 1997, who showed 
that lack of P ARP-1 potentiates the p53 response to DNA damage. Other results (Whitacre 
et ai., 1995; Wang et aI., 1998) show the opposite, with the absence ofPARP-1 (through 
down-regulation or inhibition) showing decreased basal levels of p53 as well as a failure to 
activate p53 in response to various DNA damaging agents. 
The studies summarised above highlight the controversy that exists in terms of the role (if 
any) ofPARP-1 in the regulation ofp53. However, ifPARP-l is ultimately found to 
modulate p53 activity, the next step will be to elucidate the precise mechanisms involved. 
To date, it has been shown that p53 can be poly(ADP-ribosyl)ated in vitro when p53 is 
incubated with purified PARP-l (Wesierska-Gadek et al., 1996b; Mendoza-Alvarez, 
2001). The latter study also showed that this modification ofp53 diminished the ability of 
p53 to bind to its DNA consensus sequence, as illustrated by gel-shift assays. The results 
of these studies should be interpreted with care, as activated PARP-l may be able to target 
many proteins in cell-free systems, with accessibility to glutamic acid residues likely to be 
the limiting factor. In addition, cell free systems do not represent the normal physiological 
environment for proteins. For example, within cells p53 is able to bind DNA and 
Wesierska-Gadek et aI., 1996b demonstrated in vitro that p53 bound to DNA is not 
susceptible to poly(ADP-ribosyl)ation. Therefore, cell free reactions showing that p53 is a 
target for ADP-ribosylation do not necessarily mean this is true in vivo. Free ADP-ribose 
polymer has also been shown to physically interact with p53 (Malanga et al., 1998). The 
binding was found to involve three domains of 23-26 amino acids on p53 and was 
subsequently shown to impair the ability of p53 to bind specific sequences of DNA. A 
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subsequent study has identified specific sequence motifs within ADP-ribose binding 
proteins (Pleschke et al., 2000) by blotting particular sequences onto nylon membrane and 
incubating with purified radiolabelled polymer. Thorough washing followed by 
autoradiography revealed the ability of particular sequences to bind ADP-ribose polymer. 
Proteins found to possess such sequence motifs include p53, p21, Ku70 (part ofDNA-PK) 
and XRCC 1. A mechanism whereby ADP-ribose polymer is able to interact with 
components of DNA repair pathways may be consistent with the model of PARP-I 
recruiting DNA damage response proteins to the site of the damage. For example, if 
PARP-I were to bind a strand break and automodify itself, it is possible that the polymer 
produced is able to recruit other proteins to the site that are needed for efficient repair of 
the break. 
In addition to p53 being subject to poly(ADP-ribosyl)ation, a physical interaction between 
PARP-I and p53 has been demonstrated by co-immunoprecipitation. It should be noted, 
however, that this interaction may not be direct. Rather, P ARP-I and p53 may be part of a 
nuclear protein complex. It would be interesting to analyse the immunoprecipitation 
reactions for the presence of other proteins by gel electrophoresis followed by silver-
staining. Wesierska-Gadek et aI., 2000 demonstrated co-immunoprecipitation of p53 with 
PARP-I in cultured cells expressing wild type as well as mutant p53. Interestingly, using 
rat cells expressing the temperature sensitive mutant of p53 (p53135Yal), PARP-1 was 
sequestered in the cytoplasm at the restrictive temperature (37°C). It should be noted that 
at this temperature, the p53 is cytoplasmic. Therefore, the only way the nonnally nuclear 
PARP-I could enter the cytoplasm is in a complex with p53. Transfer of the cells to 32°C 
(p53 should be nuclear at this temperature) results in both proteins accumulating in the 
nucleus. This finding is in accordance with Vaziri et al., 1997. who showed binding of 
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PARP-I to p53 in vitro and in vivo. This interaction was observed in cells treated with IR 
as well as untreated samples. It has also been suggested that P ARP-I may act to protect 
p53 from proteolytic degradation. This is based on the location of a putative poly(ADP-
ribosyl)ation site near a proteolytic cleavage site on p53. 
It is obvious that a lot more research needs to be performed investigating all aspects of the 
relationship of PARP-I with p53. What will result is likely to be a complicated picture 
involving several aspects of the processes described above and likely several additional 
mechanisms. 
1.4.7 The P ARP family 
The first intimation that more than one P ARP protein existed came from studies showing 
that the PARP-I knockout cells were still able to synthesise ADP-ribose polymer (Shieh et 
a/., 1998). Around the same time, studies analysing stress responses in plants led to the 
identification of a sequence, homologous to P ARP-l, which has subsequently been 
described as PARP-2 (Babiychuk et a/., 1998, Berghammer et al., 1999). A sequence 
corresponding to PARP-2 was also discovered in P ARP-I-I- MEFs (Arne et al., 1999). 
Further analysis by Arne and co-workers revealed that PARP-2 was a protein of 62kDa in 
mass, which possessed 60% homology to the C-terminal catalytic domain of P ARP-l. 
Like PARP-l, this protein is able to bind and is activated by breaks in DNA strands. 
However, it should be noted that the DNA binding domain ofPARP-2 is distinct from that 
of P ARP-l. Therefore, the two enzymes may bind to different substrates and hence may 
have differing biological roles within cells. Despite this possibility, a recent study has 
implicated PARP-2 in the BER pathway (Schreiber et al., 2002). This group showed that 
PARP-2 knockout MEFs are impaired in BER. This was exemplified in vivo using the 
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single cell gel electrophoresis assay (COMET assay) and treatment with MNU (an 
alkylating agent). A significant delay (2 hours) in rejoining of DNA strand breaks was 
observed in the P ARP-2 knockout MEFs compared to their wild type counterparts. The 
same study was also able to demonstrate binding ofPARP-2 to XRCCI and PARP-l 
suggesting that PARP-2 may have a role in BER as part of a multi-protein complex. 
In addition to PARP-2, six other PARP family members have now been described, all of 
which contain sequence homology to the catalytic domain of P ARP-l (which is now 
described as the P ARP signature sequence). Included in this family of P ARP proteins is 
tankyrase (P ARP-5), which is localised at telomeres and has been shown to synthesise 
ADP-ribose polymer (Smith et al., 1998). It is believed that tankyrase may playa role in 
preserving the length oftelomeric DNA. Also, a PARP protein was discovered as a 
component of the vault complex (Kickhoefer et al., 1999), a ribonucleotide assembly that 
is ubiquitously expressed in eukaryotes. The vault complex forms a barrel-like structure 
and has been implicated in cellular transport. It has been shown that other components of 
this complex can be ADP-ribosylated by Vault-PARP (Kickhoefer et al., 1999). It is 
possible that this modification alters the conformation of the vault complex such that 
transport capabilities are altered. Further analysis is needed of the other P ARP family 
members before their functions are elucidated. 
The identification of several proteins capable of poly(ADP-ribosyl)ation has perhaps 
complicated the interpretation of previous studies analysing the effect of poly(ADP-
ribosyl)ation on various cellular functions. Previous studies have assigned any effect 
observed to the activity ofPARP-l, however, it is now clear that some of these effects may 
be due to the activity of alternative PARP proteins. It will therefore be necessary to dissect 
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the role of the individual P ARPs by knocking out the particular gene or by the 
development of inhibition strategies which specifically target specific P ARP proteins. 
1.5 Aims of this study 
This introductory chapter has aimed to highlight the importance of p53 in the regulation of 
cellular functions in response to DNA damage. Having established the importance of these 
functions, it was necessary to summarise the data regarding the regulation and activation of 
this protein. Studies have been summarised demonstrating the role of Mdm2, 
phosphorylation and acetylation in the overall regulation of p53 function. The latter 
sections have addressed the potential role of PARP-l in the DNA damage-induced 
activation ofp53. Data has been described highlighting the controversial nature of this 
particular area of research. 
The principal aim of this study was to investigate the hypothesis that P ARP-l 
functions as an upstream regulator of p53 function. The methods used to address this 
hypothesis were two-fold. 
_ Mouse embryonic fibroblasts disrupted in exon 4 of the P ARP-l locus were used 
along with their wild-type counterparts to analyse the requirement for P ARP-l 
protein on p53 activation 
_ A novel potent PARP-l inhibitor (AG 14361), developed in a collaboration 
between Pfizer GRD and the Drug Development Group of the Cancer Research 
Unit in Newcastle was used to inhibit PARP-l activity in PARP-l proficient MEFs 
and human cell lines to analyse the effect of blocking PARP-l activity on the 
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ability of DNA damage to activate p53. In addition, a human tumour colorectal cell 
line with wt p53 was used to study the effects of the PARP-l inhibitor 
It should be noted that the use of P ARP-l knockout cells and a P ARP-I inhibitor represent 
very different strategies for the removal of P ARP-l activity from cells. For example, when 
using inhibitors, PARP-I protein is still present and is therefore still able to bind to DNA 
strand breaks. However, this binding is likely to become irreversible as the catalytic 
function and hence the automodification and ensuing dissociation from DNA of PARP-l is 
prevented. Therefore the strand breaks produced by DNA damage are likely to be 
'protected' by PARP-l and may conceal the breaks from other DNA damage-responsive 
proteins, such as ATM. This effect in itself may modulate 'normal' p53 activity. In 
contrast the P ARP-I-1- MEFs do not possess any P ARP-l protein, therefore the strand 
breaks should be 'visible' to other proteins. 
During the course of this study, a second hypothesis was formulated and tested. This was 
based on the observation that two independently derived immortalised clones of P ARP-l +/+ 
MEFs possessed p53 mutations. However, the P ARP-l-/- MEFs were found to express 
wild type p53. 
It was therefore hypothesised that the absence of PARP-l bypassed the requirement 
for MEFs to mutate p53 during immortalisation. 
_ This hypothesis was tested by growth selection for spontaneously transformed 
independent colonies of primary PARP-l MEFs and analysing the p53 status of the 
cells after immortalisation. 
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- During the course of these experiments, cumulative growth curves were plotted 
for each of the primary P ARP-I MEF colonies, leading to several observations 
regarding the growth rate of these cells and the consequences for DNA-damage 
induction of p53. 
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2.1 Tissue culture 
2.1.1 Cell lines 
Mouse embryonic fibroblasts (MEFs) were cultured from the embryos of mice kindly 
provided by Gilbert de Murcia (Ecole Superieure de Biotechnologie de Strasbourg). The 
MEFs were of a P ARP-l wild-type genotype (P ARP-l +1+) or a P ARP-l knockout genotype 
(P ARP-I-I-). The knockout MEFs were produced by the insertion of a targeting vector into 
embryonic stem cells. This targeting vector resulted in the insertion of a neomycin 
resistance cassette into exon 4 of the P ARP-l gene via homologous recombination (de 
Murcia et aI., 1997). These stem cells were then microinjected into blastocysts, giving 
rise to chimaeric offspring. These mice were then bred to produce mice homozygous for 
the disruption of the PARP-l gene. Disruption of the PARP-l gene, lack ofPARP-l 
expression and lack of P ARP-l activity have all been confirmed in these cells (de Murcia 
et aI., 1997). 
During this study, both primary and immortalized MEFs were used. Primary cells are 
produced by the homogenisation of embryos and the derived cells are not grown beyond 
passage 5. Primary cells will eventually reach a stage where they cease growing, called 
senescence (reviewed in Itahana et aI., 2001). In time, a population of immortalized cells 
will begin to grow from these cells, presumably by mutation of a gene controlling cellular 
growth or cell cycle arrest. Typically, immortalized cells show an increased growth rate 
and also have an infinite lifespan compared to primary cells. 
A further cell line used was HCT-116, a human colorectal tumour cell line. Previous 
studies within the department haye shown that these cells have wild-type p53 
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characteristics, with an induction of p53 protein in response to DNA damage. In addition. 
the p53 is transcriptionally active, with induction of p53 target genes such as mdm2 and 
p21 waf-l also being observed (results within this thesis; also confirmed by Famie. G. PhD 
thesis, Cancer Research Unit, University of Newcastle upon Tyne). In addition to the 
wild-type HCT-116 cells, a 'degraded p53' cell line has also been used for the validation of 
p53-responsive techniques (Section 2.7). These cells are called HCT -116 N7 and are 
stably transfected with a plasmid containing the human papilloma virus (HPV) E6 protein, 
which targets p53 for degradation, and hence these cells express only very low levels of 
p53. 
Some experiments have also been performed on a human ovarian carcinoma cell line, 
A2780. Like the HCT-116 cells, they show wild type p53 activity and were used in repeats 
of the experiments mentioned above with the aim of eliminating any possible cell-line 
specific observations. 
2.1.2 Growth conditions 
Mouse embryo fibroblasts were grown in high glucose Dulbecco' s Minimum Essential 
Medium (DMEM) supplemented with 100/0 (v/v) foetal bovine serum (FBS) and 0.01 % 
(w/v) penicillin/streptomycin. The human cell lines used (HCT-116, HCT-116 N7 and 
A2780) were grown in RPMI 1640 medium supplemented with the same concentrations of 
FBS and antibiotics. All culture medium, antibiotics and FBS were obtained from Gibco-
BRL, Paisley, UK. All cells were maintained at 37°C in a humidified atmosphere 
containing 5% carbon dioxide. Cell lines were routinely grown in 15cm tissue culture 
plates (NlmC, Illinois, USA) until 70-800/0 confluent before being sub-cultured (passaged), 
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2.1.3 Sub-culturing of cells 
To passage adherent cells, the medium was aspirated from the plate and the cells rinsed in 
phosphate buffered saline (PBS). 3ml of 0.25% (w/v) trypsin in PBS.EDTA (0.02% w/v 
EDTA) was added to the cells until they had lifted from the plate and the resultant 
suspension added to an equal volume of medium. Where necessary, to prevent clumping 
of the cells, the suspension was passed through a 19-9auge needle. Cells were then 
counted using a haemocytometer and an appropriate number plated out for specific 
experiments or placed back into 15cm tissue culture plates as routine subculture. 
2.1.4 Mycoplasma testing 
Cells were routinely tested for mycoplasma infection (once a month) according to 
DelGiudice and Happs, 1978 
2.1.5 Drug preparation and storage 
A variety of drugs were used in DNA damage experiments (see Section 2.1.6). The PARP-
1 inhibitor (AG14361, produced in a collaboration between the Cancer Research Unit and 
Pfizer GRD) was made up as a 10mM stock in 1000/0 DMSO (Sigma, Poole, UK). This 
was then diluted 1: 1 0 in PBS before being frozen in 100111 aliquots at -20°C. 
Temozolomide (a gift from Professor MGF Stevens, Cancer Research Laboratories, 
University of Nottingham, UK) was prepared as a 200mM stock in 1000/0 DMSO and 
frozen in aliquots of 500111 at -20°C. 
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2.1.6 DNA damage experiments 
Cells to be analysed by Western blotting were plated out in Scm tissue culture plates. Cells 
were prepared according to the protocol above (Section 2.1.3) before addition of S x 105 
cells to each plate. Six plates were required for each treatment, corresponding to time 
points of Untreated, Ih, 2h, 3h, 6h and 24h. The cells were grown at 37°C for 24 hours 
before treatment with the relevant DNA damaging agent. When using the P ARP-l 
inhibitor, AG 14361, it was added to the cells ISmins prior to DNA damage treatment. For 
a plate containing Sml of medium, SJ.!1 ofa ImM AGI4361 (in 100/0 DMSO; Sigma, Poole, 
UK) stock was added, to give a final concentration of 1 J.!M AG 14361 and 0.01% DMSO. 
The ImM stock was dissolved in 10% DMSO, therefore control (untreated) cells were 
treated with SJ.lI of 100/0 DMSO as 'solvent controls'. Cells were treated with three types 
of DNA damaging agents. IR was administered at three doses; 2, S and lOGy (using a 
Gamma Cell 1000 Elite, dose rate 3.64Gy/min). Alternatively, cells were treated with a 
dose of UV radiation; 20, SO or 100J/m2 using a UV Stratalink machine (Stratalink, La 
Jolla, USA). Finally, cells were treated with the alkylating agent, temozolomide at three 
different concentrations; 0.2S, O.S or ImM temozolomide. Samples for the relevant time 
points were taken and processed according to Section 2.S.2. 
DNA damage experiments were also performed on cells to be analysed by a luciferase 
assay, which will be discussed in Section 2.7 
2.1.7 SulfurRhodamine B assay (SRB) 
SRB assays (Skehan ef aI., 1990) are used to estimate the growth of cells. The principle 
involves the growth of cells over time followed by the fixing of cells with SO% (w/v) 
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trichloroacetic acid (TCA) (Sigma, Poole, UK) at various time points. The cells can then 
be stained with SRB, a bright pink amino xanthene dye, which stains total protein. SRB 
contains two sulfonic groups that bind amino acids under mildly acidic conditions. 
Therefore, the more cells present, the more protein and hence the more intense the staining 
effect. Excess stain is removed before solubilising the bound stain in relevant buffer. This 
results in the production of a purple solution, the optical density of which can be measured 
and is proportional to the number of cells originally present in the wells. This technique is 
commonly used to derive growth curves for cell lines and also to demonstrate any growth 
inhibitory effect of any treatments (e.g. drugs) being used. 
2.1.8 Growth curves 
The basic method involved plating cells into 96-well tissue culture plates (Nunc, Illinois, 
USA) at a variety of cellular concentrations (ranging from 0.625 x 104 cells/ml- 2 x 105 
cells/ml). For growth curves ten wells were used for each cellular concentration. 
Therefore one plate was set up, with six different cellular densities, for each time point. 
The outer wells of the plate were not used for growing cells, instead they contain 100JlI of 
medium to minimise any 'edge effect'. For growth curves the cells were grown over the 
course of a week and one plate of cells fixed by the addition of 25JlI 500/0 TCA every 24h. 
These plates were stored at 4°C for at least 24h before rinsing several times with distilled 
H20. After the plates had dried, 100JlI of 0.40/0 (w/v) SRB (in 1 % acetic acid) (Sigma, 
Poole, UK) was added to each well for 30mins. Excess stain was removed by washing 
with 1 % acetic acid (BOH, Poole, UK). Again the plates were allowed to dry before 
solubilising the bound stain in 100JlI of 10mM Tris.HCl, (pH 10.5) (Sigma, Poole, UK) for 
30 minutes on a plate shaker. Each plate was then analysed on a plate reader where the 
absorbance of each wdl is read at 540nm. The data is then analysed using computer 
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software (Microsoft Excel) and the data plotted with absorbance against time of gro~1h. 
The mean of the ten replicates of a particular cell density was calculated along with the 
standard error for that set of data. This process is repeated for all cell densities at all time 
points and the data plotted in the form of a line graph to generate growth curves. 
2.1.9 Growth inhibition assays 
Growth inhibition assays were performed to show that the concentration of AG 14361 used 
in DNA damage experiments did not inhibit cellular growth during the time course of 
experiments. Like growth curves, the assay was set up by plating cells into 96-well tissue 
culture plates. However, cells were plated out at only one concentration. The effects of 
drugs on growth inhibition were analysed over 72hrs. Therefore cells were plated out at a 
density such that they will be growing exponentially during this time. This optimum 
density was estimated from the growth curves previously derived for each cell line and was 
found to be 2 x 104/ml. Cells (90J,ll) were left overnight to adhere to the plates before 
addition of 10J,l1 of AG 14361 at final concentrations of 0.1, 1, 10 or 100J,lM. Each dilution 
was prepared by diluting a 10mM stock of AG14361 (in 1000/0 DMSO) with culture 
medium. AG 14361 was diluted 1: 10 upon addition to the well, therefore, concentrations of 
1, 10, 100 and 1000J,lM were prepared. The DMSO content was adjusted during dilution 
such that the two lower AG 14361 concentrations contained 0.1 % DMSO whereas the two 
higher AG 14361 concentrations contained 100/0 DMSO. Upon addition to the well, the 
final DMSO concentration will be either 0.01 % or 1 %, depending upon the concentration 
of AG 14361. Therefore. solvent controls were also included on each plate consisting of 
cells grown in 0.010/0 or 1 % DMSO. Five replicates of each AG 14361 concentration (or 
solvent control) were set up on each plate. Plates \vere then processed according to the 
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SRB assay protocol at 24, 48 and 72h. The data was analysed using Microsoft Excel 
software and the results plotted on graphs (see Section 2.1.7). 
2.1.10 Immortalization of mouse embryonic fibroblasts 
During cell culture primary MEFs grow at a constant growth rate. After a certain number 
of cellular divisions (typically between 15 and 25), the growth rate of the cells slows 
dramatically. At this stage, the cells adhere to the tissue culture plates but have withdrawn 
from the cell cycle. Cells are said to have reached senescence. Eventually, a sub-
population of cells begins to exit the senescent phase and begin to grow rapidly (Todaro 
and Green, 1963). A common feature of such cells is the mutation of the tumour 
suppressor, p53, which confers immortality on the outgrowing population. 
MEFs were derived from homogenised day 13.5 embryos. These cells were then grown 
according to the 3T3 protocol (Todaro and Green, 1963). Briefly, 1 x 106 cells were 
placed into a 10cm tissue culture plate. The cells were grown according to Section 2.1.2 
for 3 days, before the cells were trypsinised, counted and 1 x 106 cells plated into a fresh 
10cm plate. The aim of the experiment was to investigate the p53 status of immortalized 
PARP-I +/+ and PARP-l-/- MEFs, or more specifically to investigate the hypothesis that 
mutation of p53 during immortalisation is affected by P ARP-l. This hypothesis was based 
on data described in Section 4.2. For such a study it is necessary to derive several 
independent colonies of immortalised PARP-l +/+ and PARP-l-/- and to analyse the p53 
status of these colonies. Therefore, 5 plates of primary P ARP-l +/+ and 5 plates of primary 
PARP- r/- MEFs were grown. In addition 5 further plates of PARP-I +/+ MEFs were gro\\TI 
in mediun1 containing 1 JlM AG 14361. It was important to treat each plate as an individual 
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population of cells such that cross contamination did not occur. The cells were gro\\TI, 
with routine sub-culturing until they reached the senescent phase. At this stage, the plates 
were analysed by microscopic inspection for the presence of transformed cells (evident in 
the form of dense colonies of smaller cells) and the medium changed every three days. If 
transformed areas were present, the plate was trypsinised and the cells re-plated into a 
fresh 10cm plate, to allow the outgrowth of spontaneously transformed (immortalised) 
MEFs. 
The cells were counted every three days (as or when sub-cultured) and this data was 
subsequently used to produce cumulative growth curves. This involves sequential addition 
of the individual cell counts to provide a total cell number produced from the original 1 x 
106 cells. 
2.1.11 Stable transfection 
A plasmid containing the eDNA for human PARP-I (see Chapter 4 for details) was stably 
transfected into an immortalised P ARP-I-1- MEF cell line. The principle of stable 
transfection is the initial introduction of the plasmid into cells followed by the integration 
of the plasmid into the host genome via recombination. In theory, the integrated DNA will 
remain as part of the host genome and will therefore be passed on to daughter cells during 
cellular replication. Ideally, the plasmid to be transfected into cells should contain a 
selectable marker, as well as the P ARP-I sequence. For example, if the plasmid also 
contained an antibiotic resistance gene, then after transfection the cells should be grown in 
mediwl1 supplemented with the relevant antibiotic. This would allow only antibiotic-
resistant cells to grow and hence only cells that ha\'e taken up the plasmid. The plasmid 
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used in this study did not contain an antibiotic resistance gene therefore cells were co-
transfected with a second plasmid, pCR3, which contained a neomycin resistance gene. 
However, it had been overlooked that the P ARP-I knockout MEFs already possessed 
resistance to this antibiotic (see Chapter 4, Section 4.2.4), which was the probable reason 
for only one colony of stably transfected cells being isolated. 
2.1.11.1 Optimisation of transfection 
The optimisation involved altering the ratio of volume of trans feet ion reagent (FuGENE 6, 
Roche, Basel, Switzerland) to mass of plasmid DNA such that maximum expression of the 
plasmid was achieved. Three different ratios were tried, 3:2 (J.d of FuGENE 6:J..lg of 
DNA), 3:1 and 6:1. Immortalised PARP-r/- MEFs were plated into six 35mm tissue 
culture plates at 1.5 x 105 cells and incubated at 37°C for 24 hours. The cells were then 
transfected with both the P ARP-I plasmid (pP ARP32; a gift from Alexander Burkle, Dept 
of Gerontology, Newcastle General Hospital) and the antibiotic resistance plasmid (pCR3, 
neomycin resistance gene). A transfection mix (3:2 ratio) was prepared by adding 3J..lI of 
FuGENE 6 to IOOJ..lI of serum free DMEM. After 5 minutes, IJ..lg ofPARP-I plasmid and 
1 J..lg of pCR3 were added. This mixture was incubated for at least 15 minutes before 
adding to one of the plates. Other transfection mixes were prepared corresponding to 
ratios of 3: 1 and 6: 1 and added to two other plates of cells. Three blanks were also 
prepared, corresponding to the pPARP32 plasmid without PARP-I. All plates were 
incubated at 37°C for 24 hours before lysing the cells in sodium dodecyl sulphate (SDS) 
lysis buffer (see Section 2.5.2). Protein assays were performed on each of the samples and 
50J..lg ran on a polyacrylamide gel before Western blotting and subsequent probing of the 
membrane with an anti-PARP-l antibody (Section 2.5). PARP-l expression was found to 
be highest in the 3:2 ratio sanlple. 
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2.1.11.2 Stable transfection of P ARP-I-I- MEFs 
P ARP-I-I- MEFs were plated out and transfected according to Section 2.1.10.1 with a 3:2 
ratio of transfection reagent:plasmid DNA. However, after 24 hours incubation with 
transfection reagent, the cells were trypsinised and counted. Cell numbers ranging from 
100 to 100000 were then plated out into 15cm tissue culture plates. The aim is to separate 
cells sufficiently such that they can adhere to the plate as a single cell and begin to form a 
homogenous colony of cells without being contaminated by other cells added to the plate. 
It took approximately 10-14 days for distinct colonies to become visible on the plates. 
Colonies were then isolated using sterile cloning rings (Sigma, Poole, UK). Briefly, the 
medium was aspirated from the plate and the cells rinsed in PBS. The edge of a cloning 
ring was then coated with sterile petroleum jelly and the ring carefully placed over the 
colony. Sufficient pressure was applied such that the petroleum jelly formed an airtight 
seal between the base of the cloning ring and the tissue culture plate. 1 00~1 of trypsin was 
then added to the colony and left for 5 to 10 minutes. After the cells had lifted from the 
surface of the plate (this was checked microscopically), they were added to 500~1 of 
medium in the well of a 24-well tissue culture plate. Each isolated colony was then 
observed daily and when sufficiently grown, split into two 35mm tissue culture plates. 
One plate was used for Western blot analysis for P ARP-l expression and the other was 
allowed to continue growing. Colonies that turned out to be negative for PARP-l 
expression were discarded. The one positive colony that was isolated was bulked up and 
due to the problem of lack of antibiotic selection, mentioned earlier, was re-plated out for 
colonies. This was to ensure that the isolated colony was a homogenous population of 
cells. Ten colonies were analysed for PARP-I expression. all of which were positive. The 
stable transfectant was then bulked up further and aliquots frozen in liquid nitrogen. 
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2.2 Nucleic acid extraction 
2.2.1 Preparation of plasmid DNA 
2.2.1.1 Transformation of E.coli cells with plasmid DNA 
Ready-competent E.coli strain JMI09 cells (Promega, Madison, USA) were defrosted on 
ice before separating into SOJ,.l1 aliquots. 2J,.l1 of plasmid DNA was added to the cells and 
the mixture left on ice for 20 minutes (all plasmids prepared contained an ampicillin 
resistance gene). The cells were then heat-shocked for 4S-S0 seconds at 42°C before being 
placed back on ice for 2 minutes. 9S0J,.l1 of SOC medium (20/0 tryptone-B, O.S% yeast 
extract B, O.OS% NaCI, O.S% MgS04.7H20 supplemented with 20mM glucose) was added. 
The mixture was then incubated for 90 minutes at 37°C in a rotary incubator at lS0rpm. 
Finally, volumes ranging from 1-20J,.l1 of this mixture were streaked for single colonies 
onto agar plates and the plates incubated overnight at 37°C. The agar plates contained 100/0 
tryptone (w/v), 10% sodium chloride (w/v), S% yeast extract (w/v) and I.S% agar (w/v). 
The agar was sterilised by autoclaving before the addition of SOJ,.lg/ml ampicillin and 
pouring into petri dishes. Any ampicillin resistant colonies that had grown should possess 
the desired plasmid. Therefore, a colony was picked and grown up in Sml of LB 
supplemented with ampicillin at 37°C overnight. Plasmid DNA was then extracted from 
this sample using a Wizard™ mini-prep kit (Qiagen, Crawley, UK). 
2.2.1.2 Plasmid DNA preparation 
Miniprep kits have been designed for efficient purification of plasmid DNA from bacterial 
cultures. The basis of the kit used in this study (Wizard kit. Qiagen, Crawley. UK) is the 
alkaline lysis of bacteria followed by purification of DNA via binding to silica membranes 
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and subsequent elution of the DNA into buffer. Bacterial cells are lysed in a solution 
containing SDS, which solubilises phospholipids and proteins hence causing lysis of the 
cellular membrane. In addition, the solution contains sodium hydroxide, which denatures 
both chromosomal and plasmid DNA. The smaller, less complex plasmid DNA is 
solubilised first. The incubation time is optimised for the solubilisation of plasmid DNA 
alone, before addition of a buffer containing guanidium chloride (a chaotropic salt) and 
acetic acid. The acetic acid neutralizes the sodium hydroxide thus bringing about a rapid 
change in pH. This pH change in turn causes precipitation of SDS in solid complexes with 
chromosomal DNA, proteins and cell debris. The solid material is removed via 
centrifugation, with the resultant supernatant containing the plasmid DNA. This 
supernatant is then applied to a silica membrane within a spin-column (supplied within the 
Wizard kit). DNA binds to silica in high concentrations of chaotropic salt (in this case 
guanidium chloride), possibly through the formation of cation bridges with the negatively 
charged silica. Upon centrifugation, the plasmid DNA binds strongly to the silica and 
hence is purified from solution. The plasmid DNA can then be solubilised by simply 
passing distilled water across the membrane, thus reducing the salt concentration and 
hence the plasmid DNA is eluted. 
Plasmid DNA was extracted using the Wizard plus SVkit according to the manufacturer's 
instructions (Qiagen Plasmid Purification Handbook). Larger stocks of plasmid were 
produced by growing up larger quantities of transformed bacteria followed by the use of a 
Mega-prep kit (Qiagen, Crawley, UK), which was used according to the manufacturers 
protocol. 
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The plasmid was then restriction digested with an appropriate enzyme to demonstrate 
isolation of a DNA fragment corresponding to the relevant insert (Section 2.4.1.1). In 
certain circumstances it is the excised fragment that is required, therefore this fragment 
must be purified by separating it from the remainder of the original plasmid present in the 
sample. This is achieved by separation of the different sized DNA fragments using 
agarose gel electrophoresis (Section 2.3) and subsequent purification of the relevant 
fragment from the agarose gel. 
2.2.1.3 Purification of DNA fragments from agarose gel 
As described above, DNA fragments are separated using agarose gel electrophoresis. The 
fragments can then be visualised under UV light and the relevant band excised using a 
sharp, clean scalpel. As much of the excess agarose is removed as is possible without 
losing any of the DNA fragment. Any area that is not fluorescent under UV light does not 
contain any DNA and hence can be removed. The DNA fragment is then purified from the 
residual agarose using a gel extraction kit from Qiagen (QIAquick TM). This kit relies upon 
the adsorption of DNA to a silica membrane (in a spin column) in the presence of high salt. 
Upon centrifugation of the column, the relevant buffer washes any contaminant through 
the membrane with the DNA remaining attached. The DNA can then be eluted from the 
column into distilled H20. 
2.2.2 Extraction of genomic DNA from cell pellets 
Isolation of cellular DNA initially requires lysis of cells, usually in a buffer containing a 
detergent, such as SDS. NP-40 or Triton X-I 00. In addition, it is important that the DNA 
isolated does not contain protein contamination. Therefore, the lysis buffer is 
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supplemented with proteinase K. Further removal of contaminants is achieved by 
chloroform extraction and subsequent precipitation of the DNA from the aqueous phase 
using isopropanol. 
PARP-l +J+ and P ARP-I-J- MEFs were grown in IScm tissue culture dishes until 800/0 
confluent. Cells were trypsinised and 1 x 107 cells spun down for S minutes at 1000 rpm 
before rinsing in PBS. Cells were then again spun down and resuspended in Sml of 
reagent B (see appendix A) containing SOJ,.l1 of proteinase K (final concentration of 
10J,tg/ml) in a SOml Falcon tube. The pellets were homogenised by pipetting and the 
samples placed in a rotary incubator overnight at 37°C. 
The next day the sample was examined to ensure complete homogenisation before addition 
of 12S0J,.l1 of sodium perchlorate. The samples were placed on a multi-tube roller at room 
temperature for IS minutes before being transferred to a 6SoC waterbath for 30 minutes. 
An equal volume of chloroform (6.2Sml, BDH, Poole, UK) was then added and the 
samples mixed for 2S minutes at room temperature. Each sample was then centrifuged at 
2S00rpm (Mistral 2000i) for IS mins. The upper aqueous phase of each sample was then 
transferred to a fresh Falcon tube containing an equal volume of isopropanol (BDH, Poole, 
UK). Repeated inversion of the tubes should result in the precipitation of the DNA in the 
form of fine white threads. The DNA was spun down at 2S00rpm (Mistral 2000i) for S 
minutes and washed twice with 7S% ethanol (BDH, Poole, UK). Excess ethanol was then 
removed and the pellet allowed to air dry for approximately one hour. Finally, the pellet 
was dissolved in 200 - 800J,t1 of distilled H20, depending upon the size of the pellet. It 
should be noted that when using the DNA in applications involving restriction enzyme 
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digestion, it is best to avoid dissolving the DNA in 1 x Tris-EDT A as the EDT A may 
interfere with the efficiency of the restriction enzyme. 
2.2.3 Extraction of cellular RNA 
The major consideration when producing or working with RNA is the elimination of 
ribonucleases (Rnases) that will readily degrade the isolated RNA. It is therefore 
necessary to wash any equipment with RnaseawayTM (Qiagen, Crawley, UK) before use 
and to bake any glassware used at 200°C for three or four hours. Both of these methods 
are effective at inactivating Rnases. RNA was produced using the Rneasy mini kit 
(Qiagen, Crawley, UK). This technique combines the selective binding properties of 
silica-gel membranes with the speed of microspin technology. Basically, the buffer system 
used is high salt and allows the selective binding of RNA longer than 200 bases to the 
silica gel membrane. Biological samples are initially lysed in a highly denaturing 
guanidine isothiocyanate-containing buffer, which immediately inactivates Rnases and 
hence ensures isolation of intact RNA. Addition of ethanol provides appropriate binding 
conditions before addition of the sample to an Rneasy mini spin column. Total RNA binds 
to the membrane, with subsequent washing steps removing any contaminants. The final 
step is the elution of the RNA from the membrane via the addition of Rnase free water. 
Cells were grown in 15cm tissue culture plates before being trypsinised and counted. 1 x 
107 cells were then spun down (lOOOrpm for 5 mins) and rinsed in PBS. The supernatant 
was carefully aspirated. Incomplete removal of the supernatant may interfere with the 
subsequent lysis step and also dilute the sample, which may alter the optimum conditions 
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for binding of RNA to the Rneasy membrane. RNA was then isolated from the cell pellet 
according to the manufacturers protocol (Qiagen, RNeasy:B. mini handbook). 
2.2.3.1 Assessment of RNA integrity 
The quality of the isolated RNA was assessed by electrophoretic analysis of the RNA 
sample. 2J,.lg of RNA (estimated by spectrophotometric analysis, see section 2.2.4) was 
made up to 10J,.l1 in distilled H20 before addition of 3J,.l1 of loading buffer (see appendix A). 
This sample was then analysed on a 1.2% agarose gel containing 0.2SJ,.lg/ml of ethidium 
bromide (Sigma, Poole, UK) at SOV for 2 hours. The RNA was then visualised under UV 
illumination and photographed. Two bands should be clearly visible, one at Skb and the 
other at 1.9kb. These correspond to the 28S rRNA and the 18S rRNA, respectively. In 
addition, the upper band should be approximately 2.S times more intense than the lower 
band for good quality RNA. 
2.2.4 Estimation of nucleic acid concentration and purity 
The concentration and purity of nucleic acids is estimated by measuring the optical density 
at two wavelengths, 260 and 280nm using a spectrophotometer. The spectrophotometer is 
corrected to zero at each wavelength by measuring the absorbance of a 'blank', for 
example SOOJ,.l1 of distilled H20. The nucleic acid samples to be analysed were diluted 
1: 1 00 in distilled H20 by adding SJ,.l1 of sample to 49SJ,.l1 of water. This solution was mixed 
before being placed in a quartz cuvette for optical density analysis. The reading at 260nm 
provides the concentration of nucleic acid. An OD of 1 at 260nm corresponds to a 
concentration of SOJ,.lg/ml for double stranded DNA, 40J,.lg/ml of single stranded DNA or 
RNA and approximately 30J,.lg/ml of single stranded oligonucleotide. The ratio of the 
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readings at 260 and 280nm provide an indication of the purity of the nucleic acid. For 
DNA, OD26onm/OD28onm should be 1.8. For pure RNA the ratio should be 2.0. 
2.2.5 Nucleic acid storage 
Once isolated, cellular DNA and plasmid DNA are stable and were stored at 4°C or -20°C. 
However, RNA is less stable than DNA and, as such was stored at -80°C. 
2.3 Agarose gel electrophoresis 
This technique is used to separate nucleic acids based upon their size. The gel itself 
consists of a matrix of polysaccharide molecules through which the nucleic acids are able 
to migrate. Therefore, it is the size of the nucleic acids that dictates how fast they can 
move through the matrix of the gel, with smaller nucleic acids able to migrate faster. The 
application of an electric current to the gel and subsequent movement of the negatively 
charged nucleic acids towards a positive electrode brings about the migration. The agarose 
content of gels can be varied depending upon the sizes of the nucleic acids being analysed. 
For instance, when analysing small molecules, the agarose content is increased which in 
turn leads to decreased pore size within the gel. Addition of ethidium bromide to both the 
gel and the running buffer allows visualisation of the DNA as ethidium bromide 
intercalates DNA and fluoresces when exposed to UV light. 
The agarose gel is prepared by dissolving the required amount of agarose in tris-borate 
EDrA (TBE) buffer (see appendix A). The size of fragments being detected in this study 
required the preparation of a 0.80/0 gel (therefore 0.8g of agarose was dissolved in 100ml of 
TBE). It was necessary to boil the mixture to allow efficient solubilisation of the agarose. 
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This was achieved by gently heating the buffer in a conical flask in a microwave oyen. 
The gel was allowed to cool to approximately 500e before addition of ethidiurn bromide 
(0.1 J.1g/ml final concentration). The gel was poured into a gel-casting tray and allowed to 
solidify. 
Samples were prepared via the addition of one fifth loading buffer (see appendix A) before 
loading into the wells of the gel. Also included on the gel was a standard molecular weight 
marker (lkb marker, Gibco-BRL, Paisley, UK) to provide an indication of the size of 
fragments in the gel. The running buffer for the gel consisted of 1 litre of TBE containing 
ethidium bromide at a final concentration of 0.1 f.lg/ml. The gel was run at 80V for 
approximately five hours, or until the bromophenol blue had migrated near to the edge of 
the gel. Gels were visualized under UV light and photographed using a Bio Vision gel 
imaging system, which also allowed digital storage of images. 
2.4 Southern blotting 
Southern blotting (Southern, 1975) is a technique used to detect a specific fragment of 
DNA within a sample containing entire genomic DNA, rather like finding a needle in a 
haystack. The technique involves the purification of genomic DNA before digesting the 
DNA with a specific restriction endonuclease. This will result in a mixture of fragments of 
DNA of a variety of sizes, which can then be separated by running the DNA through an 
agarose gel. The DNA is then denatured to form single-stranded DNA by soaking the gel 
in sodium hydroxide before transfer of the DNA to a nylon membrane. This allows 
efficient binding of the probe to target sequences. The exact positions of the DNA in the 
gel are preserved upon transfer to the membrane. To ddect the DNA fragment of interest. 
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a single stranded oligonucleotide is produced that is complimentary to the sequence of 
interest. This oligonucleotide is then radiolabelled with 32p and allowed to hybridise with 
homologous sequences on the membrane. Probe bound non-specifically to the membrane 
is removed in several washing steps before visualisation of the membrane using 
phosphorimagery . 
This technique can be used to analyse the copy numbers of particular genes, for example, 
the amplification of a gene called MycN in neuroblastoma. Alternatively. Southern 
blotting can be used as a molecular biology tool to confirm disruption of a particular gene. 
For example, Southern blotting has been used in this study to confirm disruption of the 
P ARP-l gene via insertion of a neomycin resistant cassette into exon 4 of the P ARP-l 
locus. This results in the insertion of an extra EcoRI site, which produces a smaller 
fragment of DNA upon EcoRI digestion. Therefore Southern blotting should result in the 
probe detecting different sized bands in the PARP-l wild type and knockout MEFs (see 
Chapter 3, Section 3.2.3). 
2.4.1 Preparation of probe for Southern blotting 
The probe for P ARP-l has been inserted into a BlueScript plasmid. The plasmid was 
prepared and purifed according to section 2.2.1. In order to prepare the probe for Southern 
blotting, it is necessary to excise the relevant fragment of DNA using restriction enzyme 
digestion. 
2.4.1.1 Restriction endonuclease digestion 
Restriction endonuc1eases are naturally occurring enzymes, present in bacteria and act to 
protect the bacterium from phage infection. The basis of this defence mechanism is the 
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ability of the endonucleases to recognise specific sequences of phage DNA. nonnally 
between 4 and 8bp long, and to cut the DNA at this site. Restriction endonucleases have 
been purified from bacteria and are now commonly used as molecular biology tools within 
the laboratory. For example, it is possible to manipulate DNA by removing a sequence 
using, for example EcoRI. A different sequence, also isolated using EcoRI may then be 
inserted into this site, with the process being aided by the complementary ends of DNA left 
by the endonuclease. This is the basis for the cloning of different genes into the multiple 
cloning sites of expression vectors. 
The plasmid containing the P ARP-l probe was prepared and purified. The restriction 
digestion was perfonned in a final volume of 40IlI, consisting of 27111 of distilled water, 
2, . .tI of lOx EcoRI reaction buffer, 2111 of EcoRl (20U), 2111 of Xbal (20U), 2111 of Xbal 
reaction buffer and Sill (20llg) of DNA (all restriction enzymes and buffers were from 
GibcoBRL, Paisley, UK). The reaction components were thoroughly mixed before 
collection via brief centrifugation. The reactions were incubated in 1.5ml Eppendorf tubes 
overnight at 37°C. The efficiency of the reaction was then checked by running I III of the 
reaction mix on a 0.8% agarose gel. The IIlI sample was added to 9111 of loading buffer 
(see appendix A) before analysis by gel electrophoresis. For each restriction digest 
sample, an uncut sample of plasmid DNA was included on the gel. The migration of the 
bands in each sample was compared to a molecular weight marker, also included on the 
gel. This allows confinnation that the size of the excised band and hence the probe to be 
used for Southern blotting was of the correct size (0.8kb). A clear shift should be apparent 
between the uncut plasmid DNA and the digested sample. The 0.8kb fragment was 
excised and purified according to Section 2.2.1.3 
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2.4.1.2 Radiolabelling of probe 
Radiolabelling of the P ARP-l probe is essential for the final detection step invol\'ed in 
Southern blotting. The method used is based on a random primer extension DNA 
synthesis (Feinberg and Vogelstein, 1983). The reaction mixture contains dNTP without 
dATP, [a32P]_dATP (Amersham, Buckinghamshire, UK), probe DNA and the Klenow 
fragment of DNA polymerase-1 (GibcoBRL, Paisley, UK). During the ensuing reaction, 
the polymerase will synthesise new probe DNA, incorporating radio labelled dA TP into the 
probe sequence. 
Approximately 10ng of P ARP-1 probe was added to distilled water such that the final 
volume was 30,. . tl. The mixture was heated to 100°C for 5 mins to denature the DNA. 
After cooling, 10J..!1 of reaction mixture (containing all dNTPs except dA TP, see appendix 
A), l,.d of bovine serum albumin (BSA, from 2mg/ml stock) (Sigma, Poole, UK) and 1 f.ll 
of Klenow fragment (10 units, GibcoBRL, Paisley, UK) were added. After thorough 
mixing, the mixture was centrifuged briefly before finally adding 5f.l1 [a32P]_dA TP and 
incubating overnight at room temperature in a lead-lined container. 
2.4.1.3 Purification of labelled probe 
As well as containing labelled probe, the mixture will contain other fragments of 
radiolabelled DNA and free nucleotides. It is therefore necessary to purify the probe by 
passing the mixture down a Nick ™ column containing Sephadex SG50 (Pharmacia). This 
technique uses size exclusion chromatography to separate fragments of DNA based upon 
their size. When the mixture is placed on the column, the larger fragments of DNA are 
eluted first followed by smaller fragments and free nucleotides. 
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Before adding the probe mixture, the column was washed with Sml of 1 x TE (see 
appendix A) to equilibrate the column. The probe mixture was then added directly to the 
column before adding 200J,l1 of 1 x TE. The eluant was collected in a I.Sml eppendorf. 
Subsequent volumes of 200J,l1 1 x TE were added to the column and the eluant collected 
each time. This procedure was normally repeated 10 times such that the end result was ten 
different tubes containing different fractions from the column. A 2J,l1 sample from each 
tube was then placed in a fresh eppendorf and subjected to scintillation counting (Wallac 
1410, Pharmacia). This provides a measurement of the radioactive counts in each sample. 
The size of the PARP-l probe is such that it usually eluted in fractions 3 and 4. The 
radioactivity in each sample can be estimated by multiplying the scintillation value by the 
dilution factor, 100. 
2.4.2 Restriction enzyme digestion of total cellular DNA 
The sensitivity of Southern blotting is such that, in general, 10J,lg of genomic human DNA 
is required for the detection of a single copy of target sequence within a sample. A volume 
containing 20J,lg of DNA from each sample was placed into a I.Sml eppendorf tube. The 
lid was punctured several times with a needle and the DNA was dried down by vacuum 
centrifugation using a Speedvac SV 1 00 (Savant), at a temperature of 65°C. After one hour 
all water should have evaporated from each sample. Each pellet of DNA was then 
subjected to EcoRI digestion for 24 hours. The components of the reaction are 34J.lI of 
distilled H20 , 4J,l1 of 10 x reaction buffer (buffer #3, Gibco BRL, Paisley, UK) and 2J.lI (20 
units) of EcoRI (Gibco BRL, Paisley, UK). Samples were mixed thoroughly before 
incubating for 24 hours at 37°C 
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2.4.3 Gel electrophoresis of digested genomic DNA 
It is necessary to ensure the complete digestion of the genomic DNA before transferring 
the DNA onto a membrane. This was achieved by mixing IJlI of the overnight digest with 
5JlI of distilled H20 and 4JlI of loading buffer (see appendix A). This sample was then 
analysed on a 0.80/0 mini agarose gel at 50 volts for 1-2h before visualising the DNA under 
a UV light. If the DNA was completely digested then there should be an even smear of 
DNA down the gel with only one band, corresponding to satellite DNA. If the DNA was 
incompletely digested, there will be no satellite bands present and also the DNA will 
accumulate near the wells of the gel, due to the predominantly large fragments of DNA 
within the sample. In this situation more restriction enzyme and buffer should be added to 
the original sample followed by a further 24 hours incubation. 
Upon efficient digestion of the DNA, 10JlI of loading buffer was added to the original 
reaction mix, to give a final volume of 50JlI containing 20Jlg of digested genomic DNA. 
Half of this was then loaded onto a 0.8% agarose gel and the sample electrophoresed for 
5hrs at 80V. The DNA was then transferred to nylon membrane. 
2.4.4 Transfer of the DNA fragments onto nylon membrane 
Prior to transfer, the gel containing the digested DNA was exposed to UV for 5mins to 
fragment the DNA and improve the transfer to the membrane. At the same time, the gel 
was photographed alongside a ruler to allow estimation of the size of any bands on the 
membrane (by comparing the scale on the ruler to the molecular weight marker on the gel). 
The gel was then denatured in 1 M NaOH, 2.5M NaCI for 30 minutes followed by 
neutralization in 3M NaAOc, pH 5.5 for a further 30 minutes. Neutralization brings the pH 
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of the gel down to below 9, which increases the binding of the D A to the membrane. 
Transfer of the DNA from the gel to HybondN membrane (Amersham Bucks UK) was 
achieved by capillary flow using the system depicted in figure 2.1. An upturned agarose 
gel casting tray was placed in a large glass dish (approx 30cm2) filled with 20x C (see 
appendix A). Strips of 3MM Whatmann filter paper were laid over the tray and into the 
20XSSC to act as a wick. Four pieces of clingfilm were laid over the edges of the casting 
tray and glass dish, to prevent evaporation of the buffer. The agarose gel was then placed 
on top of the casting tray such that the edges of the gel slightly overlapped the clingfilm. 
The HybondN membrane was then laid slowly on top of the gel. Three pieces of 
Whatmann 3MM filter paper (Whatmann, Maidstone, Kent), soaked in 20xSSC were 
placed on top of the membrane before a stack of absorbent towels (approx 10cm in height). 
Bubbles were eliminated at each stage during the assembly of the system via rolling with a 
glass pipette. The transfer occurs overnight, caused by the gradual upward flow of the 
20xSSC buffer through the apparatus and into the paper towel wick. During this process 
the DNA is eluted from the gel and binds to the nylon membrane. After blotting, the DNA 
was covalently attached to the membrane by exposing the membrane to 12,OOOJ..tJ/cm2 UV 
using a Stratalink machine. It should be noted that the membrane was only handled with 
tweezers, and where possible, contacting only the edge of the membrane . 
.... ------ weight 
glass plate 
4---- paper towels 
cling film 
20xSSC~~_~~~~ __ ~ ______________ ~ ____ ~ __ ~ 
3MM Whatman filter paper 
wick covering inverted gel tray 
Figur 2.1 diagram honing the apparatu required for outh rn blotting 
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2.4.5 Hybridisation of the probe to the mem brane 
The final step in the process of Southern blotting is the binding of the radiolabelled probe 
to the target DNA sequence bound to the nylon membrane. This was achieved by 
performing a hybridisation reaction. Gilbert's solution (see appendix A) and sonicated 
salmon sperm DNA (lOmg/ml) were pre-warmed to 6Soe in a waterbath. IS0JlI of salmon 
sperm DNA was added to ISf..l1 of 1M NaOH in a l.Sml eppendorftube. The tube was 
heated at 6Soe for 10 mins in order to denature the DNA. This mixture was then added to 
ISml of Gilbert's solution (see appendix A) to form the prehybridisation solution. The 
nylon membrane was rinsed briefly in 2 x sse (see appendix A) before being sealed into a 
plastic bag containing the prehybridisation solution. Prior to sealing, all air bubbles were 
expelled from the bag by rolling with a glass pipette. This ensures that all areas of the 
membrane are exposed to the solution. The bag was then placed in a glass dish containing 
water, within a 6Soe waterbath for at least Ihr with agitation. The plastic bag remains 
immersed in the heated water at all times by laying absorbent paper on top of the bag. The 
glass container was also covered with clingfilm to prevent evaporation of the water. The 
aim of the prehybridisation step is to prevent non-specific binding of the probe to the 
membrane. Instead, the salmon sperm DNA, included in the prehybridisation solution, will 
occupy these non-specific sites. 
Whilst the membrane was incubating at 6Soe, the hybridisation solution was prepared. 
The radiolabelled PARP-I probe was denatured by adding 1I10th volume of 1 M NaOH and 
incubating at 6Soe for 10 minutes. As before, this solution was then added to ISml of 
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Gilbert's solution. Approximately 1.5 x 107 counts are required per 15ml of Gilbert's 
solution (estimated from scintillation counting of the labelled probe). The prehybridisation 
solution was poured from the opened plastic bag and replaced with the hybridisation 
solution. The bag was resealed and placed back in the dish of water at 65°C overnight. 
The next morning, the hybridisation solution was discarded and the membrane washed 
three times in a solution of 0.2xSSC/O.2%SDS (see appendix A). Each wash was for 15 
minutes and was performed in a glass dish at 70°C in a shaking waterbath. These washing 
steps should remove any unbound probe from the membrane before it is resealed in a 
plastic bag and exposed to a phosphor storage screen overnight. 
2.4.6 Use of PhosphorImager 
A phosphorImagerTM (Molecular Dynamics) was used to locate and measure the 
radioactive signal on the Southern blot membranes. As described in the previous section, 
the membrane was sealed into a plastic bag and exposed to a phosphor storage screen 
overnight. The screen itself is composed of fine crystals of BaFBr:Eu ++ in an organic 
binder. High-energy radiation (emitted from the radio labelled 32p on the membrane) 
excites an electron in the Eu ++ ions into the conduction band, which is then trapped in the 
BaFBr" complex. Loss of an electron results in Eu ++ becoming Eu +++. Exposure of the 
screen to a helium-neon laser beam on the phosphorImager results in the liberation of an 
electron from the excited BaFBr" complex. This electron then reduces Eu +++ back to Eu ++, 
releasing a photon at 390nm as it returns to the ground state. It is this photon which is 
detected by the phosphorimager and is processed by computer software to provide a digital 
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Image on a computer screen. Image analysis was performed by ImageQuant software 
(Molecular Dynamics). 
2.5 Polyacrylamide gel electrophoresis and Western blotting 
2.5.1 Polyacrylamide gel electrophoresis (PAGE): 
The process of PAGE allows the separation of proteins based upon their size. The 
separation depends upon the relative migration of different sized proteins through the 
matrix of a gel in response to an externally applied electric current. For example, a large 
protein will migrate through the pores of a gel significantly slower than a smaller protein. 
Therefore, electrophoresis leads to the formation of a 'ladder' of proteins down a geL with 
each band corresponding to a particular protein. Samples for electrophoresis are prepared 
in a buffer containing SDS, which acts to denature proteins by coating them with a 
negative charge, leading to electrostatic repulsion in folded regions. In addition, this 
charge is necessary for the migration of proteins through the gel, towards a positive 
electrode. The buffer also contains f}-mercaptoethanol to further denature proteins by 
reduction of disulphide bonds. Finally a blue dye, 2-bromophenol blue is added to the 
samples to visualise progress of the samples through the gel such that migration can be 
stopped at the necessary time. 
The acrylamide content of gels can be changed to allow for more efficient resolution of a 
particular protein band, depending upon the size of the protein in question. For example, 
high molecular weight proteins are better-resolved using low percentage acrylamide gels, 
and vice-versa. 
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2.5.2 Sample preparation: 
To prepare samples for Western blot analysis, cells (2 x 105 or 5 x 105) were grown in 2cm 
or 5cm tissue culture plates, respectively. After relevant treatment (for example, with a 
DNA damaging agent), cells were lysed in SDS lysis buffer (see appendix A). In addition, 
the lysis buffer was supplemented with a variety of protease inhibitors; aprotinin, 
leupeptin, pepstatin A and trypsin inhibitor (all from Sigma, Poole, UK). For cells in 2cm 
plates, 50J,t1 of SDS lysis buffer was used and 100J,t1 for 5cm plates. Briefly, the medium 
was removed by aspiration before rinsing the cells in PBS. Aspiration of the PBS was 
followed by addition of the SDS lysis buffer. Samples were collected using cell scrapers 
(Costar) and placed into 0.5ml eppendorftubes. Samples were then boiled for 5 minutes to 
promote the denaturation of proteins. At this stage the cell lysate was very viscous and 
difficult to pipette, due to the presence of DNA within the samples. To overcome this 
problem the samples were sonicated (Soniprep 150, MSE) for 10 seconds at 10 units, 
which shears the DNA and makes the sample more manageable. When comparing levels 
of a particular protein in a time course experiment it is necessary to load equal amounts of 
total protein from each sample onto the gel. This was achieved by performing a protein 
assay on each individual sample and, according to the protein concentration, adjusting the 
volumes of each sample loaded onto the gel. After assaying protein content, 2.5J,t1 of 
100% B-mercaptoethanol and 2.5J,t1 of 1 % bromophenol blue was added to 50J,t1 samples at 
final concentrations of 50/0 and 0.05%, respectively. For 1 OOJ,tllysates, 5J,t1 of B-
mercaptoethanol and bromophenol blue were added. 
2.5.3 Pierce DCA protein assay: 
Protein content of the celllysates was estimated using a Pierce BCA protein assay kit 
(Pierce, Illinois. USA). The basis of this assay is the production ofCu 1+ from a reaction 
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between cysteine, tryptophan or tyrosine (present in protein samples) and Cu2+ (present in 
one of the added reagents). Bicinchoninic acid is used as a sensitive detection reagent, and 
produces a soluble purple product in a reaction with Cu1+. The optical density of the 
samples is then measured at 562nm and higher values represent high Cu \+ and hence high 
protein content in the original samples. 
The assay was performed in 96-well plates and required the addition of several standards 
of known protein concentration. Each standard was loaded in quadruplicate, with protein 
concentrations ranging from 0 - 2mg/ml. Volumes of lOf.l1 were loaded into each well. 
Samples of unknown protein concentration were diluted 1: 1 0 or 1 :20 before loading, also 
in quadruplicate. A working reagent consisting of 50 parts buffer A to 1 part buffer B was 
prepared and 190f.l1 added to each well, to give a total volume of 200f.ll. The plate was 
then covered in plastic film and agitated for 30 seconds before incubation at 37°C for 30 
minutes. The OD (562nm) of each sample was analysed on a microtitre plate reader. The 
resulting protein concentration data was analysed and graphically presented using Protein 
Concentration Analysis Software (Life Science International, UK). 
2.5.4 Gel electrophoresis: 
Precast 4-200/0 gradient polyacrylamide Tris-Glycine gels (l mm thickness, lOx 10 em, 10 
well configuration, EC6025, Gibco BRL, Paisley, UK) were used for all protein 
electrophoresis work. Volumes of cell lysate containing 50f.lg of total protein were added 
to the gel. In addition, 4f.l1 of seeblue molecular weight marker (Gibco BRL, Paisley, UK) 
was loaded. The marker consists of a mixture of proteins of known molecular weights, 
which can be used to estimate the molecular weight of any proteins detected in the cell 
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lysates. Gels were processed in Novex X-Cell gel tanks (Gibco BRL, Paisley. UK) 
containing 800 ml of electrode running buffer (see appendix A). The gels were then 
connected to an electrical power supply (250/2.5 Powerpack, Bio-Rad, California, USA) 
and ran at 180 volts for approximately 90 minutes (until the blue dye had ran to the bottom 
of the gel). Upon completion, gels were carefully removed from their plastic casing and 
prepared for protein transfer via Western blotting. 
2.6 Western blotting: 
Once separated on a gel, the protein constituents of a particular sample can then be 
transferred to a nitrocellulose membrane in a process called Western blotting (Burnette, 
1981). Again, this technique, like Southern blotting, is based upon the application of an 
electric current and subsequent electrostatic transfer of the proteins from the gel to a 
membrane. The membrane is then incubated in a solution containing a specific primary 
antibody raised against the protein of interest. This antibody is in turn recognised by a 
species-specific secondary antibody conjugated to a horseradish peroxidase enzyme. The 
final step involves detection of the protein-antibody complex via enhanced 
chemiluminescence (ECL). This process basically involves the addition ofECL reagents 
to the membrane and subsequent production of light via a reaction performed by the 
horseradish peroxidase enzyme (see figure 2.2). This light is detected by exposing X-ray 
film to the membranes in an X-ray cassette. The film is then developed to show a black 
band corresponding to the protein of interest. The intensity of the band can be measured 
using image analysis computer software and is representative of the levels of the particular 
protein in the original sample applied to the acrylamide gel. 
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Figure 2.2 Diagram summarising the principles of Western blotting 
2.6.1 Protein transfer 
The components used for each Western blot are two glass fibre pads two pieces of 3mm 
filter paper and one piece of HybondC membrane (Amersham Bucks UK). All 
components were pre-soaked for 30 minutes in transfer buffer ( ee appendix A). The 
components were then assembled together in a blotting cassette with the gel adjacent to 
the membrane and placed into a blotting module (Mini Trans, Bio-Rad, California, U A). 
The Western blot was then ran at 30 volts for 15-18 hours or 65 olts for 1 hour. Upon 
completion the membrane was remo ed from the cassette and subjected to staining with 
Ponc au solution ( igma, Poole, UK). This solution stains total protein and therefore 
provide an indication of whether the samples have ran through the gel correctly and al 0 if 
th ubs qu nt blotting procedure has b en successful. Pon au can al 0 pro id an 
indi ati n of th t tal prot in in a h Ian ,th r for if th arli r prot in as a ~a 
c rr ct, h uld b tain d t approximatel th The P n u 
wa r 111 db a h f th m mbran in di till d 'v'v t r. 
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2.6.2 Protein detection: 
The membrane was placed in a blocking solution containing 5% skimmed milk in TBS-
Tween (TBST, see appendix A) for 1 hour. This step aims to decrease any non-specific 
binding when antibodies are subsequently added to the membrane. The membrane was 
then incubated in 3ml of 5% milk TBST containing the relevant primary antibody for 1 
hour before washing in three changes of TBST for 5 minutes each. The fmal incubation 
was again in 3ml of milk TBST but this time containing the relevant secondary antibody 
(mouse or rabbit HRP conjugated secondary, depending upon the particular primary 
antibody used) (Dako, Glostrup, Denmark). Details of the antibodies used and their 
concentrations are provided in the table below (table 2-1). The membrane was then 
washed in TBST for 1 hour, with the buffer being changed every 5 minutes. The final step 
in the Western blotting procedure involves detection of the protein via EeL detection. 
2.6.3 EeL protein detection 
The EeL Western blotting detection system (Amersham, Bucks, UK) is based upon a light 
emitting reaction catalysed by the horseradish peroxidase (HRP) enzyme conjugated to the 
secondary antibody. The EeL reagents added to the membrane contain a variety of 
chemicals, which react to produce light in the reaction described below. 
The reaction exploits the HRPlhydrogen peroxide catalysed oxidation of a cyclic 
diacylhydrazide called luminol in alkaline conditions. Upon oxidation, luminol is in an 
excited state and subsequently decays to a lower energy ground-state via a light-emitting 
pathway. The EeL reagents also contain phenols, which enhance the light output by 
approximately lOOO-fold (Amersham Eel ™ product information booklet). 
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The methodology used in ECL detection is very simple, the excess TBST was first 
removed from the nitrocellulose membrane using absorbent paper. The two ECL reagents 
were mixed in a 1: 1 ratio for 1 minute before being added to the membrane for a further 
minute. Excess ECL reagent was removed from the membrane using absorbent towel and 
the membrane then wrapped in Sarin-wrap. The membrane was then placed in an X-ray 
cassette and exposed to X-ray film under infra red light conditions in a dark room. 
Exposure times vary depending upon the primary antibody being used and the abundance 
of the protein being detected, but ranged between 10 seconds and 20 minutes. The film 
was removed and developed in an automated continuous roller processor (X-ray Film 
Processor, RGII, Fuji Ltd, Japan). Membranes that were to be re-probed with an 
alternative antibody were stored in TBS at 4°C. 
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Target Antibody Epitope Dilution Source 
Protein 
PARP-l H-250 C-terminal 1 :1000 Santa Cruz 
Rabbit polyclonal Biotechnology 
Santa Cruz, USA 
Mdm2 Clone 14 C-terminal 1: 1000 Dr John Anderson 
Mouse monoclonal Dept Pathology 
University of Newcastle 
upon Tyne 
p53 CM5 polyclonal 1 :1000 Novocastra Laboratories, 
Rabbit polyclonal Newcastle upon Tyne, 
UK 
Actin AC40 C-terminal 1: 1 000 Sigma, Poole, UK 
Mouse monoclonal 
Table 2-1 Table of the antibodies used to detect various proteins 
2.7 Luciferase reporter gene assay 
A reporter gene assay is a technique involving the introduction of plasmid DNA into cells. 
The plasmid usually contains a gene downstream of a promoter site, the expression of 
which can be measured. For example, the reporter gene used in this study is a luciferase 
gene. This gene was inserted into a pGL3 plasmid. In addition, a p53 responsive promoter 
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(The P2 site of the Mdm2 gene) has been ligated into the plasmid upstream of the 
luciferase gene (Laing, H, PhD thesis, Cancer Research Unit, University of Newcastle 
upon Tyne). Therefore, introduction of this plasmid into cells should result in the 
expression of luciferase in a p53-dependent manner. In addition, when included in DNA 
damage response experiments, expression of luciferase should be increased due to 
increased transcriptional activity of p53. The luciferase produced can subsequently be 
measured using a luminometer (Becton Dickinson, Oxford, UK) 
Introduction of the luciferase plasmid into cells is achieved using transient transfection. 
Transfection is a common research technique involving the introduction of foreign DNA 
into cells and monitoring protein expression. In contrast to stable transfection, the foreign 
DNA is not required to be integrated into the genome. Transient transfection can be 
achieved using a variety of methods, including calcium phosphate coprecipitation, 
electroporation, the use of viral vectors and cationic liposome mediated transfection. The 
transfection method used in this study involved a reagent called FuGENE 6 (Roche, Basel, 
Switzerland), a multi-component lipid-based transfection reagent that complexes with and 
transports DNA into the cell during transfection. 
When trying to transiently transfect a cell line it is first necessary to optimise the 
conditions needed for transfection and expression of the plasmid. This work was 
perfol111ed by a colleague in the Cancer Research Unit, who developed and validated the 
luciferase gene reporter assay as part of a PhD course (Gillian Famie, PhD thesis, 
University of Newcastle upon Tyne). The basic transfection procedure involves the plating 
of a particular number of cells into a 35mm tissue culture plate. The cells are allowed to 
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grow overnight before addition of the transfection reagent/plasmid DNA mix. The 
expression of the reporter gene is then monitored over time. Therefore the factors to be 
optimised are the cell number plated out, the amount of transfection reagent per plate, the 
ratio oftransfection ratio to plasmid DNA(s) and the time at which optimum expression 
occurs. It should be noted that in addition to a luciferase plasmid, a plasmid encoding ~­
galactosidase is simultaneously transfected into the cells. This gene is under the control of 
a cytomegalo virus (CMV) promoter, which is not DNA damage-inducible and is included 
to act as an internal control for transfection efficiency. For example when using luciferase 
production as a measure ofp53 activity, it is important to demonstrate that any increase in 
luciferase is not simply due to increased transfection of the luciferase plasmid in that 
particular sample. Therefore, the results from luciferase experiments are plotted as a ratio 
of I uciferase/~-galactosidase. 
2.7.1 Preparation of luciferase/(i-galactosidase plasmids 
Both plasmids were prepared and purified according to previously described techniques 
(Section 2.2.1). Briefly, E.coli JMl 09 cells were transformed with the plasmid DNA and 
plated out under the selection of the relevant antibiotic. The plasmid was then purified 
using DNA mini and mega-prep kits (Section 2.2.1.2). Isolation of the plasmid was 
confirmed using agarose gel electrophoresis. Stock solutions of 0.2mg/ml of each plasmid 
were prepared in distilled water. 
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2.7.2 Transient transfection of plasm ids 
As described earlier, the conditions for transient transfection of the plasmids into the cell 
lines used in this study have been optimised by Gillian Farnie (Cancer Research Unit, 
University of Newcastle upon Tyne). 
Cells were trypsinised and counted. 1.5 x 105 cells were then placed in 2ml of medium in a 
35mm tissue culture plate (Nunc, Illinois, USA). For each time point of an experiment, 
three plates were used. Therefore upon luciferase analysis, it was possible to measure the 
standard error of a particular sample and hence get a measure of the statistical significance 
of any changes observed. For a typical DNA damage response experiment, 15 plates were 
used, corresponding to time points of untreated, 1 h, 2h, 3h and 6h. The cells were grown 
for 24 hours before addition of the transfection reagent, which contained the following: 
Per plate 2JlI of FuGENE 6 
100JlI of serum free culture medium 
FuGENE 6 was added to the serum free medium in a 20ml Universal and left for 5 
minutes. It is important that during addition the FuGENE 6 reagent does not come into 
direct contact with the plastic of the tube as this can adversely affect transfection 
efficiency. 
Per triplicate 5JlI of 0.2mg/mlluciferase plasmid 
1 JlI of 0.2mg/ml ~-galactosidase plasmid 
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The relevant volume of each plasmid is then added to the serum free mediumlFuGENE 6 
mixture. After gentle mixing (no vortexing), the solution was left for 15 minutes. 100JlI of 
the mixture was then added to each plate of cells for 24h. 
After 24h transfection, the cells were ready for treatment with particular DNA damaging 
agents +/- AG14361. Samples were taken at the required time points by the removal of 
culture medium and addition of200!J.1 of lysis buffer to the plate (part of the Dual LightTM 
assay kit, Perkin Elmer, Conneticut, USA). After 5 minutes, the samples were collected by 
washing the lysis buffer over the surface of the plate twice before transfer to a O.5ml 
eppendorf microfuge tube. Samples were stored at -20°C prior to analysis. 
2.7.3 Analysis of sam pies 
Samples were analysed by measuring the levels of both luciferase and ~-galactosidase in 
each sample. Measurement involved the use of a Dual Light ™ assay kit and a 
luminometer. The analysis was performed in black and white 96-well plates (Wallac) by 
adding 5!J.I of each sample to an individual well. The plate was then inserted into the 
luminometer and the luciferase and ~-galactosidase values measured after the automated 
addition of various reagents. These reagents were supplied as part of the Dual Light Assay 
kit. 
2.7.3.1 Principles of the Dual Light Assay Ti\1 
The transcription of the plasmids transfected into cells results in the expression of both 
luciferase and ~-galactosidase. The levels of expression of each of these enzymes can be 
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monitored using the dual light assay kit. This involves adding various reagents (supplied 
within the kit) to a sample of cell lysate. The reagents contain substrates for the enzymes. 
Upon catalysis, light is emitted from the reaction. It is the intensity of this light which is 
measured by the luminometer and should be proportional to the amount of luciferase or ~_ 
galactosidase within the cellular sample. The reaction resulting in the production of light 
is summarised below: 
ATP + D-Luciferin + O2 
LUCIFERASE 
---__ .... ~~ Oxyluciferin + AMP + PPi 
+ CO2 + LIGHT 
Briefly, 25/-11 of buffer A is added to a well followed by a 15 second delay. 100/-11 of buffer 
B is then added to the same well and the light measured after a further 15 seconds. To 
measure the ~-galactosidase, the samples are left for approximately 1 hour after the 
addition of buffers A and B before adding 100/-11 of accelerator II solution. After a 15 
second delay, the light intensity is measured. All readings are converted into a ratio of 
luciferase/~-galactosidase and analysed using Microsoft Excel software. 
2.8 Measurement of poly(ADP-ribose) polymerase activity 
Two methods have been used for the measurement of P ARP-l enzyme activity in this 
study. The basis of both methods described in this section is the introduction of a short 
double stranded oligonucleotide into cells to simulate DNA strand breaks and hence 
activate PARP-I. Both techniques require the prior permeabilisation of cells by 
suspending cdls in a butTer containing digitonin (a mild detergent). This makes 
membranes' leaky' and hencl' both oligonucleotide and exogenously added NAD~ are able 
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to freely enter cells, but macromolecules such as P ARP-l cannot exit the cell. In the first 
technique described, the reaction mix also includes y-e2p] labelled NAD+, which acts as a 
substrate for PARP-l. This leads to the production of e2p] labelled ADP-ribose on various 
target proteins, which can be precipitated with TeA and bound to filters. Scintillation 
counting will then provide an estimation of the radioactive content of each sample and 
hence a measure of the P ARP-l activity. 
The second technique discussed does not involve the use of radioactivity; rather an 
immunoblotting method is used to detect the ADP-ribose polymer that is bound to a nylon 
membrane and subsequently probed with a monoclonal antibody directed specifically 
against ADP-ribose polymer. 
2.8.1 Incorporation of radio labelled NAD+ into permeabilised cells 
2.8.1.1 Preparation of 32P-labelled NAD+ 
The NAD+ used in this assay actually consists ofa cocktail of normal (non-radioactive) 
NAD+ mixed with a small amount of e2p]-NAD+. A 600mM stock solution of ~-NAD+ 
(Sigma) was prepared in distilled H20. The precise concentration of this solution was 
determined using spectrophotometry by measuring the OD at 260nm. ImM NAD+ has an 
absorbance of 18 OD units therefore it is possible to prepare a working solution of 600J,!M 
from the concentrated stock. The NAD+ was diluted in distilled H20. To this a small 
volume of e2p]-NAD+ (Amersham pharmacia biotech) was added (2 - 5J,!1 depending 
upon the activity of the e2PD. 
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2.8.1.2 Permeabilisation of cells 
The relevant number of cells was prepared by trypsinisation and counting (1 x 106 per 
assay). This suspension was spun down at 1500rpm for 5 minutes and the pellet rinsed in 
ice cold PBS. The cells were spun again, the supernatant removed and the cells 
resuspended in 1.5ml of digitonin (150J,1g1ml in sterile H20). After 15 minutes incubation 
on ice, 13.5ml of ice-cold isotonic buffer was added (see appendix A). Permeabilisation of 
the cells was confirmed by staining a small number (5J,11) with trypan blue (5J,11). The 
suspension was loaded onto a haemocytometer and the cells viewed under a microscope. 
Trypan blue can enter permeabilised cells and hence stain them blue. For efficient 
permeabilisation, > 990/0 of cells should be stained blue. After permeabilisation, cells were 
kept on ice and assayed immediately. 
2.8.1.3 PARP-l assay 
The following components were included in the reaction mix: 10J,11 of palindromic double 
stranded oligonucleotide (CGGAATTCCG, prepared at 200J,1g/ml in Tris.HCI, pH 7.8), 
50J,11 ofNAD+ cocktail (prepared as described in Section 2.8.1.1), 8J,11 of DMSO or DMSO 
containing AG 14361 and 37J,11 of distilled water. The sequence of the oligonucleotide used 
is such that it forms a hairpin structure due to the complementary nature of the bases in 
each half of the oligo. The formation of a hairpin produces a double-stranded DNA end at 
one extreme of the oligonucleotide. The reaction components were pre-incubated at 26°C 
in a shaking waterbath and the reaction started by the addition of 300J,11 of permeabilised 
cell suspension (1 x 106 cells). The initiation of individual reactions was staggered by 10 
seconds. The reaction was performed for 5 minutes before the addition of 2ml of ice cold 
100/0 TCA (w/v), 100/0 sodium pyrophosphate (w/v) (both from Sigma, Poole. UK). The 
actual reaction performed is summarised below: 
106 
+ protein 
acceptor 
PARP~ 
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(ADP-ribose )n-protein 
+ nicotinamide 
The TCA will precipitate high molecular weight material, including poly(ADP-ribosyl)ated 
proteins, whereas low molecular weight radiolabelled NAD+ will remain in solution. 
Assay blanks, to correct for non-specific binding of the radiolabel to the filter were also 
prepared by adding 2ml of TCA before the cells, thereby preventing initiation of reaction. 
All tubes were incubated for 1 hour on ice. 
The precipitated macromolecules were then bound to 25mm (GF/C) microfibre filters 
(Whatman International Ltd, Maidstone, Kent) using a Millipore filtration apparatus 
(Whatman International Ltd, Maidstone, Kent). Soluble components are able to pass 
straight through the filters therefore, only large insoluble molecules, including poly(ADP-
ribosyl)ated proteins will remain bound to the filters. The filters were soaked in 1 % TeA 
(1 % w/v TCA, 1 % w/v sodium pyrophosphate) and placed onto the filter holder. The 
funnel assembly was placed on top and the individual samples added to the funnels. Each 
sample was rinsed 4 times with 1 % TCA, under gentle suction pressure. Each filter was 
removed and allowed to dry before being placed in liquid scintillation vials (20ml, Packard 
Instrument Company, USA). 10ml of scintillation fluid was added to each filter followed 
by thorough shaking of the vials. To provide a measurement of the specific activity of the 
radiolabeL 2J.lI of the NAD+ cocktail was added to 20ml of scintillation fluid. All samples 
were analysed on a ~-particle scintillation counter (Wallac Scintillation Products) for 3 
minutes. All data points were performed in triplicate. 
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2.8.1.4 Analysis of results 
The first step in the analysis of the raw data was to calculate the number of counts 
representing 1pmol ofNAO+. This was achieved by calculating the mean OPM of the 
three standards (SM), which are the samples containing only NAO+ cocktail and scintillant. 
This figure was then divided by the concentration ofNAD+ used (600J..lM), to give value C: 
SM/4000 = OPM/pmol NAD+ 
The amount ofNAO+ incorporated into the TCA precipitate is representative of the level of 
AOP-ribose polymer formation. Therefore, the pmol NAO+ present in each of the samples 
(P) after the 5 minutes incubation was calculated. 
The mean of the To samples, TOM, was determined and subtracted from each of the sample 
counts, removing the non-specific background counts: 
P - TOM = Po 
The values of Po were then divided by the number ofOPM equivalent to 1pmol NAO+ (C, 
calculated earlier): 
PolC = pmol NAO+ in each sample, Cs 
As the volume of cells added to each sample was 300J..lI, Cs represents the pmol 
NAO+/300J..lI of cell suspension. Therefore, to determine the pmol NAO+ in 1ml of cell 
suspension (1 x 106 cells), Cs was multiplied by 3.33. The cell count taken prior to the 
experiment was then utilized to allow the final result to be represented as : 
Pmol NAO+ incorporatedll 06 cells/5min 
2.8.2 Immuno dot-blot measurement of P ARP-l activity 
This technique was developed and validated based on an assay described by Affar et al.. 
1998. It involves the initial permeabilisation of cells to allow entry ofNAD+ and double 
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stranded oligonucleotide. The oligonucleotide used is the same as that in Section 2.8.1.3. 
Detection of ADP-ribose polymer is by antibody binding. The reaction was performed for 
6 minutes and was stopped by the addition of an excess of PARP-l inhibitor. AG 14361. 
The samples were then bound to nylon membrane using a 96-well dot-blot manifold and a 
vacuum pump. The membrane was finally probed with a mouse monoclonal antibody 
directed against ADP-ribose polymers (clone 10H, a gift from Alexander Burkle. 
Department of Gerontology, Newcastle General Hospital). This antibody is a mouse 
monoclonal, raised against ADP-ribose polymer of chain length 10 - 50 units. No cross-
reactivity with other macromolecules such as RNA or DNA has been detected. In addition 
the antibody does not detect monomers of ADP-ribose and NAD (Kawamitsu et al., 1984; 
Menard and Poirier, 1987; Kupper et al., 1990). 
2.8.2.1 Permeabilisation of cells 
The required cell number was prepared by trypsinisation and cell counting. The 
suspension was spun at 1000rpm for 5 minutes at 4°C and the cells rinsed in ice-cold PBS. 
After a second identical spin, the cell pellet was resuspended in permeabilisation buffer 
(see appendix A) at a density of3 x 106 cells/l00J..l1. Each reaction required 5 x 105 cells. 
This suspension was left on ice for 1 minute before the addition of 4ml of ice-cold 
permeabilisation bufferll OOJ..lI of cells. The cells were then spun down at 1000rpm for 10 
minutes at 4°C and the pellet resuspended in ice-cold penneabilisation buffer at a density 
of 5 x 105cells/53J..l1 (therefore 53J..lI per reaction). 
2.8.2.2 PARP-l assay 
The following reaction components were added to 5 x 105 (53J..lI) cells on ice: 13J..llof 
double stranded oligonucleotide (13J..lI of 384.6J..lg/ml oligo gives a final concentration of 
50J.lg/ml) and 34J .. d of 3 x reaction butTer (appendix A) to give a total volume of 100J..l1. IIlI 
109 
Chapter 2 - Materials and Methods 
of lOOIlM AG14361 (in 1% DMSO) or 1% DMSO, as control, was also included in the 
relevant samples. The reaction was initiated by the addition of cells and transfer of the 
tubes to a shaking waterbath at 30°C. Initiation of reaction was staggered by 10 seconds 
and the reaction stopped by adding 400/.11 of 1.25/.1M AG14361 (final concentration l/.1M) 
and transferring the tubes to ice. Each tube contains 5 x 105 cells in a total volume of 
500Ill. Therefore, the concentration of cells is 1000 cells//.1l. Optimisation studies haye 
shown that 1000 cells is the optimum number to load onto the membrane. 1/.11 of reaction 
mix was added to 19/.11 of PBS and this was in tum added to Hybond N membrane 
(Amersham, Bucks, UK) which is assembled into the dot blot apparatus on top of a piece 
of Whatman filter paper. The sample was passed through the membrane by vacuum 
aspiration. The negatively charged polymer binds to the membrane. The membrane is 
then rinsed with 200lli of 100/0 TCA (w/v), 2% sodium pyruvate (w/v) and 400/.11 of 700/0 
ethanol (v/v, ethanol/H20) before the dot-blot apparatus is disassembled and the membrane 
rinsed several times in PBS. 
2.8.2.3 Detection of ADP-ribose polymer 
The membrane was incubated in a solution of 5% dried skimmed milk in PBST (phosphate 
bufferes saline, containing 0.1 % Tween20, see appendix A) for 1 hour. This step is to 
reduce any non-specific binding of the antibody in subsequent steps as proteins in the milk 
will bind to such sites and hence prevent binding of the antibody. The membrane is then 
incubated in the primary antibody (lOH at a concentration of 2.5/.1g/ml in 3ml of 50/0 milk-
PBST) for 3h before being washed 3 times in PBST for 5 minutes each and transferred to 
the relevant secondary antibody (goat anti mouse, HRP-conjugated. 1 :3000 in 50/0 milk 
PBST; Dako, Glostrup. Denmark) for 1 hour. After thorough washing in PBS, the blot was 
visualised using EeL (Amersham, Bucks, UK, see Section 1.6.3). 
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2.9 DNA sequencing 
The sequencing of cDNA is a means of analysing the nucleotide sequence of a particular 
gene, which can in tum be used to evaluate the amino acid sequence of the resultant 
protein. The precise amino acid sequence determines the secondary and tertiary structure 
of a protein. Therefore any sequence changes are likely to result in disruption of structure 
in some way, by interfering with the formation of essential chemical bonds between amino 
acids in the folded protein. This is likely to bring about an altered protein function or even 
abolishment of the function altogether. 
In this study, only the coding region of the gene of interest was sequenced. Therefore it is 
necessary to initially isolate cellular mRNA (Section 2.2.3) and then produce cDNA using 
the RNA as a template. 
2.9.1 First strand eDNA synthesis 
The production of cDNA from a cell relies heavily upon the initial isolation of an intact, 
pure sample of RNA. This RNA is then able to act as a template for a reverse transcriptase 
enzyme, which produces DNA from sequences of RNA. 
cDNA has been produced in this study using The SUPERSCRIPT™ First-Strand Synthesis 
System (Gibco BRL, Paisley, UK), which is effective when using amounts of total RNA 
ranging from 1 ng to 5J.lg. This technique is based on the polymerase chain reaction 
(Section 2.10.2) and, as such requires the initial binding of primers to the RNA before 
elongation of the primers by a reverse transcriptase enzyme. Random hexamer primers 
were used in this study. With this method, all RNAs in a population are templates for first-
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strand cDNA synthesis. This helps to ensure that the mRNA of interest is reverse 
transcribed and subsequent PCR reactions on the cDNA using designed primers will 
specifically amplify the region of interest. Other types of primers may be used, for 
instance oligo( dT) primers bind to the poly(A) tails of mRNA. However, only 1-2% of 
total RNA possesses such tails and therefore, the cDNA yield is lower using this method. 
The bound primers are then elongated using a SUPERSCRIPT II RNase H- reverse 
transcriptase (RT) that has been modified to optimise the production of cDNA. This 
enzyme has been genetically modified to eliminate the Rnase activity, which is associated 
with other RTs. This Rnase activity would obviously degrade the mRNA during first-
strand synthesis. In addition, SUPERSCRIPT II RT is not significantly inhibited by 
ribosomal and transfer RNA and can therefore be used to efficiently synthesise cDNA 
from a total RNA preparation. Finally, the enzyme exhibits increased thermal stability and 
may be used at temperatures up to 50°C. The combination of all these factors results in 
greater full-length cDNA synthesis and higher cDNA yield when compared to other RTs. 
2.9.2 The polymerase chain reaction 
The process of DNA sequencing relies heavily on a common research technique known as 
the polymerase chain reaction (PCR). This involves the amplification of a target sequence 
of DNA using a pair of oligonucleotides (called primers) complementary to regions 
flanking the target sequence of DNA. One primer binds to the sense strand and the other to 
the antisense strand of DNA. Basically these oligonucleotides bind the complementary 
flanking sequence and a DNA polymerase, included in the reaction mix, extends the ends 
of the primers using the original DNA sequence as a template. By adjusting the 
temperature accordingly, it is possible to repeat this reaction many times and hence 
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amplify the number of copies of the target sequence in the original sample. The reaction is 
explained in more detail in figure 2.3. 
113 
5' 
3' 
5' 
3' 
5' 
3' 
5' 
3' 
3' 
Chapter 2 - Materials and Method 
a b 
a' b' 
b 
b' 
c 
c' 
d 
d' 
Separate strands by 
heating to 95°C 
Hybridise primers by 
cooling to 54°C 
d 
3' 
d' 
Synthesize new DNA by 
extending primers at 72°C 
L....--___ ....I--___ ---'--___ --'_ 5' 
a' b' c' d' 
a b c 
e 
e' 
d 
5' 
......... --------~----~~~----~ : ! 
1 1 
! : 
3' 
5' 
3' 
5' 
3' 
5' 
3' 
3' 
5' 
Figure 2.3 Diagram ummari ing the polymera e chain reaction 
riginal DNA i h wn in turquoi , omplim ntar primers in blue and red and nev" I} )nth i ed D 
h wn in II v . Ne\ I nth i d DNA i abl to a t as a templat in ub qu nt cycle ofth bO\ 
rea tioll. 
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The components of the reaction are: An original source of DNA containing the sequence of 
interest (for example a sample of tumour), a heat stable DNA polymerase, a pair of primers 
that bind to complementary sequences both 3' and 5' of the target sequence and all four 
deoxyribonucleoside triphosphates (dNTPs). The actual reaction involves several heating 
and cooling cycles and is depicted in figure 2.3 
The reaction mix is heated to 95°C for 15 seconds to separate the double stranded target 
DNA. The solution is then quickly cooled to 54°C to allow each primer to anneal to target 
DNA sequences. Including the primers in large excess prevents reformation of original 
double stranded DNA. Primers are typically 20-30 nucleotides long and as such, contain 
enough sequence information to prevent binding to regions other than the target sequence. 
The final step in the polymerase chain reaction is the heating of the solution to 72°C, the 
optimum temperature for the heat stable DNA polymerase thus allowing DNA synthesis to 
occur. The orientation of the bound primers is such that the target sequence will always be 
copied as DNA synthesis occurs in the 5' to 3' direction. The DNA polymerase used 
(called Taq polymerase) is isolated from a heat stable bacterium called Thermus aquaticus. 
The DNA produced can then itself act as a template for the primers and hence the reaction 
described results in an exponential amplification of the target DNA. Most PCR reactions 
are performed for about 30 cycles, which produces a billion fold amplification of the 
sequence of interest. 
It is often necessary to optimise a PCR procedure to increase the yield and specificity of 
the reaction. For example, the concentration of magnesium chloride frequently needs to be 
modified. For example if a particular PCR reaction has too Iowa magnesium 
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concentration then the yield of PCR product is lowered. Alternatively, high magnesium 
may increase the amplification of non-specific PCR products. The reaction mix used here 
produced a good yield of the desired PCR product and hence optimisation of the reaction 
was not required. 
The cDNA used in the PCRs has been derived from PARP-1 MEFs. The process involves 
the initial isolation of cellular RNA followed by production of the corresponding cDNA by 
RT-PCR. The PCR reaction was performed originally using a 'standard recipe', the 
components of which are listed below. 
1 f.!l 
4.2f.!1 
2.5f.!1 
0.15f.!1 
1.075f.!1 
5 f.!l 
lOf.!1 
1 00 stock of each primer of a particular pair 
H20 
Reaction buffer 
Taq polymerase 
dNTP mix (0.1 mM final concentration) 
MgCh (final concentration 1.5mM) 
cDNA (diluted 1110 from original stock) 
The reaction components were mixed thoroughly and heated to 94°C for 3 minutes. This 
was followed by 30 cycles of (94°C for Imin, 58°C for 2mins and 72°C for 3mins). After 
30 cycles the temperature was held at 4°C 
It is also important to prepare a 'blank' peR reaction. This tube contained all components 
of the reaction except for the eDNA. Instead, 10JlI of distilled \vater was added to the 
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reaction mix. This ensures that any PCR products are actually a product of the target DNA 
and not just some contaminant DNA that has somehow entered the reaction. 
To demonstrate that the PCR reaction has been successful, it was necessary to analyse the 
products on an agarose gel, alongside a molecular weight marker. Comparison of PCR 
products to the marker will reveal whether the products are of the correct predicted size. 
Ideally, if the PCR reaction has been efficient and specific, only one band should be 
present in each lane. In addition, it is important that no bands are present in the lanes 
corresponding to the blank PCR reactions. The fragments of DNA were then purified from 
the agarose gel (Section 2.2.1.3). 
2.9.2.1 Design of peR primers 
The primers used were designed using DNA STAR software, which uses certain criteria 
when selecting a sequence for a primer. Generally, primers are between 18 and 30 base 
pairs long, which should ensure that the primers contain enough sequence information to 
eliminate non-specific binding of the primers. In addition the primer pair should not 
contain complimentary sequences as this may lead to primer self-annealing and thus 
prevent binding of primers to the target DNA. Ideally, primers should contain 45 - 55% of 
G or C bases. These bases form three hydrogen bonds compared to two for AT base pairs. 
This increases the binding efficiency of the primers. However, long stretches of Gs and Cs 
should be avoided in primers as this can promote non-specific binding. Likewise, for long 
stretches of As and Ts. Finally, it is best if the 3' end of the primer contains several GC 
residues. It is the 3' end that is extended during synthesis and the presence of G and C 
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bases at this point help clamp the primer to the DNA and can increase the efticiency of 
initiation and also increase the length of the PCR product. 
2.9.2.2 Primer synthesis 
All primers were kindly produced by Helen Atkins (Cancer Research Unit Uniyersitvof 
, . 
Newcastle upon Tyne), using an automated Applied Biosystems model 392 
oligosynthesiser (Applied Biosystems, California, USA). When synthesised, the 
oligonucleotides, which were dissolved in ammonia, were in the unreactive phosphodiester 
form, with their bases protected by amide groups. Before use, it was necessary to 
deprotect the oligonucleotides by heating at 55°C for 10 to 12 hours. 
2.9.2.3 Primer quantification 
The deprotected oligonucleotides were placed into 1.5ml Eppendorf tubes in 400lli 
aliquots. The DNA was dried down by piercing the lids of the tubes with a 21 G needle and 
spinning in a vacuum centrifuge (Savant, Speedvac SC 1 00) for approximately one hour. 
The primers were then resuspended in 400lli of sterile distilled H20. After thorough 
mixing, the concentration of the primers was determined according to Section 2.2.4 and 
diluted to a working concentration of 12pmolllli (laD). Reconstitited primers were stored 
2.9.3 Dye terminator cycle sequencing 
The common method for the sequencing of DNA is the Sanger dideoxy method (Sanger, 
1981 Science). In a standard PCR reaction, dNTPs are included which are used by the 
DNA polymerase to extend the bound primer. However, the sequencing reaction also 
includes ddNTPs (dideoxyribonucleoside triphosphates), which lack the 3' hydroxy 
tem1inus that is essential for elongation of the DNA strand. Therefore, when a ddNTP is 
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incorporated into a PCR product, no further elongation takes place. This results in the 
production of a mixed population of DNA fragments, all of different lengths, depending 
upon where the PCR was terminated. The ratio of dNTPs to ddNTPs is optimised such 
that long PCR products can be produced as well as only very small PCR products. The 
particular sequencing kit used in this study relies on the fact that each of the ddNTPs used 
contains a different fluorescent tag whose excitation and emission spectrum is in the near 
infrared region. The reaction mixes are then ran through a gel (that will separate the 
fragments based upon their size) and the separated bands of DNA are then detected by 
their fluorescence as they emerge from the gel. For example, termination at A may give a 
red fluorescence and termination at C may give a blue signal. Detection of the fluorescent 
signal by an automated sequencing machine (Beckman CEQ 2000) allows for the sequence 
to be derived as each of the fragments emerges from the gel. It should be noted that each 
sequencing reaction contains only one of a primer pair. This ensures that every double 
stranded DNA product from a standard PCR reaction is analysed in both the sense and 
antisense direction during sequencing. 
2J.d of the purified PCR products from Section 2.10.2 were added to SJlI of H20 and 3JlI of 
loading buffer (see appendix A) and analysed on a 1 % agarose gel to confirm the 
purification of fragments of the desired size. These products were then used in the 
following sequencing reaction mix: 
Distilled H20 SJlI 
lOx reaction buffer 2JlI 
dNTP mix 1 JlI 
ddUTP dye terminator 2J..lI 
ddGTP dye terminator 2J..lI 
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ddCTP dye terminator 2111 
ddA TP dye terminator 2111 
DNA polymerase 1 III 
cDNA 1 III 
primer (10 D stock) 2111 
All components were supplied in a CEQ TM2000 Dye Terminator Cycle Sequencing Kit 
(Beckman Coulter) except for the cDNA and primers. The reaction was performed in 
200lli PCR tubes according to the following thermal cycling program: 
96°C 20 secs 
50°C 20 secs 
60°C 4 mins 
for 30 cycles followed by holding at 4°C 
Each of the sequencing reactions was then transferred to a 0.5ml eppendorftube containing 
4111 of Stop Solution (1.5M NaOAc + 50mM EDTA) and 1 III of20mg/ml glycogen. The 
salt and glycogen present facilitate subsequent precipitation of the DNA from the reaction 
mix. It is important that the stop solution is prepared immediately before use and that it is 
kept at room temperature otherwise the EDT A may precipitate out of solution. The 
components were mixed thoroughly before addition of 60111 of ice cold 95% (v/v) 
ethanol/H20 and mixed thoroughly to aid optimal precipitation of the DNA. The samples 
are then centrifuged at 14000rpm (Eppendorf 5417R) at 4°C for 15 minutes. After 
spinning, a pellet should be visible in the base of each tube. The supernatant is carefully 
removed with a micropipette before \\ashing the pellet a further two times in ice cold 700/0 
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ethanol. After each wash the samples are centrifuged at 14000rpm at 4°C for 5 minutes. 
The purpose of the washing steps is to remove the residual salts in the sample. Since salts 
are preferentially loaded on the CEQ, fewer sequencing fragments will be loaded. In 
addition, it is important not to leave the samples in ethanol for too long as this may actually 
cause precipitation of the salts that you are trying to remove. After the final washing step, 
as much ethanol as possible was removed from the pellet before allowing the DNA to air 
dry for approximately one hour. It is important to allow the pellet to dry completely as 
residual ethanol will suppress the signal on the CEQ. Finally, the DNA pellet was 
thoroughly resuspended in 40,.d of deionised formamide and the sample transferred to a 
CEQ sample plate. A drop of mineral oil was then placed on top of each sample. The oil 
protects the dyes and hence increases their stability. The plate is loaded into the CEQ and 
the samples analysed. 
2.9.4 Analysis of sequencing data 
The sequencing data derived from the CEQ was saved onto a CD and analysed using CEQ 
sequence analysis software. The raw data is in the form of a trace of peaks of 4 different 
colours, one for each of the four bases. From this trace, the software predicts a sequence of 
bases and displays the sequence on the screen. 
The sequence produced was copied and pasted into a BLAST2 sequence alignment 
program (available on the world wide web through www.NCBI.com). The sequence was 
aligned to a \\"ild type murine p53 sequence that had been deposited previously into the 
BLAST database (accession # XO 1237). The program aligned tht: inputted sequence to the 
preYiously published sequenct: and complementary sequences are shown alongside each 
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other, with matching bases joined by lines. Any abnormalities in the inputted sequence are 
highlighted by the lack of a line between bases. These areas may be due to the CEQ being 
unable to read that particular area of sequence. Such areas can be checked by analysing 
the results from the complementary strand of DNA. For example, imperfect areas of 
sequence on the sense strand of a particular DNA fragment can be validated using the 
sequencing information from the antisense strand of the same fragment. In addition, 
abnormalities in sequence should be referenced back to the actual raw data derived from 
the sequencing machine. On occasions, the sequencing software does not recognise a 
particular peak as a base even though the raw data clearly shows a peak corresponding to a 
particular base. Alternatively, any mismatched bases in the inputted sequence may 
actually be due to a mutation at this point. Again, the raw data should be checked and the 
sequencing data of the other strand analysed. For a homozygous mutation (where both 
copies of the gene have been mutated), both the sense and antisense strand will show 
exactly the same mutation. In the presence of a heterozygous mutation (where one copy of 
the gene remains wild type), the raw data trace should show two peaks at that point, one on 
top of the other. 
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3.1 Introduction and objectives 
The principal aim of this project was to test the hypothesis that p53 is regulated by PARP-1 
in response to DNA damage. The obvious way to test this hypothesis is to remove P ARP-
1 from cells and investigate the DNA damage-induced p53 response. Several techniques 
have been used to remove P ARP-1 activity from cells. These include the use of antisense 
RNA, a dominant-negative strategy involving the overexpression of the DNA binding 
domain of P ARP-1, use of small molecule inhibitors of P ARP-1 and finally knocking out 
the PARP-1 gene (Simbulan-Rosenthal et aI., 1998; Lu and Lane, 1993; Wang et aI., 1998; 
Agarwal et aI., 1997; de Murcia et ai., 1997; Masutani et aI., 1999). All strategies have 
been successful to a large extent in removing PARP-1 activity. However, there is currently 
no consensus of opinion on the subsequent effect of loss of P ARP-1 function and/or 
protein on p53 induction and activity. The data presented in this thesis compared two 
techniques for removing PARP-1 activity:- knockout cells (de Murcia et al., 1997) and a 
potent PARP-1 inhibitor (AG14361, provided by Pfizer GRD). It should be noted that the 
P ARP-1 knockout cells are mouse embryonic fibroblasts, disrupted in exon 4 of the P ARP-
1 gene (Figure 3.l). Other groups have also produced mice disrupted in exon 1 (Masutani 
et aI., 1999) and exon 2 (Wang et ai., 1997), and again p53 studies on cells derived from 
these mice are not consistent. The inhibitor used in this study, AG14361, was developed 
by the Experimental Therapeutics Group (University of Newcastle upon Tyne) in 
collaboration with Pfizer GRD. It is a competitive inhibitor (i.e. competes with NAD+ for 
the active site ofPARP-1) and has been shown to have a k i < 6nM in cell-free assays. As 
such, it is approximately 1000-fold more potent than the archetypal PARP-1 inhibitor, 3-
aminobenzamide (k i = 5.7J..lM). 
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The aim of this chapter was to confirm that the P ARP-l knockout cell lines obtained from 
Gilbert de Murcia were disrupted in the P ARP-l gene, and to demonstrate the loss of 
P ARP-l protein and enzyme activity. In addition, the effects of AG 14361 alone on 
enzyme activity and on cell growth were studied, using the SRB assay (Section 2.1.7). 
This chapter contains results showing the effectiveness of the strategies used to remove 
P ARP-l activity from cells. These include Southern blots and enzyme assays. In addition, 
SRB assays are presented showing that AG14361 alone has no growth inhibitory effect 
during the time-scales of experiments (24 - 72 hours). Finally, results are presented 
showing the development, validation and optimisation of two techniques used to estimate 
levels of poly(ADP-ribosyl)ation within cells. These techniques were set up to evaluate 
the ability of AG14361 to inhibit PARP-l in PARP-l proficient MEFs and human HCT-
116 cells. Also, these techniques were used to confirm that the disruption of P ARP-l in 
the PARP-rl- MEFs resulted in the loss ofPARP-l enzyme activity. 
3.2 Results 
3.2.1 Disruption of exon 4 in P ARP-l MEFs 
Figure 3.1 shows the disruption of the P ARP-l gene by the insertion of PGK -neo 
(phosphoglycerate kinase promoter) into exon 4 of the PARP-l locus (de Murcia et aI., 
1997). The disruption of P ARP-l in exon 4 leaves a significant part of the P ARP-l gene 
intact, with both zinc fingers of P ARP-l being encoded by regions upstream of exon 4. 
Importantly, studies using Northern blotting and Western blotting with antibodies 
recognising the zinc finger domains did not detect any truncated version of PARP-l in 
PARP-I-1- MEFs (Trucco et aI., 1998). The wild type PARP-l gene contains two EcoRI 
sites, which upon digestion give rise to a fragment of 9.6kb. The disruption of the PARP-l 
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gene introduces an extra EcoRI site into the P ARP-l locus and hence upon EcoRI 
digestion, produces a fragment of 3.3 kb. Therefore, Southern blotting should produce 
bands at the corresponding sizes when using the radiolabelled probe (shown in figure 3.1). 
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Figure 3.1 Disruption of ex on 4 in PARP-I-1- MEFs. 
The wild type PARP-1 locus has two EcoR1 (E) sites, separated by 9.6kb. The insertion of a 
neomycin resistance cassette (PGK-neo) into exon 4 in the PARP-1 knockout MEFs results in the 
insertion of an extra EcoR1 site. The highlighted 5' probe detects different sized genomic DNA 
fragments in the PARP-1+1+ and PARP-1 -1- MEFs. Xb = Xbal restriction site 
(Diagram adapted from de Murcia et al., 1997) 
3.2.2 Preparation of the probe for outhern blotting: 
The plasmid containing th probe for outhern blot analysis f g n mic DNA from \ ild-
typ and kno k ut mou e ti u and M \ a kindl pro id d by ilbert d Mur ia 
( Ie up ri ur de Bi t chn 1 gie d tra burg). h pr b nit d fa O.8kb 
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EcoRl- XbaI genomic fragment. E.coli 1Ml 09 cells were transformed with the plasmid 
and streaked onto agar plates supplemented with ampicillin. Resistant colonies were 
picked and bulked up initially in 50ml of LB. The plasmid was then purified from these 
cells using a mini-prep kit (Qiagen) and digested with EcoRI. The resultant products were 
analysed by electrophoresis on a 0.8% agarose gel. A band corresponding to the 0.8kb 
probe was clearly seen alongside the uncut plasmid sample (data not shown). As can be 
seen in Figure 3.1 , centre panel, the 0.8kb probe should bind to the 5' end of the PARP-l 
gene, which is intact in both the P ARP-1 +1+ and P ARP-1-1- MEFs and should recognise a 
9.6kb fragment in the wild-type DNA and a 3.3kb fragment in the knockout DNA. Greater 
numbers of transformed E.coli cells were grown in 500ml LB and larger stocks of the 
P ARP-l probe were produced using a mega-prep kit (Qiagen) followed by EcoRl 
digestion. Agarose gel electrophoresis again confmned the isolation of a 0.8kb fragment 
of DNA. Several such bands were excised from the gel and the DNA purified using a gel 
extraction kit (Qiagen). Finally, a sample of purified PARP-1 probe was checked by 
electrophoresis on a 0.8% agarose gel confirming the success of the purification step 
(Figure 3.2). 
lkb O.8kb 
• PARP-1 
O.5 kb 
Figure 3.2 Ilro C gel h \\ ing uncut p8 pIa mid a nd Eco RI dige ted and purifi dO. kb fra ment 
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3.2.3 Southern blotting 
After preparation of the P ARP-I probe, it was necessary to isolate genomic DNA from the 
PARP-I MEFs and perform EcoRI digestion of the DNA before separating the fragments 
on an agarose gel. DNA extraction and purification was performed on pellets of 1 x 107 
cells (PARP-I +1+ and PARP-I-1- immortalised MEFs). 20J,!g of DNA for each cell line was 
then digested overnight with EcoRI. 1 J,!g of the digestion was checked by electrophoresis 
on a 0.8% agarose mini-gel to confirm efficient digestion of the DNA. If the DNA was not 
properly digested extra restriction enzyme and buffer was added to the sample and again 
left overnight. Inefficient digestion is indicated by a gathering of high molecular weight 
DNA near the top of the gel. Instead, the DNA should be well-spread down the length of 
the gel and there should also be a clear band corresponding to satellite DNA about two-
thirds of the way down the gel. Once efficient digestion was confirmed, 10J,!g of DNA was 
separated on a 0.80/0 agarose gel (figure 3.3A) before being transferred, by capillary 
blotting, to Hybond-N membrane (Section 2.4.4). 
The membrane was then incubated overnight in a hybridisation solution containing C2P]-
labelled PARP-I probe. The next day, unbound probe was removed by thorough washing 
in 0.2xSSCIO.20/0SDS at 70°C before performing autoradiography using a phosphorimager 
(Section 2.4.6). Figure 3.3B shows the resultant Southern blot autoradiograph for the 
P ARP-l MEFs and bands can clearly be seen at the expected sizes for the P ARP-l +/+ 
(9.6kb) and the PARP-l"/-MEFs (3.3kb). A sample from a Balb/c mouse strain was also 
included on the Southern blot to act as a positive control for a wild type PARP-l locus. 
This Southern blot confirms that a fragment of DNA has been inserted into and hence 
disrupted the PARP-l gene. The PARP-l-/- MEFs were then further characterized to show 
lack of both PARP-I prokin and activity (see below). 
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Figure 3.3 Southern blot ofPARP-l+l+ and PARP-r/- MEFs 
1 2 3 
+1+ -1- Balb/c 
A. Ethidium bromide stained garose gel showing EcoR1 digestion of genomic DNA. Efficient 
digestion was confirmed by the presence of satellite bands. 8 . Southern blot of EcoRI-digested 
DNA from cell pellets (lanes 1 and 2) and from mouse tail section (lane 3) . M = 1 kb ladder 
molecular weight standard. 
3.2.4 Western blot analysis ofPARP-l expression in PARP-l MEFs 
To confirm the absence ofPARP-1 protein in the PARP-rl-MEFs, Western blotting was 
performed, as described in Section 2.6. Samples of both wild type and knockout MEFs 
were lysed in SDS lysis buffer and SOlJ.g of protein separated by electrophoresis on a 4-
20% polyacrylamide gradient gel. The proteins were transferred to nitrocellulose 
m mbrane and the membrane probed with a rabbit polyclonal antibody raised again t 
PARP-l (H-2S0 r cognises c-terminal ofPARP-I, corresponding to residues 764 - 1014; 
anta ruz Biot chnology). A positi e control of purified PARP-l was also included on 
th g 1. A can b s n in figur 3.4, th P RP-I-1- MEF contain d no d t ctabl P RP-I 
pr tin. 
129 
1 
+/+ 
113kDa ~ 
2 
-/-
Chapter 3 - Re ult 1 
3 
PARP-1 
Figure 3.4 Western blot showing PARP-l protein in PARP-l+1+ and PARP-r/- MEFs. 
Lane three contains a positive control of purified P ARP-l 
3.2.5 Measurement of PARP-l activity: 
3.2.5.1 Incorporation of [32Pl-NAD+ into acid-precipitable material 
The final step in the characterization of the P ARP-l MEFs involved the use of an 
enzymatic assay, measuring P ARP-l activity. The P ARP permeabilised cell assay is a 
technique commonly used to measure the P ARP activity within cells. The details of this 
assay have been described in Section 2.8.1. Briefly, l x 107 cells are permeabilised in 
isotonic buffer supplemented with digitonin. The cells are then spun down and 
resuspended in a buffer containing C2PJ-Iabelled NAD+ and a short double stranded 
oligonucleotide. This oligonucleotide simulates DNA strand breaks and hence stimulates 
PARP activity. Radiolabelled NAD+ is then used as a substrate, resulting in the production 
of C2PJ-labelled ADP-ribose polymer covalently attached to proteins. The protein-bound 
polymer is precipitated, bound to a filter and then detected and quantified by scintillation 
counting. The PARP inhibitor AG14361 was also included in some samples. Figure 3.5 
hows an exrunple of a PARP-permeabilised cell assay performed in P ARP-l +/+ and 
P ARP-1-1- MEFs. In the wild-type cells, the oligonucleotide greatly stimulated PARP-l 
acti ity , with acti ity ri ing from 108 to 621 (finol NAD incorporated per 106 
11 Iminut ). In addition thi acti ity was completely abolished by tr atment of c II v ith 
l)..lM A 14361 (an a ti ity [ nl 14fM I NAD incorp rat d p r 106 cell Iminut \\ 
mea ured) h wing th tT ti n f 14361 in inhibiting P RP-1 a ti it ' . <lgun:: 
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3.5 also shows that the PARP-l knockout cells possessed approximately 50/0 PARP activity 
compared to their wild-type counterparts. This activity may be attributed to alternative 
PARP proteins, which have recently been described (for example PARP-2. V -PARP and 
tankyrase). Interestingly, this activity was independent of the presence of oligonucleotide 
and was completely abolished by treatment of cells with 1 ~M AG 14361. This suggests 
that AG14361 is not just specific for PARP-l, but also inhibits alternative PARP enzymes. 
It should be noted that permeabilised cells are not in the normal physiological state and, as 
such it could be argued that this assay does not demonstrate the entry and activity of the 
P ARP-l inhibitor in intact cells. However, previous studies within the department have 
involved treating intact cells with AG 14361 before washing the cells with PBS (to remove 
residual inhibitor) and subsequently performing the permeabilised cell assay in the absence 
of added inhibitor. These experiments demonstrated complete inhibition of P ARP-l 
probably due to the inhibitor being very tightly bound to P ARP-l prior to the 
permeabilisation process (Stephany Veuger, Cancer Research Unit, University of 
Newcastle upon Tyne, unpublished results) and therefore not diffusing out of the cell. 
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Figure 3.5 PARP Permeabili ed cell a ay mea uring the incorporation of radiolabelled AO+ 
h re ult f r PARP_I .. , t MEF ar ho\ n in th upp r chart and the PARP-I" - MEF in the 10\ er chart. 
a h t of re ult how the effi t of th pr enc or ab en of double trand d oligonu leotide and 1 ~M 
1436 1 n PARP-I a ti it). 
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Although this method is commonly used and effectively shows the inhibitory activity of 
AG14361, it does have limitations, which will be described in Section 3.3.2. For example, 
there is some concern whether the incorporation of radioactivity being measured by 
scintillation counting can be solely attributed to the activity of P ARP-I. The strongest 
indication that this assay measures P ARP-I activity is the fact that the activity is activated 
by oligonucleotide and that it is absent in the P ARP-I-1- MEFs. Therefore, confirmation of 
this assay was sought by an alternative strategy using antibody detection of ADP-ribose 
polymer formation. 
3.2.5.2 Immuno dot-blot method to detect ADP-ribose polymer formation: 
This assay has been developed based on a technique first described by Affar et al (1998) 
and relies on immunodetection of ADP-ribose polymer bound to a membrane. The 
antibody used (clone 10H, Biomol) binds ADP-ribose polymer and has shown no cross 
reactivity with DNA, RNA, monomers of ADP-ribose or NAD (Kawamitsu el al., 1984; 
Menard and Poirier, 1987; Kupper et al., 1990). The methodology is very similar to a 
standard P ARP permeabilised cell assay but does not involve the use of radiolabelled 
NAD+ and has the advantage of using much smaller cell numbers. However, it is still 
necessary to permeabilise the cells and use oligonucleotides to stimulate P ARP activity, as 
even the antibody detection is insufficiently sensitive to detect the very small levels of 
ADP-ribose polymer synthesised in intact cells, even in response to DNA damage in the 
normal range generated by therapeutic doses of IR or chemotherapy. 
Briefly, 5 x 105 cells were permeabilised, as before, in isotonic buffer supplemented with 
digitonin. Cells were then spun down and resuspended in a reaction buffer containing 
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NAD+. Double-stranded oligonucleotide was also included in the reaction to stimulate 
PARP-1 activity. The reaction was performed at 30°C for 6 minutes and was stopped by 
the addition of an excess of AG 14361 and transfer of the samples to ice. Samples were 
then vacuum aspirated onto Hybond-N membrane (Amersham) via a dot-blot manifold and 
the membrane probed with the clone 10H ADP-ribose polymer-specific mouse monoclonal 
antibody (full details of this method can be found in Section 2.8.2). 
During the development and validation process, a variety of experimental factors have 
been varied. These included the concentrations ofNAD+ and oligonucleotide used as well 
as the number of cells bound to the membrane. In addition, purified ADP-ribose polymer 
has been used to show that the signal generated by ECL detection decreases with dilution 
of the polymer standard. The effect of each of these factors will be discussed in the section 
below. All initial experiments were performed on HCT -116 colorectal cells. 
Purified ADP-ribose polymer 
------------~------------( ~ 
100 10 2 1 ng 
Figure 3.6 Dot blot howing the ADP-ribo e antibody used is sensiti e to level of purified pol mer 
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Figure 3.6 shows that the dot blot procedure is sensitive to detection of purified polymer. 
By diluting the polymer added to the membrane, the signal intensity of the dot is 
decreased, i.e. the signal intensity is dose-dependent. 
Oligonucleotide concentration 
---------------~---------------
r " 2.5 10 50 Ill.!/ml 
Figure 3.7 Optimisation of oligonucleotide concentration 
Figure 3.7 shows that increasing the concentration of double stranded oligonucleotide 
results in an increase in signal intensity, attributable to an increase in PARP-l activity. 
Based on this result, it was decided to use an oligonucleotide concentration of 50jlg/ml in 
all subsequent dot-blot experiments. 
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Figure 3.8 Optimisation of the cell number added to the dot blot membrane 
Oligonucleotide was included at a concentration of 50jl.g/ml 
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The next factor to be optimised was the number of cells to be added to the membrane such 
that maximum sensitivity was achieved. The aim was to achieve maximum signal intensity 
in the + oligo sample, whilst maintaining maximum differentiation between these samples 
and the inhibitor-treated samples. Figure 3.8 shows that the optimum cell number appears 
to be 5000 as these samples clearly showed polymer formation in the oligonucleotide-
treated samples. In addition, this polymer formation was abolished when 1 J.lM AG 14361 
was included. Increasing cell number resulted in loss of this differentiation to a certain 
degr e. This may be due to the oligonucleotide treated sample already being at a saturation 
point in terms of signal intensity. In addition, the samples without oligo show a basal Ie el 
f ADP-ribose polymer formation, possibly as a consequence of the permeabilisation 
proc which ha pr viou ly been shown to induce DNA strand breaks and hence acti at 
PARP-l . Ther for ,adding xtra cells would only add to the basal Ie els of pol m r bing 
in ignal int n ity in the (--oligo) amp I ; but inc th + 
li g ) ignal wa alread aturat dI ad t a I f di ff! r ntiati n. Thi ugg ti n \\ 
furth r upp rted b the fa t that 14 1 pre nt d thi appar nt in r a · in p Iymt:r 
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formation in the (-oligo +AG14361) samples (data not shown). This was due to AG14361 
inhibiting basal levels of polymer formation. Addition of even more cells 100 000 
resulted in blockage of the wells and the inability of the samples to be aspirated through 
the dot-blot apparatus. This resulted in no polymer being bound to the membrane and 
hence no polymer was detected. 
The final step in the optimisation of the dot blot assay was to show that no ADP-ribose 
polymer was detected in the P ARP-I-1- MEFs 
PARP-l +1+ 
_~A,-_......, ( \ _~A ....... _......, ( \ 
+ + + + Oligo 
+ + __ lJlM AG14361 
Figure 3.9 Dot blot assay showing lack of ADP-ribose polymer formation in PARP-r/- MEFs 
As can be seen in figure 3.9, little or no ADP-ribose polymer was formed in the PARP-l 
knockout cells, even in the presence of oligonucleotide. P ARP-l proficient cell lines were 
also assayed in parallel to act as positive controls. 
Th abo xperim nts confirm that the P ARP-l MEFs to be used in experim nts are of 
the orr ct gen typ and ph notyp . In addition treatment of cells with a potent PARP-l 
inhibitor G 14361 (k, < 6nM) ha b en hown to be an effective altemati e trat gy D r 
th r m 11 . B fI ruing th inhibit r in D damag 
re. p n ,'pcrimcnt, it wa n ary t h V\ that 14 61 al n did n t ha\ e an [J ct 
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on basal p53 levels over time. In addition, AG 14361 should not have any effect on cellular 
growth during the course of the experiment, since it has been demonstrated through the 
construction of P ARP-1 knockout mice that P ARP-1 is not essential for normal 
development and growth. However, it is possible that the use of a chemical inhibitor of 
P ARP-1 could have non-specific effects on the growth of cells. 
3.2.6 Cytotoxicity studies of AG 14361 alone 
3.2.6.1 SRB assays showing growth of cells after treatment with AG14361 
To investigate the growth of cells treated with AG 14361, SRB assays were performed on 
cells treated with different concentrations of the PARP inhibitor. HCT-116 and MEF cells 
were plated into 96-well plates at 2 x 104/ml and grown overnight before adding medium 
containing O.1J,.lM, 1J..lM, 10J..lM or 100J..lM AG14361. AG14361 was stored at a stock 
concentration of 10J,.lM in 10% DMSOIPBS (v/v) and added to the cells such that the final 
concentration ofDMSO was 0.01 or 10/0. In addition, plates contained two controls 
consisting of 0.01 % and 1 % DMSO. Plates were fixed at 24 hour time points (24h, 48h 
and 72h) before being washed and stained with SRB. The plates were analysed on a plate 
reader and the results plotted to show the effect of different concentrations of AG 14361 on 
cell growth. As can be seen in figure 3.10, 1J..lM AG14361 (the concentration used in all 
subsequent DNA damage experiments) had no short-term effect on cell growth compared 
to the DMSO controls (0.010/0). This was true for both PARP-1 MEFs and also HCT-116 
colorectal cells. Higher concentrations of AG 14361 (10 and 100J..lM) were growth 
inhibitory, due to some non-specific effects of the PARP inhibitor, which only become 
significant when AG 14361 is used at a high concentration. It should be noted that the two 
higher concentrations of AG 14361 had to contain a final DMSO of 1 % for solubility 
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purposes. However, the lower concentrations of AG 14361, 0.1 and 1 J..lM contained a final 
DMSO concentration of 0.01% DMSO, as in the DNA damage experiments. Therefore, to 
control for possible effects of the DMSO, cells were grown in either 0.01 % or 1 % DMSO 
for comparison with the inhibitor treated cells. 
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Immortalised P ARP-l +1+ MEFs 
Growth inhibition after 24h 
0.01% DMSO O.IJ..lM AG14361 IIlM AG14361 
Immortalised PARP-I-1- MEFs 
Growth inhibition after 24h 
O.OI%DMSO O.IJ..lM AG14361 IIlM AGI4361 
lOJ..lM AG14361 100J..lM AG14361 
lOJ..lM AGI4361 100J..lM AG14361 
HCT-116 human colorectal cells 
Growth inhibition after 24h 
O.OI%DMSO O.IJ..lM AG14361 IJ..lM AGI4361 lOJ..lM AGI4361 IOOJ..lM AGI4361 
Figure 3.10 SRB assays showing effect of 24 hours treatment" ith AG 14361 on cellular growth 
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3.2.6.2 Western blot showing basal p53 levels after AG14361 treatment 
Western blot analysis ofp53 levels was carried out at various time points after treatment of 
exponentially growing HCT-116 cells with IJ..!M AG14361. As can be seen in figure 3.11, 
AG14361 alone did not cause a change in p53 levels over a 24h period. In addition, no 
change was observed in the levels of the p53 target gene, mdm2 (results not shown). This 
suggests that AG 14361 alone does not stress cells in any way that might result in an 
increase in p53 levels or its transcriptional activity. This information is obviously essential 
before including the compound in any experiments analysing p53 responses. 
u 1 2 3 6 24 (Hours) 
.... ___ ..... ..-,. _d_-· ~ p53 
Figure 3.11 Western blot analysis showing p531evels over time after treatment of HCT-116 cells 
with IJ.LM AG 14361 
3.3 Discussion 
3.3.1 Summary of Results 
The data presented in this chapter aimed to verify the techniques chosen to remove P ARP-
1 activity from cells. This involved confirming the genotype and phenotype of the P ARP-
1 MEFs, using Southern blotting and Western blotting, respectively. The data presented in 
this chapter confirmed the disruption of the P ARP-l gene in the knockout MEFs and 
Western blotting confirmed the lack of PARP-l expression in these cells. A PARP 
permeabilised cell assay measuring the incorporation of e2p]-NAD+ into acid-precipitable 
material showed that the P ARP-l +/+ MEFs possessed a PARP activity that was stimulated 
by oligonucleotide. This activity was inhibited by including 1 J..!M AG 14361 in the assay. 
The same assay demonstrated that the P ARP-I- I- MFFs possessL~d approximately 50/0 PAR? 
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activity compared to their wild type counterparts. This activity was independent of added 
oligonucleotide but was also inhibited by AG 14361. The effectiveness of AG 14361 was 
also demonstrated in a different assay, using an immunoblotting technique for the 
measurement of ADP-ribose polymer. Finally, using SRB assays, 1JlM AG14361 was 
shown to have no growth inhibitory effects during the time course of DNA damage 
experiments performed in the subsequent chapters (24h) . and did not alter the basal levels 
ofp53 over the same time course. 
3.3.2 Analysis of PARP permeabilised cell assay using radio labelled NAO+ in P ARP-
1 +1+ and P ARP-I-1- MEFs 
A PARP-permeabilized cell assay measuring the incorporation of counts from e2p]-NAD+ 
into acid-insoluble material showed that the P ARP activity was >900/0 reduced in the 
P ARP-1-1- MEFs, consistent with the disruption of the P ARP-1 gene. However, it should 
be noted that the P ARP-1 knockout cells did possess approximately 50/0 P ARP activity, 
which cannot be attributed to PARP-1. It is likely that this activity is due to other members 
of the recently described PARP family, which now includes up to seven members (see 
Section 1.4.7). 
This activity has been described previously in PARP-1 knockout MEFs (Shieh et ai., 
1998), who showed that the residual activity was inducible by DNA damage. PARP- 1-1-
cells treated with 1 36JlM MNNG were able to synthesise polymer, which was 
indistinguishable in structure to that synthesised in the PARP-1 wild-type cells. Also. this 
polym~r production resulted in a decrease in intracellular NAD+ concentration, suggesting 
that this activity is due to a PARP protein. but obviously not PARP-I. Interestingly. unlike 
the study mentioned above. the activity described here was not inducible by DNA ends. 
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However, it should be noted that Shieh et al used a different method for stimulating P ARP 
activity, with damage to endogenous DNA being used rather than the introduction of an 
exogenous oligonucleotide. In addition Shieh and colleagues used a method for measuring 
P ARP activity, which did not involve cellular permeabilization. Permeabilization has 
actually been shown to cause DNA damage and hence induce intracellular stress responses. 
Therefore, it is possible that the alternative P ARP activity detected in this present study is a 
consequence of the permeabilization procedure, resulting in endogenous DNA damage. 
Alternatively, the oligonucleotide used in this study may not be suitable for the activation 
of the alternative PARP activity. Recent unpublished data in the Cancer Research Unit 
suggests that the oligonucleotide used (10 bp) is incapable of activating DNA-PK, which is 
known to be activated by DNA ends. Instead it was necessary to use a longer 
oligonucleotide to efficiently activate this kinase (Stephany Veuger, unpublished results). 
However, what is not in doubt is that the PARP-rl- cells possess an alternative PARP 
activity, distinct from PARP-l, which is also inhibited by the PARP-l inhibitor, AG14361. 
Subsequent studies have attributed this activity to PARP-2 (Arne et al., 1999), which was 
shown to be inducible by both DNA strand breaks and DNA damage. Another group 
assigned this activity to an alternative product of the PARP-l gene, called sPARP-l which 
lacks the DNA binding domain and as such has activity that is independent of strand 
breaks but can be induced by DNA damage (Sallmann et al., 2000). The cloned cDNA for 
this PARP protein was identical to the catalytic domain of PARP-l and consisted of 1732 
base pairs. The authors proposed that sP ARP-l was produced by transcription of the 
PARP-l gene from an alternative transcription start site, downstream of the disrupted area 
of exon 2 in these particular PARP-I-I- MEFs. Importantly. in the exon -+ PARP-I 
knockout MEFs used in this thesis. the disrupted area of the PARP-l gene is also upstream 
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of this putative alternative transcription start site. Therefore, sP ARP-l could, in theory. be 
produced in these cells. The characteristics of sP ARP-l described by Sallmann et aI., 2000 
are more concurrent with the data presented here, however no specific attempts have been 
made to identify the enzyme responsible for the activity in the knockout cells used in this 
study. It should be noted that the PARP-l antibody used, H-250, was raised against a C-
terminal epitope of P ARP-I and should therefore detect any sP ARP-l present within cells. 
However, no such protein was detected in any of the cell lines used in this study (data not 
shown). 
It is important to note, in terms of the interpretation of results, that 1 J,lM AG 14361 was 
able to inhibit the PARP activity in both the PARP-I proficient and deficient MEFs. 
Assuming that the P ARP activity detected in the P ARP- r l- MEFs is also present in the 
P ARP-l +1+ MEFs, then when the latter cells are treated with AG 14361, more than one 
P ARP activity is being inhibited. More specifically, P ARP-l will be inhibited, as will the 
other' P ARP activity' that has been detected in the P ARP-l knockout cells. Therefore, any 
effect observed in PARP-I +1+ MEFs cannot automatically be attributed to P ARP-I. 
However, the involvement ofPARP-1 could be demonstrated if the effect was observed in 
the PARP-l knockout MEFs. It will also be possible to determine whether the alternative 
PARP activity detected in the PARP-I-I- MEFs is involved in p53 regulation by treating 
these cells with AG 14361 and DNA damage. In this situation, the alternative PARP 
activity will be inhibited and any effects observed cannot be due to PARP-I in these cells. 
As the PARP activity in the PARP-I-I- MEFs has not yet been assigned to a particular 
P ARP enzyme, only general conclusions can be derived. 
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As described in a previous section (Section 104.7), the PARP family members share 
significant sequence homology within the catalytic domain. As such, it is perhaps not 
surprising that an inhibitor that is competitive for NAD+ binding to the catalytic domain of 
P ARP-l, is also able to inhibit the catalytic activity of other P ARP enzymes. 
Having discussed the implications of treating PARP-l proficient and deficient MEFs with 
AG 14361, it should be noted at this stage that knocking out PARP-l and its inhibition are 
two distinct phenomena. When inhibited, PARP-l is still able to bind DNA strand breaks. 
However, it is likely to bind strand breaks permanently as it cannot perform its catalytic 
function and therefore cannot automodify itself and dissociate from the DNA. In P ARP-1-
/- knockout cells, there is no PARP-1 protein present and hence DNA strand breaks will 
remain vacant or will be occupied by other DNA-binding proteins. These facts will need 
to be considered when analysing any results. 
3.3.3 Development of a P ARP permeabilised cell assay using antibody detection of 
ADP-ribose polymer 
The technique commonly used for the estimation of P ARP activity (discussed in the 
previous section) has some limitations. For example, each sample requires 1 x 106 cells. 
As each reaction is performed in triplicate, this means a minimum of 6 x 106 cells are 
required for a simple +/- AG 14361 inhibitor experiment. In addition, there is some 
concern whether the counts being measured by scintillation counting can be solely 
attributed to the activity of PARP-l. It is possible that other NAD+ -utilising metabolic 
pathways are responsible for some of the 'PARP activity' being measured. For example, 
ADP-ribosylation reactions are also carried out by mono(ADP-ribosyl) transferases and 
NAD+ glycohydrolases. as well as other members of the PARP-l family (e.g. PARP-2, v-
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PARP etc). Therefore, some of the activity measured may be as a consequence of these 
enzymes rather than P ARP-I. Also, where possible it is best to eliminate the use of 
radioactivity in experiments, for improved safety reasons and to reduce the disposal of 
radioactive waste. Finally, although label from the ADP-ribose moiety ofNAD is 
incorporated into acid-insoluble counts, this does not itself constitute proof of ADP-ribose 
polymer formation. Therefore, a non-radioactive, immunoblotting method for the 
measurement of ADP-ribose polymer has been developed and validated. 
The technique developed involves the permeabilisation of cells and activation of P ARP-l 
by oligonucleotide. However, non-radio labelled NAD is used in the assay. To measure 
P ARP-l activity, samples are blotted onto membrane and an antibody used to detect the 
levels of ADP-ribose polymer synthesised in the individual reactions. As shown in Figure 
3.6 the detection method for the assay was sensitive to purified polymer, with the intensity 
of dot changing in accordance with the amount of polymer bound to the membrane. In 
addition, no ADP-ribose polymer was detectable in the PARP-l knockout cells and only in 
P ARP-l wild type cells treated with oligonucleotide was there any significant detectable 
polymer formation. There is a small amount of antibody binding evident, even in the 
presence of AG 14361. This may be non-specific antibody binding, or because only de 
novo synthesis of polymer is inhibited in the actual assay, any pre-existing polymer in the 
cells prior to permeabilisation will not be affected. 
One of the major benefits of this new method is that each reaction is performed on 5 x 103 
cells. which is 1/20th of the cell number required for the radiolabelled NAD+ method. In 
addition, studies have shown that 5000 cells (or less) are the optimal number bound to the 
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membrane to allow detection of polymer without increasing the background signal too 
much. Therefore, it may be possible to scale down further the number of cells used per 
experiment. Affar et aI., 1998 used a 24-well dot-blot manifold and as such had to load 
more cells (up to 250,000) per well to optimise the signal. 
As well as proving very useful throughout this project, this technique is now being 
optimised in the Cancer Research Unit for use in clinical trials of potent P ARP-l 
inhibitors, where patients are treated with P ARP-l inhibitors to potentiate the effects of 
chemo- and radio-therapy in tumour cells. Blood samples will be taken and peripheral 
blood lymphocytes of treated patients analysed to confirm inhibition of P ARP-l by the 
inhibitors. The relatively small amount of blood that can be taken from patients during 
sampling meant that the development of a technique involving smaller cell numbers was 
essential. Also, the optimisation of this technique for a 96-well format allows the testing 
of many samples during a single experiement. 
The results above show that the immortalised P ARP-l MEFs can be used as a paired cell 
line, which are proficient and deficient in P ARP-I. The effect of PARP-I protein and 
activity on the DNA damage-induced p53 response can be analysed using these cell lines. 
In addition to characterizing the PARP-l MEFs, this chapter also aimed to show the 
effectiveness of AG 14361 as an alternative strategy for the removal of PARP-l activity. 
Results have been presented showing that AG 14361 itself did not alter p53 levels or 
activity over time. Also. SRB assays showed that 1 JlM AG 14361 was not growth 
inhibitory during the time course of the planned experiments. These observations are 
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essential when using the compound to analyse any modification of the DNA damage-
inducible p53 response. As described in Sections 3.3.2 and 3.3.3, 1JlM AG14361 also 
effectively inhibited P ARP-1 activity in the assays described. 
The results in this chapter have comprehensively characterized the P ARP-1 MEFs as well 
as the P ARP inhibitor AG 14361. Both gene knockout and inhibitor strategies have been 
employed to remove P ARP activity from cells in DNA damage response experiments, the 
results of which will be presented in the following chapter. 
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4.1 Introduction and objectives: 
A summary of data suggesting a functional relationship between P ARP-l and p53 has been 
presented in Chapter 1, Section 1.4.6. As described, different groups obtained apparently 
conflicting results when analysing the DNA damage-induced p53 response in the presence and 
absence of P ARP-l. The principal aim of this thesis was to use both P ARP-l knockout cells and 
a novel potent PARP-l inhibitor, AG 14361, to remove PARP activity from cells and to analyse 
the DNA damage induced p53 response. However, it became apparent from initial DNA 
damaging experiments in this study that the immortalised PARP-l +1+ MEFs were probably 
expressing mutant p53 whereas the PARP-l knockout cells were expressing wild type p53. A 
second independently derived spontaneously immortalised MEF cell line pair was generated, but 
subsequent analysis revealed the same pattern in terms of p53 status in these cells. 
Based on these results it appeared that the P ARP-l +1+ MEFs tend to develop p53 mutations 
during immortalisation whereas the P ARP-I-I- MEFs do not. It was therefore decided that it may 
be futile to immortalise any further MEFs if the p53 in the PARP-l +1+ cells was likely to become 
mutated. One option available was to perform experiments on primary MEFs. However, these 
cells have a substantially slower growth rate than immortalised cells (see Chapter 6) and are also 
more difficult to transfect. Transfection is an essential component of the luciferase reporter gene 
system, which was to be used to measure p53 activity. It was therefore decided to stably 
trans feet the immortalised PARP-I-1- MEFs, which possessed wild-type p53, with a construct that 
expresses P ARP-l. This would hopefully lead to the production of a paired cell line proficient 
and deficient in PARP-I with wild type p53. In addition, these immortalised cells would grow 
well and be suitable for transfection studies using the reporter gene assay. Finally, and perhaps 
most importantly, the cell line pair would ha\'e identical genetic backgrounds, except of course 
for the stahle transfected plasmid expressing PARP-I protein. 
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Therefore, due to the mutant p53 status in the P ARP-l +1+ MEFs, the aim of this chapter was to 
produce a cell line pair proficient and deficient in PARP-l that both expressed wild type p53. 
This was achieved by stable transfection of PARP-l into the PARP-I-1- MEFs. This chapter also 
contains sequencing data concerning the p53 status (mutant or wild-type) of the immortalised 
MEFs. In addition, results are shown demonstrating the production of a P ARP-l stable 
transfectant, which has been validated in terms ofPARP-l expression and activity. 
4.2 Results 
4.2.1 The response ofPARP-l+l+ and PARP-I-I- MEFs to IR and UV 
PARP-l +/+ and -/- MEFs were plated at 5 x 105 cells in 60mm tissue culture plates and 
incubated at 37°C for 24 hours. The cells were then treated with 2, 5 and lOGy IR and 20, 50 
and 100J/m2 UV. Samples were taken after 3,6 and 24h as well as an untreated (control) 
sample. Western blot analysis was performed on all celllysates and the membranes probed for 
p53, mdm2, PARP-l and actin (as a protein loading control), see figure 4.1. 
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Figure 4.1 Western blot analysis of immortalised PARP-l MEFs in response to IR and UV. 
An initial observation from the Western blots was the very high levels of p53 in the P ARP-l +1+ 
ce ll . There was no apparent p53 induction in these cells, and despite the high p53 levels, there 
were only low Ie els of mdm2 which were not induced. This was true for both of the D A 
damaging agents us d at all do . These ob r at10ns are consistent with the expre ion of a 
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mutant and functionally inactivated p53. In contrast, the PARP-1-/- MEFs showed a p53 
induction, which peaked at 3 hours after IR and UV treatment. There was also a corresponding 
mdm2 induction in these cells, which peaked at 3h after IR before decreasing. After UV 
treatment, mdm2 levels appeared to remain high for longer although this may be due to a longer 
exposure time of the membrane to X-ray film. This explanation is in accordance with the 
apparently higher basal levels of mdm2 in the P ARP-1-1- MEFs used in the UV experiment 
compared to the same cells used in the IR experiment. Importantly, there is no P ARP-1 
expressed in the PARP-1-1- MEFs compared to the PARP-1+1+ MEFs. Nor was there any 
evidence of UV - or IR-induced PARP-1 expression in the P ARP-1 +/+ MEFs. The hypothesis that 
the PARP-1 +/+ MEFs were expressing mutant p53 was investigated by sequencing the p53 in 
these cells. The p53 in the PARP-1-/- MEFs was also analysed. 
cDNA sequencing was performed according to the method described in Section 2.10. As can be 
seen below (figure 4.2), the results confirmed that the PARP-1 +/+ MEFs were expressing a 
mutant p53, with a single G to C base change in codon 278 producing an Asp to Glu amino acid 
substitution (GAC to GAG codon change). Codon 278 is within the DNA binding domain of 
p53 and a mutation in this area would be consistent with the observed lack of p53 target gene 
transactivation (i.e. the lack of mdm2 induction observed in figure 4.1). In addition, lack of 
mdm2 transactivation would mean less mdm2 mediated degradation of p53 and hence this would 
explain the very high p53 levels observed. The PARP-1-/- MEFs were found to express wild type 
p53, again consistent with the observed p53 induction by DNA damage (figure 4.1). 
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Figure 4.2 Sequencing data highlighting the pS3 mutation in the immortalised PARP-l+l+ MEFs. 
Mutation highlighted is a C - G change within codon 278, producing an Asp to Glu amino acid change (GAC to 
GAG codon change) . PARP-I-1- MEFs express wild type p53 . 
G 
Due to the presence of a p53 mutation in the immortalised PARP-l +1+ MEFs, the above DNA 
damage experiments were repeated in a second independently derived immortalized MEF cell 
line pair from the same Gilbert de Murcia derived PARP-l knockout mice (which will be 
hereafter be referred to as GPARP-l+1+ and GPARP-I-1-). Western blots and enzyme assays 
confirmed the lack ofPARP-l expression and activity in the GP ARP-I-1- cells (data not shown). 
Unexpectedly, Western blot analysis in response to IR (figure 4.3) produced a very similar 
pattern of p53 and mdm2 induction as the previously described immortalized MEFs (figure 4.1). 
Again, the PARP-l +1+ MEFs showed very high levels of p53 , no apparent induction and lack of 
p53 target gene (mdm2) transactivation, whereas again the PARP-I -1- cells showed both p53 and 
mdn12 induction, indicati e of wi ld type p53 . 
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Figure 4.3 Western blot analysis of GPARP-l MEFs in response to JR. 
As for the other pair of immortal ised MEFs, the GPARP-I +/+ MEFs express a p53 with mutant characteristics 
whereas the GPARP-r/- MEFs have p53 with wild type characteristics. 
Subsequent cDNA sequencing of the p53 in the GPARP-l MEFs revealed a mutant p53 in the 
GPARP-l +1+ MEFs and a wild type p53 in the GPARP-r/- MEFs (figure 4.4) . Interestingly, this 
mutation was also in codon 278 but with a C to G base change, resulting in an amino acid change 
fA P to GIn (GAC to CAC codon change). 
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Figure 4.4 Sequencing data highlighting the p53 mutation in the immortalised GPARP-l+1+ MEFs. 
Mutation highlighted is a C - G change within codon 278, producing an Asp to Gin amino acid change (GAC to 
CAC codon change). GPARP-I -I- MEFs express wild type p53 . 
This suggested the interesting possibility that PARP-l +1+ MEFs tend to develop p53 mutations 
during immortalisation, but P ARP-I-I- MEFs do not develop such mutations. This was 
investigated further in chapter 6. However, for the purposes of comparing the DNA damage 
induced p53 response in PARP-l +1+ and PARP- r /-MEFs, it was decided to stably transfect the 
wt p53 PARP-I-I- MEFs with a P ARP-l expression construct, as a means to generate a P ARP-I 
xpre ing immortalised MEF cell line. 
4.2.2 The stable transfection of PARP-r/- MEFs with a plasmid construct expressing 
PARP-l 
h pIa mid con tru tcontained a3. 1kbfragm nt corresponding to human PARP-1 cD (an 
I el aI. , 19 7). hi qu nc ha b en ins rted into a eukaryotic e 'pres ion ector, 
d wn tr am f a MY pr m t r (figur 4.5~ an Go I et al.. 1997 . Th pIa mid (pP RP31 
wa kindl pr id d by 1 ,' nd r Burkle (D partm nt f r ntol gy, wca tIe n r 1 
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Hospital). The technique of stable transfection has been discussed in detail in Chapter 2, Section 
2.1.10. 
a.er 
Ie nr 
HCMV Prom t-----r-...:;&:::.:....-r--...... 
S.er s_r 
Figure 4.5 Plasmid map ofpPARP31 
4.2.3 Preparation of plasmid 
%mar 
pPARP31. 
7.1. kb 
Xb.r 
Hinerr 
Aecr 
s.~r 
Hi. neil: r r 
The first step in the process of stable transfection was the preparation and purification of the 
pPARP31 plaslnid, according to the methods described in Chapter 2, Section 2.2.1 To confirm 
isolation of the plasmid, it was subjected to EcoRI digestion and the products analysed by 
lectrophoresis on a 0.8% agarose gel (Figure 4.6). The size of the resultant DNA fragments was 
e timated and should correspond to the predicted fragment sizes from the plasmid map (3.1 2.0 
and 1.1 kb) The plasmid was diluted to 0.5/-tg/m1 in distilled water and stored at -20°C. 
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EcoRI-digested pPARP31 after DNA mega-prep 
A B ---------~---------( , 
3kb -
2kb -
2kb -
lkb -
lkb -
Figure 4.6 Preparation and purification of the PARP-l plasmid 
A. EcoRJ digestion of plasmid showing isolation of the correct sized fragments according to the plasmid map. B. 
Sample of EcoRI digested plasmid after DNA Mega-prep (QIAGEN) 
4.2.4 Transfection and optimisation 
The conditions required for efficient transfection and hence expression of a plasmid differ, 
depending both upon the size of the plasmid and also the particular cell line to be transfected. 
P rhaps the most important factor is the ratio of the volume oftransfection reagent used 
(FuGENE 6) to the amount of plasmid DNA, as it is the transfection reagent which acts as the 
'vehicle for transport of the plasmid DNA into cells. 
PARP- r /-MEFs were plated out at 1.5 x 105 cells into 35mm tissue culture plates and grown for 
24 h ur . The cells were then tran fect d with the plasmid at three differ nt ratios of 
tran ~ ti n r ag nt (J.!l):DNA(J.!g). Th rati s cho en were 3 :2, 3: 1 and 6: 1, as recommend d in 
lhe manu[acturt;r pr t 01. Till blank plat wer al 0 tran fi ct d with an empt) vect r (i .. 
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not containing the P ARP-l insert) at the same ratios. After 24 hours incubation the six plates of 
cells were lysed in 50~l of SDS lysis buffer and a protein assay performed on the indi idual 
samples. 50~g of total protein of each sample was then separated on a 4-200/0 polyacrylamide 
gel before transfer to nitrocellulose membrane for Western blot analysis. The membrane was 
then probed with an anti-P ARP-l rabbit polyclonal antibody. As can be seen in Figure 4.7 the 
3:2 ratio oftransfection reagent:DNA resulted in the highest expression ofPARP-l with a 
gradual decline in expression when the ratio was increased. There is a slight difference in size 
between the transfected P ARP-l and the positive control, likely due to the purified positi e 
control protein containing a tag to aid purification. It was therefore decided to use a 3:2 ratio in 
the actual stable transfection procedure to try and ensure good expression levels of P ARP-l. As 
expected, the three blank samples contained no P ARP-l. 
~I FuGENE 6:~g DNA Blanks 
r~------~ ...... ---~~ 
+'ve 3:2 3: 1 6:1 
__ -----A ...... -----. 
r " 
PARP-l ~ 
Figure 4.7 Optimisation of the transfection conditions. . . 
We t rn blot showing levels of PARP-l protein 24h post-transfection. The lanes show the effect of dIfferent ratIo 
ofFuGENE 6 (I .. d):~g of plasmid DNA used (lanes 2 - 4). Purified PARP-l was used as a positive control (lane 1). 
Blanks consisted of PARP-l-1- MEFs transfected with an empty vector using the previously described FuGENE 6 
:DNA ratios. 
tabl tran fection of the P ARP- r l- MEFs was achie ed using the conditions de cribed abo 
fh c II wer d d onto two 35mm plat s and tran fected as before. It should be not d that 
th tabl tran Ii ction pr dur al included a co-tran .tI ct d plasmid containing a n my in 
(g n ti iJ 41) r i tan e gen (p R3 pIa mid) t 
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incubation in transfection mixture, the cells were trypsinised and counted before plating various 
numbers of cells into 15cm tissue culture plates, containing 600J,!g/ml 0418. The cell numbers 
plated out were 100, 1000 and 10000. The aim of plating out low numbers of cells is that a 
colony will grow from a single cell and if this initial cell is stably transfected, a homogenous 
population of cells should be produced. In addition, it is important to be able to isolate 
individual colonies of cells. If a plate contains too many cells it may become impossible to 
isolate a single colony without contaminating the population with cells from a neighbouring 
colony. After approximately 10-14 days, colonies were present on the plates and were isolated 
using sterile cloning rings followed by trypsinisation. The cells were placed initially into a well 
of a 24 well tissue culture plate. When suitably confluent, they were transferred to two 35mm 
tissue culture plates, with the cells being split at 750/0 and 25% into the two plates. The higher 
density plate was subsequently lysed in SDS lysis buffer (usually within 2-3 days) and analysed 
by Western blot for PARP-I expression (Figure 4.8). Out of98 0418 resistant colonies isolated, 
one PARP-l positive clone was identified, clone 23. As described in Chapter 2, Section 2.1.10, 
the cells were initially transfected with a neomycin resistance plasmid as well as the P ARP-I 
plasmid. The colonies were subsequently grown in medium containing 600J,!g/ml geneticin. 
However, as explained in Chapter 2, Section 2.1.10, the P ARP-I-I- MEFs already contain a 
neomycin resistance cassette and hence will already be resistant to the antibiotic used. This may 
be the reason for isolating only one positive colony. Because of this oversight, it has also been 
necessary to perform additional experiments to confirm the homogeneity of the isolated stable 
transfectant and also to rule out the possibility of cross contamination by an alternative PARP-
1 +1+ cell line. The positive clone was grown to sufficient numbers before re-plating the cells out 
for colonies. as before. This was to ensure that the stable transfectant cell line was indeed a 
homogenous population of cells, all expressing P ARP-I. Several colonies were again isolated 
and analysed for PARP-l expression using \\'estern blotting (figure 4.8). All colonies isolated 
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were positive for P ARP-l and were grown for several weeks before freezing of 1 x 106 aliquots 
of cells in liquid nitrogen. 
Negative colonies 
r..-----.A--.---_~ 23 +'ve 
PARP-1 
Figure 4.8 Western blot showing identification of a positive clone for PARP-l expression 
PARP-1 • 
Independent colonies 
derived after reselection of 
PARP-1 stable transfectant 
..-------~-------
r '" 
Figure 4.9 Reselection of colonies confirming homogenous population of PARP-l stably transfected cells 
Western blot analysis of six independent colonies derived after reselection of P ARP-l stable transfectant all show 
PARP-I expression. 
4.2.5 Validation of PARP-l stable transfectant 
The derived stably transfected cell line (hereafter referred to as clone 23) has been shown to 
pre PARP-l protein. However, in order to utilise this cell line in DNA damage experiments 
a a PARP-l proficient counterpart of the PARP-I-1- MEFs it was essential to demon trate 
a ti ity of the transfl cted enzyme. In addition it was necessary to demonstrate that the isolation 
of a PARP-I profici nt c 11 line \ a du to transfection and not simpl cr s -contamination of 
th culture by a diff! r nt P RP-l profi i nt Ulin . 
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PARP-l activity in the stably transfected cell line was demonstrated by performing a P ARP 
permeabilised cell assay followed by immuno dot blot detection of ADP-ribose polymer (as 
described in Methods Section 2.8.2). P ARP-1 activity was stimulated by the presence of a short 
double-stranded oligonucleotide that simulates DNA strand breaks. The assay was also 
performed using the PARP-1·1. MEFs at the same time. 
As can be seen in Figure 4.10, clone 23 possessed P ARP-1 activity which was activated by DNA 
ends and was also inhibited by treatment with l/lM AG 14361. This was in contrast to the 
P ARP-1 knockout MEFs, which did not synthesize any detectable ADP-ribose polymer in the 
presence of double stranded oligonucleotide. This assay confirmed the presence of PARP-1 
activity in the PARP-1 stable transfectant but not in the P ARP-1·1. cells. 
A B C 
...... 
,...... 
1.0 1.0 
M M 
I I 
- -co co 
f-. f-. 
+ + 0 0 0 0 0 0 ~ bJ) Ol) Ol) Ol) Ol) .-~ 
-Purified ADPrpolymer 0 0 0 0 0 0 
+ + + + 
• 
Figure 4.10 Confirmation of PARP-l activity in clone 23. 
Panel A is a po itive control showing the decrease in dot intensity with decreasing amount of purified ADP-rib~ e 
polym r. The central panel hows the oligonucleotide dependent PARP-l activity in the stably transfected celllme 
(cIon 23), whi his aboli h d by treatment of cells with l~M of the PARP-l inhibitor AGJ4361. Panel Chow 
th r lati e lack of ADP-ribo e pol mer formation in the PARP-I '" MEFs. 
162 
Chapter -I - Results 2 
Although no obvious morphological or growth rate changes were apparent between clone 23 and 
PARP-I-1- MEFs, it was important to demonstrate that the stable transfectant was not a product of 
contamination. This was achieved by repeating the Southern blot analysis described in the 
previous chapter (Section 3.2.1). With the O.8kb 5' probe described in Section 2.4.1, the clone 
23 MEFs should still produce a smaller 3.3kb fragment when the genomic DNA is subjected to 
EcoRI digestion as the disrupted P ARP-I locus should remain unchanged. As can be seen 
below, the PARP-I stable transfectant gives an identical Southern blot result as the PARP-I-I-
cells. As no other PARP-I proficient cell line would give rise to a fragment of this size the 
possibility of contamination is eliminated. A P ARP-l +1+ sample has also been included in the 
blot to act as a control. It should be noted that the P ARP-l stable transfectant lane does not 
contain any higher bands corresponding to those produced in the P ARP-I wild type MEFs. This 
is because the probe used is actually directed against intronic DNA whereas only PARP-l cDNA 
(i.e. exonic) is present in the clone 23 MEFs. Therefore, no probe-specific fragment will be 
produced from EcoRI digestion of this plasmid. In addition, it should be noted that each DNA 
damage experiment performed on the stably transfected cell line, described in the following 
chapters, always included a Western blot to check for P ARP-l expression. Therefore, if for any 
reason, the transfected cell line ceased to express the P ARP-I protein, this would have been 
detected immediately. This additional precaution was particularly necessary since it was not 
possible to maintain antibiotic selection for the retention of the plasmid. 
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Figure 4. t t Confirmation of homogenicity of clone 23 by Southern blotting 
The gel on the left shows efficient EcoRI digestion ofgenomic DNA from PARP-l +I+, PARP-l"/- and clone 23 
MEFs. The Southern blot on the right shows that clone 23 MEFs retain the 3.3kb band due to the disrupted 
endogenous PARP-l locus in these cells . The Southern blot was probed with the O.8kb probe that binds the 5' end 
of the PARP-I gene. 
4.3 Discussion 
4.3.1 Mutant p53 tatus ofPARP-l+l+ MEFs 
The initial p riments d crib d in thi hapt r 111 01 ed the D A damag indue d p53 
re p n in th inlffi rtali d P RP-l M F. nun xp t d b rvati n was mad in th t th 
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P ARP-1 +1+ cells were found to express mutant p53 whereas the PARP-1-1- cells expressed wild 
type p53. A literature search regarding the loss of p5 3 function during immortalisation of MEF s 
revealed that this may be a common event. For example, Rittling and Denhardt. 1992, 
demonstrated the acquisition of p53 mutations in 2/3 independently derived MEF cell lines 
immortalised using the 3 T 12 protocol. This protocol is similar to the 3 T3 method used in this 
thesis (see Chapter 2, Section 2.1.9), except that four times as many cells are re-plated into fresh 
medium upon sub-culturing. The p53 mutations detected were, like those in this thesis, within 
the DNA binding domain of p53. A further study demonstrated that the inactivation of p53 using 
antisense RNA allowed primary MEFs to form colonies in culture (Camero et aI., 2000). 
Briefly, antisense RNA was introduced into passage 3 MEFs using a retrovirus delivery system 
and the cells plated out for colonies. Cells infected with an empty vector (i.e. not expressing 
antisense RNA) and uninfected primary MEFs were also plated out. Only those cells with 
inactivated p53 were able to form colonies, suggesting that loss of p53 function was sufficient to 
confer a transformed (immortalised) phenotype upon primary MEFs. On reflection, as 
immortalisation is an essential event in tumourigenesis and p53 mutation occurs in over 50% of 
cancers, perhaps the formation of p53 mutations during immortalisation of cells is not totally 
unexpected. However, what is interesting in this thesis is the observation that the PARP-I-1- cells 
do not appear to undergo the same genetic changes during immortalisation, and do not require 
inactivation, by mutation, of p53. Some other component regUlating cellular growth and lifespan 
is likely to have been mutated for these cells to surpass the senescent phase. These observations 
have been made in two independently derived pairs of PARP-1 MEFs. It should also be noted 
that the mutations detected in the two independent P ARP-l +1+ MEF cell lines are in the same 
codon, 278 and it would seem unlikely that this is a coincidence. A different base is mutated, 
with the result of either an Asp to Glu or an Asp to GIn amino acid change in the two cell lines. 
Codon 278 is within the DNA binding domain of p53, suggesting selection for inactivation of the 
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transcriptional transactivation function of p53 during the immortalisation of P ARP-l +.T MEFs. It 
is interesting that several studies in the literature have described lower p53 levels in the PARP-l 
knockout MEFs compared with wild-type MEF controls and assigned this observation to a 
decreased stability of p53 in the absence of P ARP-l (Wesierska-Gadek et ai., 1999). However. 
no sequencing data is presented in these studies to indicate the p53 status of the P ARP-l +1+ 
MEFs. It may be that it is actually the P ARP-l +1+ cells expressing higher levels of p53 due to a 
mutation somewhere in that gene rather than the P ARP-I-I- cells expressing less p53. Further 
studies into this interesting phenomenon have been performed and will be discussed in Chapter 
6. 
4.3.2 P ARP-l stable transfectant 
The observations in the initial experiments that revealed the mutant p53 status of immortalised 
P ARP-l +1+ MEFs made it necessary to develop an alternative strategy to analyse p53 responses in 
P ARP-I proficient and deficient cells. This was achieved by stably transfecting the P ARP-I-1-
MEFs with a construct containing P ARP-l regulated by a eukaryotic promoter. This chapter has 
included data showing the derivation and validation of the transfected cell line, with both the 
presence and activity of P ARP-I being demonstrated. In addition, by re-plating clone 23 for 
colonies and analysing several of these, the possibility of the derived cell line being a 
heterogeneous population of cells has been eliminated. Also, to eliminate the possibility of cross 
contamination with a different P ARP-I proficient cell line during transfection, a Southern blot 
was performed. This Southern blot showed that the P ARP-I knockout cells had an identical 
EcoR 1 restriction pattern to that seen in the PARP-l stably transfected cell line. This is expected 
as the disrupted PARP-l gene is still present in the derived cell line and hence will produce a 
3.3kb fragment upon EcoRI digestion of the genomic DNA. To sum up, PARP-l"/- MEFs have 
been transfected with PARP-l cDNA. These cells have been re-selected and the genetic 
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background of the cells confirmed, eliminating any possibility of heterogeneity or contamination 
of the cells. 
The stable transfection procedure has produced a P ARP-1 proficient cell line that is wild type in 
p53. This cell line was subsequently used in DNA damage response experiments, along with 
PARP-1 knockout MEFs and the human colorectal cell line, HCT -116, the details of which will 
be explained in the next chapter. 
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5.1 Introduction and objectives 
The data presented in chapters 3 and 4 have described and validated the techniques used to 
remove PARP-1 protein and/or activity from cells. PARP-I-I- MEFs have been shown to 
lack both PARP-l protein and activity. In addition, the PARP-1 inhibitor. AG14361 has 
been shown to effectively inhibit P ARP-1 activity in P ARP-1 +1+ cell lines. Further data has 
been presented highlighting the need to derive a P ARP-l stably transfected cell line by the 
introduction of P ARP-1 eDNA into the P ARP-1-1- MEFs. Briefly, immortalised PARP-1 +1+ 
MEFs were found to express mutant p53 and hence could not be used to analyse p53 
responses. The stably-transfected cell line has been shown to possess both P ARP-l protein 
and activity and as such has been used as the P ARP-1 proficient counterpart (referred to 
hereafter as clone 23) of the P ARP -1-1- MEF s in DNA damage experiments. 
Several studies have been published which suggested a functional relationship between 
PARP-1 and p53. However, no consistent pattern was apparent when analysing the data in 
the literature. For example, there are discrepancies in results involving different PARP- r /-
cells as well as studies involving PARP-l inhibitors (See Section 1.4.6 for details). 
In summary, the p53 induction in PARP-r/- MEFs disrupted in exon 1 was found to be 
identical to their wild type counterparts in response to IR (Masutani et al.,. 1999). In 
addition, the transcriptional transactivation activity ofp53 was unaffected (as measured by 
Western blot analysis of p53 target genes). A reduced p53 induction was observed in the 
exon 2 PARP-l knockout cells in response to IR (Agarwal et at., 1997), with a 
corresponding reduction in p53 trasncriptional activity (measured by Western blot analysis 
and luciferase reporter gene assay). Finally, a recent publication using exon 4 knockout 
MEFs suggested differential regulation of p53 by PARP-l. depending upon the type of 
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DNA damaging agent used. When compared to PARP-I +/+ MEFs, the P ARP-I-I- cells 
showed a reduced p53 induction in response to IR but an enhanced p53 response after 
treatment with the monofunctional alkylating agent, MNU. In addition, several studies 
have been published using P ARP-I inhibitors and analysing the p53 response. As with the 
P ARP-l knockout studies, results have been inconsistent with some groups reporting an 
enhanced p53 response (Lu and Lane, 1993) and others reporting a reduced or delayed 
response (Wang et aI., 1998). It may be that differences between groups were due to 
different cell lines being used. Alternatively, different DNA damaging agents may activate 
p53 by different pathways, some involving P ARP-l and others not involving PARP-l. It 
also needs to be considered that different DNA damaging agents may activate P ARP-l to 
different extents, or that P ARP-l may be more or less implicated in the repair pathway 
involved, and thus may affect the strand break signalling levels (e.g. mediated by A TM) to 
p53. A similar situation is apparent when looking at the involvement of particular protein 
kinases in p53 activation in response to different DNA damaging agents. A more detailed 
description of the putative role ofPARP-l in p53 regulation has been provided in Section 
1.4.6 
Data presented in previous chapters has validated the use of PARP-I-I- cells and AG 14361 
as efficient means for the removal of P ARP-l activity from cells. Therefore the aim of this 
chapter was to use a combination of P ARP-I +/+ and P ARP-I-/- MEFs and a potent PARP-I 
inhibitor to try and clarify some of the conflicting data which exists within the literature. It 
should be emphasised that the inhibitor used in this study is approximately 1000-fold more 
potent than the previously most commonly used PARP-l inhibitor, 3-aminobenzamide. 
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Experiments were carried out using immortalized clone 23 MEFs (PARP-l proficient) and 
PARP-I-1- (PARP-l deficient) MEFs as well as a human colorectal cell line, HCT -116, all 
of which have been demonstrated to contain wild-type p53 (see figures 5.4 - 5.6). The p53 
response was analysed in response to a variety of DNA damaging agents, including IR, UV 
and the monofunctional alkylating agent, temozolomide. Each agent induces a distinct 
form of DNA damage, which is in tum repaired by a particular DNA repair pathway or 
combination of pathways. The hypothesis was that PARP-I-I- MEFs (or, alternatively, 
PARP-I inhibited cells) would show an altered p53 response to their wild type, or PARP-l 
active counterparts. In addition, the use of different DNA damaging agents may show that 
PARP-l only regulates p53 in response to particular types of DNA damage. 
Data presented in this chapter consists of Western blot analysis of the cell lines treated 
with DNA damaging agents in the presence or absence of IJ.lM AG14361. Western blots 
are included for p53 (to show any change in p53 protein levels), mdm2 (to demonstrate 
transcriptional activity ofp53), PARP-l and actin (to show equal protein loading in each 
lane). In addition, a luciferase- based reporter gene assay is used to measure p53 activity. 
Data is presented showing the validation of this assay before it was used in DNA damage 
response experiments. 
5.2 Results 
5.2.1 Validation of the luciferase reporter gene assay 
A reporter gene assay is a technique involving the introduction of plasmid DNA into cells 
(Section 2.7). The plasmid usually contains a gene downstream of a promoter site, the 
expression of which can be readily measured. The plasmid used in this study contained a 
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luciferase gene downstream of the P2 promoter of the MDM2 gene (pGL3-P2, generated 
by Laing, H, PhD thesis, Cancer Research Unit, University of Newcastle upon Tyne). The 
P2 promoter is p53-responsive, therefore introduction of this plasmid into cells should 
result in the production of luciferase in a p53-dependent manner. In addition, luciferase 
levels should increase in response to DNA damage due to the increased transcriptional 
activity ofp53. To eliminate the possibility that increases in luciferase were simply due to 
increased transfection, a control plasmid, containing a B-galactosidase gene is co-
transfected with the luciferase plasmid. The B-galactosidase gene is not downstream of a 
p53 responsive promoter (CMV promoter) and as such levels of B-galactosidase should not 
increase in response to DNA damage to the same extent as luciferase. An increase of B-
galactosidase may be observed over time due to the constant transcription of the plasmid. 
Obviously, the rate of breakdown of this protein will determine whether increases are 
observed. That said, after DNA damage the luciferase levels should increase markedly 
compared to the B-galactosidase levels. To control for transfection efficiency, a ratio of 
luciferaselB-galactosidase is measured. 
The first step in the validation of the assay was to show that the introduction of the P2 
plasmid (containing the luciferase gene) resulted in luciferase expression when compared 
to the same plasmid without the P2 promoter site. HCT -116 cells were therefore 
transfected with either the P2 plasmid (pGL3-P2) or the empty vector (pGL3) along with 
the B-galactosidase plasmid. The empty vector consists of the pGL3 vector containing the 
luciferase gene but lacking the P2 promoter. Samples were taken after 24h. 30h and 48h 
and the samples analysed using a luminometer. 
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Luciferase production in HCT-116 cells 
transfected with the P2 plasmid or empty vector 
24 30 48 Time (hOUIS) 24 30 
pGL3 -P2 pGL3 
48 
Figure 5.1 The transfection of cells with the pGL3-P2 plasmid results in the expression of luciferase 
Cells transfected just with the pGL3 plasmid express approximately 400-fold less luciferase than cells 
transfected with the pGL3-P2 plasmid 
Figure 5.1 above clearly shows the significant production ofluciferase in cells transfected 
with the P2 plasmid. In contrast, the levels of luciferase produced from the plasmid 
without the P2 promoter (empty vector) are virtually undetectable (approximately 400-fold 
reduced) when plotted on the same graph. In addition, it should be noted that the ratio of 
luciferase/S-galactosidase did not increase over time in the absence of DNA damage. This 
is an important experiment as the assay was used in subsequent experiments wher 
increa e in the ratio was interpreted as increases in p53 acti ity. 
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The next and perhaps most important step in the validation process was to show that the 
expression of luciferase occurred in a p53-dependent manner. This was achieved by 
transfecting the P2 plasmid into p53 wild type and p53 deficient cell lines. HCT -116 cells 
are p53 wild type whereas HCT -116 N7 cells have been stably transfected with the E6 
protein from HPV, which targets p53 for degradation. Therefore, the N7 cells would be 
expected to express lower levels of p53 and, as a consequence produce lower luciferase 
values in the gene reporter assay. Samples were taken 24, 30 and 48h after transfection. 
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174 
data i 
Chapter 5 - Results 3 
As can be seen in figure 5.2, the HCT -116 N7 cells expressed much lower levels of p53 
and mdm2 protein compared to the HCT-116 cells (shown by Western blot analysis). This 
reduced p53 level correlated with a greatly reduced level ofluciferase in the HCT-116 N7 
cells. It should be noted that this experiment has been repeated in a p53 mutant cell line 
(immortalised P ARP-I +1+, data not shown), which express very high p53 levels. However, 
because the p53 is mutated in the DNA binding domain, it is unable to bind the P2 
promoter and only very low levels of luciferase were produced. This set of results clearly 
shows that the expression of luciferase was dependent upon both p53 levels and p53 status. 
The final stage of the validation of the luciferase assay was to show that the levels of 
luciferase increased in response to DNA damage. As described in Section 1.2.2, p53 is 
subject to a variety of post-translational modifications that activate p53 in response to 
DNA damage. The basis ofp53 activation is thought to involve disruption of the p53-
mdm2 complex along with an increase in the DNA binding activity ofp53. Therefore, 
cells transfected with the P2 plasmid should show an increase in luciferase due to increased 
p53 levels as well as increased DNA binding of the activated protein in response to DNA 
damage. The induction and activation ofp53 normally occurs within 2-4h after DNA 
damage. HCT-116 cells were transfected with the P2 plasmid and incubated for 24 hours 
at 37°C. The cells were then exposed to 50y IR and samples taken after 3 and 6 hours, as 
well as an untreated (control) sample. 
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Measurement of p53 activity in p53 wild-type and p53-
degraded cell lines in response to 5Gy IR 
U 3h 6h U 3h 6h 
\. ) \. ) 
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p53 --a~~~._il· 
mdm2 ,...., -........ 
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Figure 5.3 The effect of IR on the production of luciferase 
H T-116 or HCT-116 N7 cells were treated with 5Gy IR for 3 and 6h and luciferase : ~-galactosidase alu s 
mea ured. Western blot ana lysi of p53 and mdm2 was performed in parallel. 
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Figure 5.3 shows that exposure of cells to a DNA damaging agent brings about an increase 
in luciferase expression, with a greater than 2-fold increase observed at 6h in the p53 wild-
type cells. This is associated with an increase in both p53 and mdm2 protein, as measured 
by Western blot analysis. The HCT-116 N7 cells have much lower p53 levels, consistent 
with the lower luciferase values observed. However, there is an increase in luciferase after 
IR, likely due to a small amount of functional p53 within these cells that has not been 
targeted for degradation via binding of the E6 protein. This is consistent with the slight 
increase in mdm2 protein levels observed in these cells (Figure 5.3, right hand panel). 
In conclusion, the validation experiments presented in this section have demonstrated that 
the luciferase reporter gene assay can be used as a sensitive and reliable indicator of DNA-
damage- inducible p53 activity within cells. 
5.2.2 Analysis of the IR induced p53 response in cells lacking PARP-l 
IR is a form of DNA damage that directly induces both single and double stranded DNA 
breaks. In addition, free radicals (reactive oxygen species) are produced, which can 
chemically modify DNA bases via oxidation. Common products of this oxidation are 
thymine glycols, produced by oxidation of a thymine base. With such an array of DNA 
damage produced, repair involves several different pathways, some which may require 
P ARP-I and some not. 
Studies to date have reported that animals or cells lacking PARP-l are hypersensitive to IR 
(de Murcia el al., 1997. Wang el a/., 1997), suggesting a positi\'t~ survival function of 
PARP-l in response to this type of damage. Under normal circumstances, P ARP-l is 
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thought to bind to certain breaks generated after IR and recruit other repair proteins to the 
site of damage. Additionally, P ARP-l has been implicated in recombinational repair, 
where it is thought that P ARP-l may bind to the double stranded ends of DNA and protect 
them from further damage by nucleases before the lesion is eventually repaired. 
Studies into p53 activation in response to IR have focussed predominantly on the role of 
kinases. In particular, the ATM kinase is thought to activate p53 via direct 
phosphorylation of Ser15 and indirect phosphorylation of Ser20 (via activation of a second 
kinase, Chk2). In addition, ATM is believed to phosphorylate mdm2 on Ser395. All of 
these events may lead to the disruption of the p53-mdm2 complex and hence activation of 
p53. Several groups have also reported that PARP-l is necessary for efficient p53 
induction and activation in response to IR. Mechanisms proposed for this activity include 
protein-protein interaction between PARP-l and p53 or poly(ADP-ribosylation) of p53. 
Contrary to this model, Lu and Lane, 1993, described an increased IR- induced p53 
response in cells lacking PARP-l activity due to PARP-l inhibition. This increased 
accumulation ofp53 was argued to be a consequence of the persistence of DNA strand 
breaks due to the lack of PARP-l and the consequent inhibition of DNA repair, resulting in 
increased signalling to p53. A similar pattern ofp53 induction has been observed in 
PARP-I-I- cells treated with alkylating agents (Oliver et aI., 1999; Beneke et aI., 2000). 
The aim of this section, therefore, was to analyse the IR-induced p53 response in cells 
lacking PARP-I through either inhibition or knocking out of the PARP-l gene. 
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Clone 23 and PARP-I-1- MEFs or HCr -116 cells were co-transfected with the P2 and ~­
galactosidase plasmids and incubated for 24 hours. The cells were then treated with 5Gy 
IR and samples taken after 1,2,3 and 6 hours as well as an untreated (control) sample. 
These samples were used for the luciferase reporter gene assay. Western blot samples 
were also taken in parallel at the same time points but also included a 24-hour time point. 
Samples were analysed for p53 activity (by luciferase assay) and for levels ofp53 and 
mdm2 protein (by Western blotting). 
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Western blot analysis reveals no significant difference in p53 induction in the clone 23 
MEFs compared to the PARP-rl- MEFs (figure 5.4) in response to IR. Levels ofp53 
begin to increase after 1 h and reach a maximum at 2h before beginning to decrease. The 
mdm2 induction is also identical in the different cell lines, with an initial decrease in 
mdm2 followed by a maximum induction at 6h. This pattern of mdm2 induction suggests 
that the absence of P ARP-l does not affect p53 activity in response to IR. 
Treatment of clone 23 MEFs with AG 14361 also has no effect on the IR-induced p53 
response, with identical p53 and mdm2 inductions being observed (figure 5.4). As well as 
treating the PARP-l stable transfectant with AG 14361, human HCT -116 cells have been 
analysed and again show no difference in p53 or mdm2 induction in response to 5Gy of IR 
(figure 5.6). The pattern observed, however, is different to that in the PARP-l MEFs. For 
example, in the HCT -116 cells, p53 levels begin to increase at 1 h and gradually increase 
up until 24h. In contrast, p53 levels in the PARP-l MEFs peak at 2h before decreasing. 
Preliminary Western blot experiments have been performed in a second human cell line, 
A2780 ovarian carcinoma cells, and show an identical pattern of p53 response to HCT -116 
cells in the presence or absence of 1 J-lM AG 14361. As described in a previous chapter, 
AG14361 inhibits the 5% PARP activity still present in the PARP-l knockout MEFs. This 
activity must be due to one or more of the alternative P ARP proteins recently described. 
Western blot analysis ofPARP-rl- MEFs treated with IR +/- AG14361 (figure 5.4) 
therefore suggest also that this alternative P ARP activity is not involved in the regulation 
of p53 in response to IR. 
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The results of the luciferase reporter gene assay, measuring p53 activity suggest that 
PARP-l is not involved in the activation of p53 in response to IR. PARP-l proficient cells 
(both clone 23 MEFs and HCT-116 cells) treated with AG 14361 show a very similar 
pattern of induction to cells without the inhibitor. In clone 23 MEFs, luciferase levels 
begin to increase at 3h and show an approximately three-fold increase at 6h (figure 5.5). 
The HCT -116 cells show a slight increase in p53-dependent luciferase activation at 3h 
which has approximately doubled at 6h (figure 5.6). In accordance with the Western blot 
analysis, p53 activity, as measured by luciferase production increases with mdm2 protein 
in all of the cells analysed. However, an unexpected result was obtained in the P ARP-I-1-
MEFs. As can be seen in figure 5.5, these cells showed no apparent increase in the 
luciferase/p-galactosidase ratio over the whole time period (6h) and had lower values 
overall compared to the PARP-l proficient MEFs. For example, the untreated luciferase 
value in the clone 23 MEFs is 3899 RLU (figure 5.7), whereas the same sample in the 
PARP-I-1- MEFs has a luciferase value of just 380. A similar decrease is also observed in 
the p-galactosidase values in the PARP-I-I- MEFs compared to clone 23 MEFs. Initially 
this could be interpreted as an inability to efficiently activate p53 and hence reduced 
expression of luciferase in these cells. However, this would not be in agreement with the 
clear induction ofmdm2 in the PARP-l knockout Western blots. In addition, closer 
analysis of the raw data reveals that both the luciferase and p-galactosidase values (see 
figure 5.7) were dramatically lower (about 10-fold) than in the clone 23 MEFs. This 
suggests that the absence of P ARP-l protein adversely affects the transfection and/or the 
expression of the exogenous plasmids. As such. the luciferase data in the PARP-l 
knockouts cannot be interpreted as an accurate representation of p53 activity within these 
cells. This observation will be discussed in more detail in Section 5.3.1. It should be 
noted that treatment of clone 23 MEFs with AG 14361 did not have a similar effect on the 
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raw data values (see figure 5.7). Therefore the effect observed must be a consequence of 
the absence of P ARP-l protein rather than its activity. This effect has also been observed 
in response to all of the DNA damaging agents used, eliminating the possibility that it is a 
damage-specific effect. 
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Luciferase and ~-galactosidase raw data values after 5Gy IR treatment 
of clone 23 and PARP-r/- MEFs 
Clone 23 PARP-1 -1-
Luciferase B-gal Luc/B-gal Luciferase B-gal Luc/B-gal 
Untr 2563 16662 0.153823 376 1850 0.203243 
5920 15332 0.386121 455 2265 0.200883 
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10993 19420 0.566066 573 1781 0.321729 
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In conclusion, the data presented in this section has shown that PARP-I is not involved in 
the p53 response to IR. p53 induction and activity were identical in the presence and 
absence of PARP-I. However, with relation to previously published work, it cannot be 
excluded that the effects observed are cell line specific and P ARP-I may playa role in the 
regulation of p53 in other cell lines. 
5.2.3 Analysis of the UV-induced p53 response in cells lacking PARP-l 
The exposure of cells to UV radiation results in the distortion of genomic DNA by the 
formation of intra-strand linkages. Nucleic acid bases absorb the ultra violet light, with the 
resultant influx of energy inducing chemical changes. The most common photoproducts 
are the consequence of bond formation between adjacent pyrimidines within a strand of 
DNA, and of these the most frequent are cyclobutane dimers. The result of this bond 
formation is distortion of the normal helical structure of DNA, which may subsequently 
affect the efficiency of DNA transcription or replication. Pyrimidine dimers are repaired 
by nucleotide excision repair. This process involves a large multi-protein complex, 
containing several XP proteins, which recognises the altered DNA structure, following 
which incisions are made on the damaged strand both upstream and downstream of the 
altered bases. The excised fragment is removed before filling of the gap by a DNA 
polymerase. This type of repair is not thought to involve P ARP-I. 
As for IR, the activation of p53 in response to UV radiation is thought to be orchestrated 
by kinases. For example, the A TM-related kinase, A TR is induced after exposure to UV 
and phosphorylates p53 on Ser15 and Ser37, with the likely result of disrupting binding to 
mdm2. In addition, ATR brings about phosphorylation of two C-terminal residues, 
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increasing the DNA binding activity ofp53. To date, PARP-I has not been implicated in 
the p53 response to UV. 
This section contains data analysing the UV -induced p53 response in cells lacking PARP-l 
through either inhibition or disruption of the P ARP-I gene. 
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The response of P ARP-l MEFs to 50J/m2 ultra-violet radiation 
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Samples were taken at 1, 2, 3, 6 and 24h post-IR and subject to Western blot analysis . 
Controls consist of cells treated with 0.01 % DMSO. 
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MEFs were treated with 50J/m2 UV and samples taken after 1,2,3 and 6h and luclferase :~­
galactosidase values measured. Controls consisted of cells treated with 0.01 % DMSO. 
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The response ofHCT-116 human colorectal cells to 50J/m2 UV 
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Western blot analysis (figure 5.8) revealed no significant difference in p53 induction when 
comparing clone 23 MEFs with P ARP-1 knockout MEFs. The induction began at 2h and 
reached a peak at 3h before beginning to decline. The corresponding mdm2 induction 
peaked at 3-6h and was also preceded by an initial drop in mdm2 levels at 1 h, as observed 
in response to IR. However, the pattern of induction was the same in both PARP-1 
proficient and deficient cell lines, suggesting no difference in p53 transcriptional activity in 
the presence or absence of P ARP-1 protein. 
Treatment ofPARP-I proficient cells with AG 14361 had no effect on both p53 induction 
and activity. This response has been observed in clone 23 MEFs. as well as HCT-II6 cells 
(figures 5.8 and 5.10, respectively). The pattern of p53 and mdm2 induction in clone 23 
MEFs has been described in the previous paragraph. As for IR, HCT -116 cells showed 
different kinetics of p53 induction compared to the MEFs, with levels beginning to 
increase at 2h and increasing gradually up to 24h. Treatment of the P ARP-I-/- cells with 
AG 14361 did not alter the p53 and mdm2 induction in these cells, suggesting that the 
alternative PARP activity detected in these cells is not involved in the UV -induced p53 
response. 
Luciferase analysis revealed a very similar pattern to the response observed after IR, with 
the most significant increase apparent at 6h, in accordance with the Western blot analysis 
for mdn12. This was true for both PARP-1 proficient cell lines that were tested. in the 
presence or absence of AG 14361. In addition, no significant differences were observed at 
any time point after treatment with UV in the presence or absence of AG 14361. However, 
the PARP-I-/- MEFs, as was the case with IR, showed overall lower values. Analysis of 
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the raw data again showed reduced luciferase and ~-galactosidase values (approximately 
10-fold, data not shown), suggesting a requirement for PARP-l protein to enable efficient 
transfection and/or expression of the plasmids in this cell line. 
The luciferase and Western blot data presented in this section clearly show that neither 
PARP-l protein nor activity are involved in the p53 response to UV light in the cell lines 
tested. This section of data is in agreement with Valenzuela et aI., 2002, who showed no 
difference in p53 induction or activity in response to UV -irradiation in PARP-I +1+ and 
PARP-I-I- MEFs. 
5.2.4 Analysis of the temozolomide-induced p53 response in cells lacking PARP-l 
Temozolomide is a monofunctional alkylating agent that has been developed within the 
last ten years and is currently used in the treatment of certain human tumours, particularly 
malignant brain tumours (for a review oftemozolomide structure and function, see 
Newlands et aI., 1997) Alkylating agents act by directly modifying DNA bases, 
predominantly in nucleophilic regions, with the principal lesion induced by temozolomide 
being N7-methylguanine. The damage produced is repaired by the base excision repair 
(BER) pathway (see Section 1.4.3). Although this process will be discussed as being one 
pathway, it should be noted that there are several variations, each specific for a different 
type of modified base. However, all of the pathways have features in common. For 
example. the damaged base is first recognised by a DNA glycosylase, which appears to 
diffuse along the minor groove of DNA. The base is then removed to create an abasic site. 
The damaged strand is then nicked by an AP endonuclease upstream of the abasic site. 
This creates a 3' OH overhang. which is essential for the synthesis of new DNA. This 
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synthesis is performed by DNA polymerase ~, which displaces and nicks the damaged 
strand before sealing of the DNA strand by DNA ligase III. 
Studies have shown that in the absence of P ARP-l, cells or animals are particularly 
hypersensitive to treatment with alkylating agents (Wang et al., 1998; de Murcia et aI., 
1997; Delaney, et al., 2002). It is thought that after the excision of the damaged base, 
P ARP-l binds to the single strand break as part of a BER complex (consisting at least of 
XRCC1, PARP-l and DNA ligase III). The exact role ofPARP-l is unclear, however, a 
study has implicated PARP-l in the DNA synthesis step (in association with XRCC 1), 
possible by recruiting DNA polymerase to the site of damage (Dantzer et aI., 1999). 
Previous studies have identified an increased p53 response to alkylating agents in the 
absence ofPARP-l (de Murcia et aI., 1997 and Venezuela et aI., 2002). This altered 
response was explained in terms of a persistence of DNA damage due to the lack of P ARP-
1, subsequent impaired BER pathway and hence increased signalling to p53, possibly 
caused by hyperactivation of kinases such as ATM. 
This section contains data analysing the temozolomide-induced p53 response in cells 
lacking P ARP-l through either inhibition or knocking out of the P ARP-l gene. 
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Treatment ofPARP-1 proficient MEFs with O.5mM temozolomide and AG14361 slightly 
increased the p53 induction when compared to the DMSO-treated control cells. The 
induction of p53 began at 1 h in the inhibitor treated cells, whereas no induction was y~t 
apparent in the control cells, and remained more elevated at 3 and 6h. Although this sl ight 
effect has been observed on three independent occasions, it should be noted that this effect 
was not observed in HCT-116 (figure 5.13). Instead, these cells exhibited identical p53 
inductions in the presence or absence of P ARP-l activity when treated with temozolomide. 
In addition, there was no significant difference in mdm2 induction or luciferase production 
in the clone 23 MEFs in the presence or absence of AG14361. Finally, it might be 
expected that any effect observed with the P ARP-l inhibitor will also be evident in the 
PARP-1 knockout MEFs. However, as can be seen in figure 5.1 L the p53 induction 
observed in the PARP-l"/- MEFs was almost identical to that in the DMSO-treated PARP-I 
proficient MEFs, again suggesting that PARP-1 is not involved in the regulation ofp53. 
Taken together, it seems that the increased p53 induction observed in the Western blot 
analysis of clone 23 MEFs may be due to expected minor variations that occur during 
experiments. However, it cannot be excluded that the effect is genuine and indeed has 
been observed previously in cells lacking P ARP-l treated with an alky lating agent (de 
Murcia et al., 1997). If time had permitted, these experiments would have been further 
repeated to confirm these results. In additon, other alkylating agents, for example MNU 
and MNN G would have been used. 
5.3 Discussion 
This chapter addressed the main aim of this thesis, which was to iny~stigate the hypothesis 
that PARP-l functions as an upstream regulator of p53 in response to DNA damage. 
Previous studies suggesting such a relationship does exist have been described in detail in 
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Section 1.4.6 and also summarised at the start of this chapter. It is immediately obvious 
from these studies that the nature of any regulation of p53 by P ARP-I remains highly 
controversial, with some groups reporting a reduced p53 response in the absence of P ARP-
1 and other groups reporting an enhanced p53 response under similar circumstances. 
However, these studies have involved the use of different cell lines, a variety of DNA 
damaging agents and also several different mechanisms have been employed to remove 
PARP-I activity from cells. 
This chapter contains data analysing the p53 response in mouse as well as human cell lines. 
Also, a range of DNA damaging agents have been employed, to vary the DNA lesions 
induced and hence subsequent repair pathways utilised by the cell. In addition, two 
different methods for the removal of P ARP-I activity have been used, that is the knocking 
out of the PARP-I gene and also the use ofa novel potent PARP-I inhibitor, AG14361. 
As described previously in this thesis, it is of note that AG 14361 is more potent than any 
previous PARP-I inhibitor used to analyse p53 responses. Furthermore, the most 
commonly used PARP-I inhibitor in the p53-related literature, 3-AB is approximately 
IOOO-fold less potent than the inhibitor used in this thesis. Finally. the generation of a 
P ARP-I stably transfected cell line produced a P ARP-I proficient and deficient cell line 
pair with identical genetic backgrounds. The p53 status of these MEFs has been confirmed 
as wild-type. It should be noted that previously published studies involving the use of 
immortalised P ARP-I MEFs have not analysed the p53 status of these cells. Taken 
together, a comprehensive set of data has been compiled addressing all of the major 
variables within the literature. 
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As well as analysing p53 levels and activity by Western blot analysis (by monitoring the 
levels of mdm2 and confinning nonnal p53 and mdm2 induction in the cell lines used), a 
luciferase reporter gene assay has been used to measure the transcriptional activity of p53. 
This assay is based on the transient transfection of a plasmid containing a luciferase gene 
downstream of the P2 promoter of MDM2. This P2 promoter is p53-responsive therefore, 
after DNA damage of the transfected cells, luciferase levels should increase in accordance 
with an increase in p53 activity. To control for transfection efficiency, a plasmid 
containing a ~-galactosidase gene was co-transfected with the luciferase plasmid and a 
ratio of luciferase/~-galactosidase calculated to represent p53 activity. Before using the 
reporter gene assay to measure p53 activity, it was necessary to validate the assay. This 
was achieved by showing that the P2 promoter was necessary for the expression of 
luciferase by transfecting cells with the luciferase plasmid with and without the P2 
promoter. Figure 5.1 shows that the plasmid containing the P2 promoter resulted in much 
greater expression of luciferase. Furthennore, it was shown that this luciferase expression 
was dependent on p53 status, with a p53 degraded cell line (HCT -116 N7) producing lower 
luciferase levels compared to the corresponding p53 wild-type cell line (HCT-116). 
Finally, it was necessary to show that the luciferase assay was responsive to DNA damage. 
Therefore, HCT -116 cells were treated with 5Gy IR and luciferase levels measured over a 
period of 6h. The data showed an increase in luciferase 6h after IR treatment, 
corresponding to an increase in p53 and mdm2 protein levels as measured by Western blot 
analysis (figure 5.3). This assay was therefore used as a validated measure of p53 activity 
in all subsequent DNA damage response experiments. 
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5.3.1 Analysis of the reduced luciferase and ~-galactosidase levels observed in the 
luciferase assay in P ARP-l-/- MEFs 
Initial experiments using PARP-l proficient and PARP-l-/- MEFs treated with 50y IR 
produced interesting results in the luciferase assay. Plotting of the results in a bar chart 
showed that the P ARP-l knockout MEFs had reduced luciferase/~-galactosidase values 
compared to the P ARP-l proficient cells. In addition, these values did not increase with 
time after DNA damage (figure 5.5). Initially this could be interpreted as a reduced p53 
activity in the absence ofPARP-l. However, closer analysis of the raw data values reveals 
a large reduction in both luciferase and ~-galactosidase values (approximately 10-fold). 
This phenomenon has been described previously, with Agarwal et aI., 1997 describing a 
reduced luciferase expression in PARP-l-/- MEFs compared to their P ARP-I +/+ 
counterparts. However, the reduction observed was only 100/0, whereas the reduction 
observed in this thesis was up to 900/0 in the actual raw data values compared to the PARP-
1 proficient MEFs (see figure 5.6). The study of Agarwal et aI., 1997 showed only the data 
obtained from the calculation of ratios ofluciferase to a transfection control (which was 
LacZ expression in that study). Therefore, it is possible that the raw data values (for 
luciferase and LacZ) may have decreased significantly compared to the PARP-I +/+ MEFs. 
However, this would not significantly alter the resultant ratio. If the raw data values of 
such an experiment alter to the extent observed in this thesis, then the results could not be 
used as a reliable indicator of p53 activity. It should also be noted that the PARP-l 
proficient MEFs used in this thesis were produced by the stable transfection of PARP-l 
into the PARP-I knockout MEFs. Therefore, these cells are predicted to be genetically 
identical except for the expression ofPARP-l in the stably transfected cell line, thus 
excluding the possibility that different genetic backgrounds of the cells were influencing 
the luciferase assay. Treatment of the PARP-l stable transfectant with AG 14361 did not 
alter the expression of luciferase or ~-galactosidase, therefore the effect observed in the 
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PARP-l-1- cells is possibly a result of the lack ofPARP-l protein rather than activity. As 
described in section 1.4.5, PARP-l protein has been implicated in the control of 
transcription, with studies showing that PARP-l can bind and/or ADP-ribosylate several 
components of the transcriptional machinery. However, Western blot analysis of mdm2 
revealed that the absence ofPARP-l protein did not influence the IR-induced increase in 
expression of this endogenous (as opposed to transfected) gene. Transcription of this gene 
relies upon the same promoter used in the luciferase assay (the P2 promoter of .\fDAf2). 
Therefore, it appears that the observed decrease in plasmid expression in the PARP-I-1-
MEFs was either due to reduced transfection efficiency or reduced expression, specifically, 
of exogenous plasmids in the absence of P ARP-l protein. These hypotheses are further 
supported by the fact that ~-galactosidase values are also significantly reduced in the 
absence of PARP-l protein. The fact that PARP-l inhibition does not reduce luciferase or 
~-galactosidase values suggests that it may be that PARP-l interacts with certain proteins, 
or indeed the exogenous DNA itself, resulting in stabilisation and/or expression of the 
plasmid gene. If time had permitted, this interesting observation would have been 
investigated further. For example, transient transfection of PARP-l into PARP-l-1- MEFs 
may have resulted in an increase in luciferase expression. However, there would be no 
way of knowing what percentage of cells had actually been transiently transfected with 
PARP-l in this system, making the interpretation of such results difficult. 
5.3.2 Analysis of the p53 response to different DNA damaging agents in the 
presence and absence of P ARP-I 
The p53 response was analysed using Western blotting and a luciferase reporter gene 
assay. Three different DNA dan1aging agents were used, IR, UV and temozolomide. In 
addition. experiments were performed in MEFs (PARP-I proficient and deficient) and 
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human HCT -116 cells. PARP-l activity was abolished in the PARP-l proficient mouse 
and human cells by treating with IJ..lM AG14361. 
5.3.2.1 IR treatment 
The P ARP-l proficient MEFs showed an identical pS3 induction to the P ARP-l knockout 
MEFs, as measured by Western blot analysis (figure S.4). In addition, the induction of the 
pS3 target gene, mdm2 was identical. This indicates that PARP-l is not required for the 
efficient induction or activation of pS3 in response to IR. This result is in agreement with 
Masutani et aI., 1999, who observed similar responses in PARP-l +/+ and P ARP-l-/- MEFs 
treated with 8Gy IR. However, other studies have suggested a reduced pS3 response in the 
absence ofPARP-l after treatment with IR. For example, after SOy IR treatment, PARP-
1-1- MEFs (disrupted in exon 2) were found to have a reduced pS3 induction 
(approximately 20% compared to PARP-I +/+ MEFs) (Agarwal et a/., 1997). However, 
only 24h time points were analysed in this study, whereas pS3 has usually been maximally 
induced between 2 and 4h before gradually returning to basal levels. This study also 
demonstrated that downstream effects ofpS3 were unaffected by this reduced pS3, with 
P ARP-l knockout MEFs demonstrating an intact G 1 arrest after IR. A similar study using 
different PARP-rl - MEFs (disrupted in exon 4 as are those used in this thesis) also showed 
a reduced p53 response to 6Gy IR (Valenzuela et a/., 2002). In fact, in that study the pS3 
induction observed in the PARP-I-1- MEFs was barely detectable by Western blot analysis. 
In contrast, a massive pS3 induction is observed in the PARP-l +/+ MEFs, beginning at 2h 
and reaching a peak at 6h. Despite the huge difference in pS3 induction, that same study 
did not show any difference in cell survival between immortalised PARP-I proficient and 
deficient MEFs after IR treatment. Given that the principle role of pS3 in the cell is to 
induce cell cycle arrest to allow time for DNA repair to occur or to induce apoptosis, the 
lack of an effect on cdl survival is perhaps surprising. It may be important to the 
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interpretation of results that the two studies discussed in this section have both used 
primary MEFs to analyse p53 responses (immortalised MEFs were used for cell survival 
assays). As described in the next chapter (chapter 6) of this thesis, the primary PARP_l"/-
MEFs investigated here grow much more slowly than the P ARP-l +1+ MEFs. A retardation 
of growth to this degree indicates that there is a major defect in one or more pathway(s) 
regulating cellular proliferation. This is very likely to have consequences in terms of how 
the cell responds to genotoxic stress via the activation of p53, which is itself important in 
the regulation of cellular proliferation. Results obtained in such circumstances may not be 
representative of the normal cellular response to DNA damage. 
Studies have also been performed on immortalised MEFs. For example, basal p53 levels 
in immortalised PARP_l"/- MEFs (disrupted in exon 2) were substantially lower than in 
PARP-l +1+ MEFs (Wesierska-Gadek et al., 1999). In addition, a reduced p53 induction in 
response to doxorubicin (a topoisomerase II poison) was observed in the absence of PARP-
1 in the same study. However, results presented in this thesis have suggested a propensity 
for the P ARP-l +1+ MEFs to undergo p53 mutations during immortalisation whereas the 
PARP-I-I- MEFs retain wild-type p53 (see Chapter 4, Section 4.2.1). Indeed, several 
studies have been published describing a tendency for MEFs generally to develop p53 
mutations during immortalisation (Rittling and Denhardt, 1992; lenkins et ai, 1984; 
Harvey and Levine, 1991). The observed phenotype of the immortalised MEFs in this 
thesis, in terms of p53 expression, is higher basal levels in the p53 mutant P ARP-l ++ 
MEFs compared to the p53 wild type PARP-I-I- MEFs. Therefore, when considering 
studies with immortalised MEFs, that do not present sequencing data, the possibility 
cannot be excluded that the cells an: expressing mutant p53, which would abolish or alter 
the p53 induction usually observed in response to DNA damage. In this thesis, by the 
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transfection of P ARP-l into P ARP-l knockout MEFs, a cell line pair has been produced 
that both express wild type p53 but are either proficient or deficient in PARP-l. Therefore, 
the results presented in this thesis have circumvented the potential problems of p53 
mutations which tend to be selected for during the immortalisation of MEFs. Also, the 
immortalised MEFs, by definition, have a faster growth rate than the primary MEFs, 
eliminating any of the potential problems encountered with very slow-growing primary 
cell lines (see Chapter 6 for further details). In addition, the results obtained in the PARP-
1 knockout MEFs have been replicated using the PARP-l inhibitor, AG 14361, further 
supporting the conclusion that P ARP-l is not involved in the regulation of p53 in response 
to IR. 
As briefly described above, If..lM AG14361 does not alter the p53 response after IR 
treatment. This was true in the clone 23 MEFs and also the human HCT-116 cells. 
Western blot analysis ofp53 and mdm2 in both cell lines showed identical patterns of 
induction with or without If..lM AG14361. In addition, in the PARP-l proficient cell lines, 
where transfection efficiencies were not reduced, and it was possible to derive conclusions 
from the luciferase reporter gene assay, again 1 f..lM AG 14361 did not affect the observed 
increase in p53 activity over time in both cell lines. 
Previous studies analysing p53 responses after IR treatment using PARP-l inhibitors have 
produced conflicting results. For example, Lu and Lane, 1993, observed an increased p53 
response after treatment of cells with 3-AB and IR. The authors proposed that the 
increased p53 was due to a persistence of strand breaks, caused by PARP-l inhibition and 
slowing of repair, resulting in increased signalling to p53. Conversely, 'Nang et aI., 1998, 
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showed that the pS3 induction in glioblastoma cells treated with 3-AB was significantly 
reduced 1.Sh after IR treatment. This corresponded with a reduction in the levels of both 
p2l and mdm2. However, the effect observed was only transient with no reduction in p53 
evident at later time points. It should be strongly noted that both of the studies mentioned 
used 3-AB, a 1000-fold less potent and less specific PARP-l inhibitor than AG1436L the 
inhibitor used in this thesis. Therefore, some of the effects observed with this inhibitor 
may be due to non-specific effects of the inhibitor (e.g. Hunting et at., 1985), which is 
influencing the pS3 response to IR. It also cannot be excluded that the differences 
observed are due to different cell lines being used in the studies described. 
The results summarised in this section strongly suggest that P ARP-I is not involved in the 
IR-induced pS3 response. Contradictory published data has been summarised, along with 
possible explanations for the contradictory data described. The results presented within 
this thesis allow conclusions to be derived, which will not have been influenced by such 
factors as the pS3 status of immortalised MEFs or the probable lack of inhibitor specificity. 
Instead, PARP-l proficient and deficient MEFs, with proven wild-type pS3, have been 
used along with an inhibitor that has been shown to abolish ADP-ribose polymer formation 
at a concentration of 1 J,lM. This is in marked contrast to the> millimolar concentrations of 
3-AB required to achieve similar PARP-l inhibition. As well as Western blot analysis, an 
intact cell reporter gene assay has been used to measure pS3 activity. Taken together, a 
comprehensive set of data has been amassed showing that PARP-l is not involved in the 
regulation of pS3 in response to SGy IR. 
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The advantages of the cell lines (in terms of known p53 status in the MEFs) and inhibitor 
used, which have been described in this section, will also apply to the following sections 
where results of identical experiments with different DNA damaging agents are discussed. 
5.3.2.2 Ultra violet radiation 
The majority of studies analysing the involvement of P ARP-l in the cellular response to 
UV have suggested that PARP-l is not involved in the repair of UV -induced damage, with 
no sensitisation to UV observed in the absence of PARP-l. In addition no poly-ADP-
ribose was synthesised in response to UV treatment (Satoh et al., 1993; Molinete et al., 
1993, Wang et al., 1995). Contrary to these findings, several earlier studies showed that 
PARP-l activity increases in human lymphoblastoid cell lines after UV treatment (see 
Section 1.4.3.2). Interestingly, this activation was abolished in xeroderma pigmentosum 
lymphoblast cells, which are unable to excise pyrimidine dimers (Berger et al., 1980). 
This suggests that the strand break generated after dimer excision is able to activate P ARP-
1. It is therefore possible that this PARP-1 activation could influence the downstream 
activation ofp53. However, the results presented in this thesis suggest this regulation does 
not occur in MEFs or the established HCT -116 cells. 
PARP-1 proficient MEFs treated with 50J/m2 UV showed the same pattern of p53 and 
mdm2 inductions, both quantitatively and with the same time course, as P ARP-1 knockout 
MEFs. as shown by Western blot analysis. This is in agreement with Valenzuela et al., 
2002. who showed an identical pattern of p53 induction in PARP-l +/+ and PARP- r/- MEFs 
after 40J/m2 UV. No conclusions could be derived from the luciferase assays comparing 
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the PARP-1 proficient and deficient MEFs in this thesis, for the reasons discussed in 
section 5.3.1. 
Experiments involving the use of AG 14361 to remove P ARP-l activity from P ARP-l 
proficient cell lines have also shown that P ARP-l is not involved in the p53 response to 
UV -irradiation. Both PARP-l proficient MEFs and HCT -116 human colorectal cells 
showed identical patterns of p53 and mdm2 induction in the presence or absence of 1 J..lM 
AG 14361. In addition, luciferase assays measuring p53 activity in these cell lines also 
showed that AG14361 did not change the observed response to UV (figures 5.8 and 5.9). 
Studies elsewhere showing an altered p53 response in the absence of PARP-I after 
treatment with certain DNA damaging agents suggest one of two mechanistic explanations. 
Firstly, some groups suggest that the absence of P ARP-l leads to a prolongation of strand 
breaks in response to DNA damage and hence an increased p53 response, presumably due 
to e.g. increased ATM kinase signalling to p53. Such a response has been observed with 
IR and MNU (Lu and Lane, 1993; de Murcia et al., 1997). This is obviously not a direct 
regulatory role of PARP-1 on p53. Rather, it is a side-effect due to an impaired DNA 
repair pathway in the absence of P ARP-l, leading to persistence of DNA strand breaks. 
The fact that several studies have shown that P ARP-1 is not involved in the repair of UV-
induced DNA damage (Satoh et al., 1993; Molinete et al., 1993, Wang et al., 1995) 
suggested that an increased p53 response to UV in the absence of P ARP-l would not be 
expected. This is in agreement with the results presented in this thesis. The second 
explanation provided for an altered p53 response to DNA damage is that PARP-l is 
directly regulating p53. putatively by poly(ADP-ribosyl)ation or protein-protein 
interaction. Several studies han~ shown that PARP-l is not activated in response to UV 
(Satoh d a/., 1993: Molinete el aI., 1993), suggesting that post-translational modification 
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ofp53 by PARP-l could not occur after exposure to UV, and hence the p53 response 
would not be altered in the absence of P ARP -1. Again this is consistent wi th the results 
presented in this thesis. 
5.3.2.3 Temozolomide treatment 
Several studies have been published showing that animals and cells lacking P ARP-l are 
hypersensitive to treatment with alkylating agents, with the relevant data being summarised 
in Section 1.4.3 (Wang et al., 1997; de Murcia et aI., 1997; Masutani et al.. 1999). The 
putative basis for this sensitivity was a defect in the base excision repair pathway that 
would usually repair lesions caused by alkylation damage, hence causing a potentiation of 
the DNA damage and the consequent decrease in survival. In such circumstances it might 
be expected that the prolongation of strand breaks would bring about an enhanced p53 
response. This effect has indeed been observed in PARP-l MEFs treated with MNU, a 
monofunctional alkylating agent (de Murcia et aI., 1997; Valenzuela et aI., 2002). 
The data presented in this thesis did show a slight potentiation of the p53 induction in 
PARP-l proficient MEFs treated with temozolomide and 1 ~M AG 14361 when compared 
to control cells. This observation would be in agreement with those studies described 
earlier in this section. However, an enhanced p53 induction may be expected to bring 
about an increased mdm2 induction due to increased transcriptional transactivation activity 
ofp53. However, this was not observed, since very similar mdm2 inductions were seen in 
the presence or absence of AG 14361 in the PARP-l proficient MEFs. The lack of a 
change in p53 transactivation activity is also demonstrated in the luciferase assay, where 
AG 14J61 clearly had no effect on the p53 activity in the clone 2J MEFs. It is important to 
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note that an increase in p53 activity depends upon a variety of post-translational 
modifications, including phosphorylation and acetylation on several amino acid residues. 
It therefore cannot be excluded that p53 levels are increasing, but the post-translational 
modifications required to increase DNA binding are not occurring. Despite this, a change 
in p53 response observed in the presence of AG 14361 would perhaps be expected to occur 
in the PARP-r l- MEFs also. However, as was seen in figure 5.12, the PARP-l- - MEFs 
produced p53 and mdm2 inductions very similar to the control clone 23 MEFs. In 
addition, experiments performed in HCT -116 cells showed that both p53 levels and 
activity were unchanged in the presence and absence of I/lM AG 14361. The enhanced 
p53 levels in clone 23 MEFs treated with AG 14361 may be due to a cell-line specific 
effect that does not occur in HCT -116 cells. In addition, in the P ARP-l MEFs, the 
difference between inhibiting P ARP-l and knocking out P ARP-l may account for the 
apparent discrepancy between PARP-1 inhibited MEFs and PARP-l knockout MEFs. 
F or example, in response to temozolomide treatment, strand breaks are generated in both 
PARP-l proficient and deficient MEFs, as PARP-l is not involved in the actual removal of 
the damaged base or the incision event at the AP site (Shall, 1984). In the clone 23 MEFs 
treated with AG 14361, P ARP-1 would bind to the strand break and remain bound due to 
inhibition of catalytic activity and hence lack of P ARP-l automodification which \\'ould 
result in its release. The bound P ARP-1 may in turn block access of other repair enzymes 
to the site of damage and hence the strand break persists, potentially leading to 
hyperactivation of DNA damage response kinases, such as A TM or A TR, and increased 
signalling to p53. In this situation, the effect would not be observed in the PARP-l 
knockout cells as access of repair enzymes to the strand break is not blocked by the 
presence of P ARP-l. Although this hypothesis would explain the data obtained after 
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treatment ofPARP-l MEFs with temozolomide +/- AG14361, it is not in agreement with 
several published studies showing that PARP-I-I- MEFs have seriously inhibited repair of 
alkylation damage. If time had permitted the above experiments would have been repeated 
to try and confirm the described effect. It would then have been possible to design 
experiments to test the proposed model for increased p53 induction in the P ARP-l MEFs. 
5.3.3 General conclusions 
This chapter contains data that is relevant to the initial hypothesis of this thesis, which was 
that P ARP-I functions as an upstream regulator of p53. The data presented summarising 
the p53 response to UV was in accordance with those previously published data, which 
indicated the p53 response is independent of P ARP-l. The p53 response observed after 
alkylating agent treatment was partially in agreement with published data, with PARP-l 
proficient MEFs treated with AG 14361 and temozolomide producing a slightly enhanced 
p53 induction compared to DMSO-treated control cells. However, such an observation 
was not repeated in the P ARP-l knockout MEFs. If time had permitted, an alternative 
alkylating agent would have been used, such as MNU, which has previously been shown to 
potentiate the p53 response in P ARP-l knockout MEFs compared to P ARP-l proficient 
MEFs. The involvement of PARP-l in the p53 response to IR is perhaps the area of 
research where most studies have been performed. Curiously, these studies have not 
produced any firm or coherent conclusions regarding the nature of any regulation of p53 by 
P ARP-I. In fact, different groups have produced opposing results, with some showing no 
involvement of PARP-I and others suggesting a role for PARP-l in the regulation of p53. 
There are many potential explanations for these discrepancies, including the different cell 
lines analysed and the different techniques used to remove PARP-l activity from (dis. 
With particular regard to this thesis, I ha\'t~ shown that the p53 status of immortalised 
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MEFs and the growth rates of primary MEFs should also be taken into consideration when 
performing experiments and when deriving conclusions from them. Of particular concern 
is the tendency of PARP-l +1+ MEFs to develop p53 mutations during immortalisation: a 
phenomenon which interestingly was not observed in the P ARP-I-I- MEFs. In addition, 
data within this thesis (Chapter 6) has shown a much reduced growth rate in the primary 
PARP-I-1- MEFs compared to their P ARP-l wild-type counterparts and raised doubts 
regarding their suitability for analysing p53 responses. Finally, doubts have been raised 
regarding the specificity of 3-AB, used in many studies analysing PARP-l function. In 
this thesis, a very potent P ARP-l inhibitor (AG 14361) has been used, which is 
significantly more potent than any other inhibitor that has been used to analyse p53 
responses within the literature. 
One or more of the factors mentioned above could influence the p53 response to DNA 
damage. However, data from this thesis would suggest that P ARP-l does not directly 
signal to, or modify p53 in the cell systems analysed. Any change in the p53 response that 
has been observed was after temozolomide treatment in P ARP-l inhibited MEFs, with the 
effect likely attributable to an impaired BER pathway. 
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6.1 Introduction and objectives 
The initial aim of this thesis was to use immortalised P ARP -1 +1+ and P ARP_l-i - MEF s to 
investigate the potential role ofPARP-l in the DNA damage-induced regulation of p53. 
The immortalisation procedure involves the isolation and growth in culture of primary 
MEFs obtained from the homogenisation of mouse embryos. These cells are then 
continuously passaged until they reach a stage of growth called senescence. This state is 
characterised by the halting of cellular growth. Senescent cells actually arrest with a G 1 
DNA content and cannot be stimulated to resume proliferation by mitogenic stimuli. 
Eventually, out of this population of essentially non-cycling cells, an immortalised sub-
population of cells will grow. Several studies have been published implicating p53 in 
cellular senescence. For example, p53 transcriptional activity increases with the ageing of 
cells (ltahana et al., 2001). In addition, wild type p53 is necessary for growth arrest in 
senescence (Sugrue et al., 1997). Finally, a high percentage of cells that escape senescence 
have lost wild type p53 activity (see Section 6.3). 
During this study, it was discovered that two independently derived lines of immortalised 
P ARP-l +1+ MEFs were expressing mutant p53 (Chapter 4, Section 4.2.1). However. the 
corresponding PARP-I-1- MEFs expressed wild type p53. Bearing in mind the putative role 
for p53 in cellular senescence and immortalisation, this was a very interesting observation. 
It suggests that, for some reason, the absence of PARP-l bypasses the requirement of 
MEFs to mutate p53 during immortalisation. The PARP- r '-MEFs have been described as 
being genetically unstable, characterised by an increase in sister chromatid exchanges (de 
Murcia et al., 1997). Although the P ARP-I-I- mice are not tumour prone, perhaps the 
genetically unstable cells adopt a mutation to a different gene. other than p53, allowing 
them to escape senescence. Alternatively, there may be a more functional explanation. 
214 
Chapter 6 - Results ./ 
whereby P ARP-l and p53 may both have roles to play in senescence and immortalisation. 
In the absence of P ARP-l it may be necessary for the MEFs to retain wild type p53 
whereas it may be beneficial to lose p53 function in the presence of PARP-l. In addition 
to being an interesting observation in this study, this finding may have relevance in terms 
of previously published data. As highlighted several times during this thesis. discrepancies 
exist regarding the role (if any) ofPARP-l in p53 regulation. In studies using 
immortalised MEFs, without directly sequencing the p53 and testing its functional 
integrity, it cannot be excluded that the PARP-l+1+ MEFs possess a p53 with an altered 
function due to mutation or other mechanism of functional inactivation, such as 
amplification of MDM2. 
The aim of this chapter was to demonstrate whether the p53 mutation was indeed a 
consequence of the immortalisation process. It was therefore necessary to show that both 
the primary MEFs and the P ARP-l mice, from which they were derived, expressed wild 
type p53. The p53 in primary PARP-l MEFs was sequenced and also examined by 
Western blot analysis. 
A further aim of this section was to repeat the immortalisation procedure in five 
independently derived PARP-l +1+ and PARP-I-1- primary MEFs to gain a more statistically 
reliable figure, in terms of the p53 status in immortalised MEFs in the presence and 
absence of P ARP-l. 
As well as monitoring growth during the immortalisation experiments, observations \\ere 
made regarding the morphological changes that occurred to the primary M EFs during the 
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course of the experiment. The cells were photographed at the pre-scenescent and 
scenescent phases. 
As will be described in the following sections, all colonies of primary MEFs were lost 
before immortalisation had occurred, due to infection. Despite this, other significant and 
interesting observations were made during the growth of the cells. Most importantly, the 
P ARP-I-I- cells had a greatly reduced growth rate compared to the P ARP-l +1+ rvlEF s. 
Data presented in this chapter is in the form of Western blot analysis and cDNA 
sequencing to analyse the p53 status of P ARP-l cells or tissues. In addition cumulative 
growth curves are presented showing the effect of AG 14361 on the long-term growth of 
primary and immortalised MEFs. Finally, photographs are included to demonstrate the 
morphological differences between primary and senescent MEFs. 
6.2 Results 
6.2.1 P53 expression and status in primary and immortalised P ARP-l MEFs 
As previously described, the immortalised PARP-l +1+ MEFs that were to be used in this 
study were found to be expressing mutant p53. This section reintroduces the data 
confirming the p53 status of these immortalised MEFs. In addition, corresponding data is 
presented from primary MEFs, demonstrating the expression of wild type p53 in both the 
PARP-l +1+ and PARP-I-1- cells. 
Western blot analysis was performed on celllysates from two independ~ntly derived 
immortalised pairs of MEFs as well as on the primary rvlEFs. The levels of p53 expression 
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were measured. Frequently, p53 mutations are indicated by ery high basal Ie els of p-3 
expression due to increased stability and resistance to mdm2-mediated degradation. In 
addition, cDNA sequencing of p53 was performed in all cell lines to complement the 
Western blot analysis. 
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Figure 6.1 Western blot analysis of pS3 levels in untreated immortalised and primary PARP-l MEF 
Figure 6.1 shows that both of the independently derived immortalised P ARP-1 +/+ MEFs 
express significantly higher p53 levels than the primary MEFs from which they were 
derived. It should be noted that all of the data presented in Figure 6.1 are from Western 
blots that were processed under identical conditions and the exposure times of the Western 
blots to X-ray film were constant. As described above, high basal levels ofp53 are 
indicitive of a mutation within p53. Frequently this mutation increases the half life of p53 
possibly by reducing mdm2-mediated degradation. Sequencing data for P ARP-l +/+ and 
GPARP-l +/+ immortalised MEFs has been presented in Chapter 4, Section 4.2.1. 
However for the pw-poses of this section, this data will be reintroduced and mpar d t 
additional data deri ed from the primary PARP-I +/+ MEFs (pa ge 1 . 
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Figure 6.2 p53 sequencing data from immortali ed and primary PARP- J MEF 
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Figure 6.2 shows that in the immortalised pairs ofPARP-1 MEFs, the PARP-I++ and 
GPARP-I +1+ MEFs express mutant p53. Both have a mutation within codon 278. but with 
a different base change within that codon. The immortalised P ARP-I + ~ MEFs have a C to 
G change producing an Asp to Glu amino acid change. The immortalised GP ARP-I ++ 
MEFs have a G to C change, producing an Asp to GIn amino acid change. It is surprising 
and interesting to note that both of the mutations are within the same codon. Western blot 
analysis revealed an inability to transactivate mdm2 in both of these P ARP-I +1+ 
immortalised MEF cell lines (Chapter 4, Sections 4.2.1 and 4.2.3), consistent with the 
codon 278 alterations representing loss of function mutations. abrogating the 
transcriptional transactivation function of p53. Figure 6.2 also shows that the immortalised 
PARP-I-1- and GPARP-I-I- MEFs both express wild-type p53. 
6.2.2 p53 expression in PARP-l mouse tissues 
The data presented in the previous section clearly shows that p53 mutations have 
developed during cell culture, probably during the immortalisation process since they were 
not present in the early passage primary MEFs. As a further confirmation of this, tissues 
were isolated from the PARP-l mice and analysed for p53 expression using Western blot 
analysis. It was important to check whether low basal p53 levels are expressed in a variety 
of tissues, not only for this study but also to validate other studies which have been 
performed on these mice within the Cancer Research Unit. Frozen tissues were 
homogenised using a pestle and mortar and liquid nitrogen, before being dissolved in hot 
SDS lysis buffer. After protein estimation, 50~g of total protein were subject to \Vest~rn 
blot analysis. Tissues were isolated from three P ARP-I +1+ and P ARP-I-1- mice and all 
samples analysed. As a controL samples from the relevant immortalised PARP-I MEFs 
were also included on the Western blot. 
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Figure 6.3 Western blot analysis of p53 levels in P ARP mouse tissues, probed with the rabbit 
polyclonal eM5 antibody 
p53 
As can be seen in the Western blots above (figure 6.3), tissues from the PARP-l +1+ mice 
expressed very low levels of p53 compared to the immortalised +/+ MEFs derived from 
these mice. These lower levels were virtually undetectable and are indicative of wild type 
p53, further confirming that the p53 mutation has developed during cell culture. The 
tissues from the PARP-I-1- mice also possessed lower levels of p53 to the -/- MEFs derived 
from these mice. This may suggest that when placed in cell culture, which is a non-
physiological situation, the MEFs become stressed and as a consequence slightly up-
regulate p53. 
6.2.3 The immortalisation ofPARP-l MEFs 
The results presented earlier in this chapter show that two independently deri ed colonie 
of immortalised P ARP-l +1+ MEFs express mutant p53. This is in contra t to the 
corresponding inlll10rtalised PARP-I-1- MEFs that express wild type pS3 . In additi n. it 
has been shown that the primary MEFs (both +/+ and -/-) expre wild typ P 
Therefor , it is possible that iDllnortalisation of the PARP-l +/+ MEF in ti n r r 
p53 mutati n . In contra t, the ab en of PARP-l m 11 '" the r quiremenl t mut· lc 
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pS3 during the immortalisation process to be bypassed. To test this hypothesis further, the 
immortalisation procedure was repeated using a greater number of independent colonies of 
PARP-l MEFs. 
The immortalisation process was set up according to the standard 3T3 protocol (Todaro 
and Green, 1963). Briefly, 1 x 106 cells (passage 1) were placed into a 100mm tissue 
culture dish and allowed to grow for 3 days. The cells were then counted and re-plated at 1 
x 106 cells per plate. This process was repeated until the cells had reached senescence. 
This phase in cellular growth is characterised by a halting of proliferation. At this point, 
upon splitting, cell numbers had actually decreased. It was therefore decided to stop 
splitting every three days and to simply observe the cells, looking for evidence of 
transformed (immortalised) cells. Such areas are apparent in the form of dense patches of 
small cells, which is in contrast to the large, irregular-shaped senescent cells (see figure 6.S 
for the morphology of cells). Five independent plates were set up for each of the P ARP-
1 +/+ MEFs, the P ARP-l-/- MEFs and also P ARP-l +/+ MEFs grown in the presence of 1 J..lM 
AG 14361. By setting up five independent plates of 1 sl passage cells and keeping them 
growing independently, it was ensured that any immortalised colonies eventually isolated 
that contain pS3 mutations will have arisen by independent events. AG 14361 will inhibit 
PARP-l activity in these cells and, as in PARP-l-/- MEFs, may allow immortalisation 
without mutation of pS3. The cell counts for all IS independent colonies were plotted in 
the form of cumulative growth curves (Figure 6.4). 
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Cum ulative growth curves of primary P ARP-l MEFs 
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Figure 6.4 C umulative growth curves of primary PARP-l MEFs 
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As can be seen in figure 6.4, the primary P ARP-l +/+ MEFs grew with a constant growth 
rate for approximately 20 days, with an average doubling time of 40 hours. At this point. 
after around 12 cell doublings, cellular proliferation slowed dramatically. as the cells 
entered senescence. Associated with entry into senescence was a change in morphology. 
from small densely packed cells to large, flat and irregular shaped cells (see figure 6.5). 
Unfortunately, during senescence all P ARP-l +/+ MEFs were lost due to infection. One 
plate of P ARP-l +/+ MEFs showed signs of transformed areas of cells with several colonies 
evident under the microscope. This plate was split in order to spread the cells over the 
whole area of the plate. There was evidence of a small increase in cell number. indicative 
of immortalisation. However, this plate was also lost to infection before any analysis of 
p53 status could be carried out. 
The P ARP-l-/- MEFs showed a much reduced growth rate compared to the PARP-l +/+ 
MEFs, despite being plated out at the same cell number initially. Because of this, these 
cells were split less often to try and allow the cell numbers to increase. Despite this, the 
P ARP-l-/- MEFs grew extremely slowly. with a doubling time of around 200 hours. It 
appeared from microscopy that a significant proportion of the P ARP-l-/- cells had entered a 
premature senescence, with the cells adopting a senescent morphology early in the 
immortalisation process (see figue 6.5). Again these cells were lost to infection before any 
immortalised colonies were derived. Interestingly, growth of PARP-l +/+ MEFs in medium 
containing 1 J..lM AG 14361 retarded the growth of these cells (doubling time of 
approximately 180 hours) to a level comparable to the PARP-l knockout cells. AG 14361 
also acted to induce a premature senescent morphology in the PARP-l +/+ MEFs, with large, 
flat cells being apparent early in the immortalisation procedure. The PARP-l +/-t ~tEFs did 
not adopt a scenescent morphology until day 20 of the immortalisation procl:ss. However, 
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both the P ARP-l-/- and P ARP-l +/+ inhibitor-treated cells adopted this phenotype within 5-7 
days of cell culture. Unfortunately, the inhibitor-treated cells were also lost due to 
infection before any immortalised cells had emerged. The difference in growth rate 
between primary PARP-l +/+ and P ARP-l-/- MEFs was not observed in the immortalised 
P ARP-l MEFs, where both the P ARP-l proficient and deficient MEFs grew with a 
doubling time of 20 hours (data not shown). 
To eliminate any potential effect of the DMSO (in which AG14361 is dissolved) on cell 
growth, a control plate was set up containing 0.010/0 DMSO. These cells showed identical 
growth characteristics to the PARP-l +/+ MEFs (data not shown). 
Due to the time restraints involved in the completion of a PhD, it was impossible to repeat 
the above long-term experiment. 
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Figure 6.5 Photograph showing the morphology of prima ry and cene cent P RP- l l EF ' 
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Although the immortalisation experiment did not produce any immortalised cells from 
which p53 data could be derived, it did reveal interesting growth characteristics in the 
presence and absence of P ARP -I. For instance, in the absence of P ARP -1. either through 
knocking out the gene or through chemical inhibition by AG 14361, the growth of primary 
MEFs was slowed dramatically. In addition, these cells appeared to enter a premature 
scenescence after only 5-7 days in cell culture. 
6.3 Discussion 
6.3.1 Summary of results 
The data presented in this chapter has shown that the p53 mutation detected in two 
independently derived colonies of immortalised PARP-I +/+ MEFs developed during cell 
culture. Western blot analysis showed that these cells expressed high basal levels of p53 
compared to primary PARP-I +/+ MEFs. In comparison, tissues derived from PARP-l +/+ 
mice had virtually undetectable levels of p53 (figure 6.3). This Western blot data 
suggested that both the PARP-I +/+ mice and primary MEFs were expressing wild-type p53. 
This was confirmed by cDNA sequencing, clearly showing the expression of wild-type p53 
in primary P ARP-l +/+ MEFs whereas the immortalised P ARP-l +/+ MEFs were shown to be 
expressing mutant p53 (figure 6.2). Western blot data of primary and immortalised PARP-
1-/- MEFs showed low basal levels of p53, as did data from PARP-l-'- tissues. This 
indication of wild-type p53 in these cells was confirmed by cDNA sequencing (figure 6.2). 
Taken together, this data showed that the p53 mutation detected in the two colonies of 
immortalised PARP-I +/+ MEFs developed during cell culture. In addition, the data 
suggests that the absence of PARP-I bypasses the requirement of MEFs to mutate p53 
during immortalisation. An experiment was performed to test this hypothesis but cells 
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were lost to infection before analysis of p53 status could take place. Despite this, 
interesting data was obtained from this experiment, with cumulative growth curves 
showing that primary P ARP-I-1- MEFs grew very much more slowly than the primary 
PARP-I+1+ MEFs. In addition, the absence ofPARP-1 appeared to induce a premature 
senescence, with P ARP-I-1- MEFs adopting a morphology typical of senescence after only 
" 
5-7 days in cell culture (figure 6.5). The PARP-I +1+ MEFs did not enter senescence until 
20-22 days in culture. Significantly, a slower growth rate and apparent premature 
senescence were also observed in primary P ARP-I +1+ MEFs treated with 1 J.LM AG 14361. 
6.3.2 Analysis of the p53 status of primary and immortalised P ARP-l MEFs 
The initial aim of this thesis was to use immortalised PARP-l +1+ and P ARP-I-I- MEFs to 
analyse the requirement of PARP-l in the DNA damage induced p53 response. However, 
initial experiments on two independently derived pairs of immortalised PARP-l MEFs 
revealed that both colonies ofPARP-l +1+ MEFs were expressing mutant p53. It was shown 
in this chapter that these mutations occurred during cell culture by sequencing the p53 in 
primary PARP-I +1+ MEFs and revealing that the p53 was wild type in these cells (figure 
6.2). These primary MEFs are the pre-cursor cells for the immortalised PARP-l +/+ MEFs. 
indicating that the p53 mutation had occurred during cell culture. A literature search 
regarding the immortalisation of MEFs revealed that the mutation of p53 was a fairly 
common event during immortalisation. 
Unda normal circumstances, primary MEFs will undergo a finite number of cell divisions 
before entering a phase called senescence (reviewed in Itahana el a!., 2001). At 
senescence, cells have stopped growing and ha\'e essentially withdrawn from the cell 
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cycle. Human cells are thought to enter senescence due to telomere shortening. Telomeres 
are sequences of repetitive DNA that cap the ends of linear chromosomes. During DNA 
replication, there is a stretch of DNA at the end of chromosomes that is not replicated, the 
area covered by the DNA polymerase bound to the DNA template. This stretch of 
unreplicated DNA can be up to 200bp in length. Therefore, telomeres act to protect the 
essential genomic information within chromosomes by capping the ends of chromosomes 
and hence it is this telomeric DNA that is not replicated rather than DNA containing 
genetic information. It was therefore hypothesised that the acquisition of one or more 
critically short telomeres results in human cells entering replicative senescence, to prevent 
the possible loss of genetic information during DNA replication. Supporting this 
hypothesis is the finding that prevention of telomere shortening by the ectopic expression 
of telomerase, which acts to elongate telomeres, resulted in the abrogation of senescence in 
some human cells (Bodnar et al., 1998; Vaziri and Benchimol, 1998). 
The putative role of telomere shortening in inducing senescence in human cells may not be 
true for mouse cells. F or example, cells from laboratory mouse strains have very long 
telomeres and in some cases express telomerase. Despite this, mouse cells have a shorter 
replicative lifespan than human cells. The fact that mouse cells have longer telomeres than 
human cells but shorter replicative lifespan suggests that telomere shortening is not an 
important factor in the induction of scenescence in mouse cells (Wright and Shay, 2000). 
With particular relevance to this thesis, it should be noted that PARP-l-/- mice have been 
reported to have shorter telomeres compared to P ARP-l +/+ mice, with reductions in length 
of around 300/0 being observed (d'Adda di Fagagna el al .• 1999 and Tong t.!I al., 2001). 
Despite this, it should be noted that neither study makes reference to a premature 
scenescence in the absence of P ARP-I and no firm functional explanation is provided for 
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the apparent shortening oftelomeres in PARP-I-I- mice. Other studies have proposed that 
cells enter scenescence due to the stressful conditions of cell culture (reviewed in Sherr and 
DePinho,2000). Although most cells grow when placed into cell culture, it should be 
noted that the environment is far from physiological. For example, there is a disruption of 
cell-cell contacts, lack of heterotypic interactions between different cell types, persistent 
Ras activation by mitogens, hyperoxic conditions and contact with the plastic of the culture 
dish may all induce stress responses. One or more of these factors is likely to gi ve rise to 
DNA damage and induce the relevant response within the cell and subsequent cell cycle 
arrest. As senescent cells arrest with a G 1 content of DNA, it is possible that under 
permanent conditions of cellular stress, the mouse cells undergo a permanent cell cycle 
arrest. An example of the 'background' DNA damage that occurs during cell culture is 
provided by the observation that A TM null cells sustain a high level of chromosome 
breakage. In the presence of ATM, this damage would usually be repaired, however, this 
damage persists in the absence of ATM and induces a premature senescence in these cells 
(Westphal et al., 1997). 
Further support for the 'culture shock' hypothesis of cellular senescence may be provided 
by several studies showing that entry into senescence requires functional p53 (a stress 
response protein) and that subsequent immortalisation and exit from senescence requires 
loss of p53 function. Perhaps the simplest indication that p53 was required for senescence 
was provided by Harvey et al., 1993, who studied the growth characteristics of p53' . and 
p53-1- primary MEFs. Cumulative growth curves demonstrated that the p53-1- MEFs grew 
fairly rapidly and did not enter a senescent phase. However, cells possessing wild type p53 
(p53+1+) grew more slowly initially before entering senescence. This slov .. er grov .. th rate 
may be indicative of a permanent activation of a DNA damage response leading to slowing 
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of the cell cycle. Prolonged activation of this checkpoint may lead to long-term gro\\th 
arrest in senescence. A further study showed that the introduction of wild-type p53 into 
human tumour cells lacking functional p53 was able to induce a senescent phenotype 
(Sugrue et al., 1997). This study transfected a tumour cell line (expressing mutant p53) 
with an inducible plasmid construct containing wild type p53. The effect of expression of 
wild-type p53 was an apparent halting in cellular proliferation, associated with a change in 
cellular morphology. Cells adopted an increased and flattened morphology, with elongated 
cellular processes, consistent with the changes in cell shape associated with senescence 
(Hayflick and Moorhead, 1961). 
Perhaps the most compelling evidence that p53 function is required for senescence is the 
common observation that immortalised cells that exit the senescent phase have lost p53 
function (Harvey and Levine, 1991; Rittling and Denhardt, 1992). This loss of function 
may occur due to p53 mutation, or in the presence of wild type p53, be associated with a 
mutation to the tumour suppressor, p19ARF (pI4ARF in humans). p19ARF binds to mdm2 and 
prevents the inhibitory action ofmdm2 upon p53. Therefore, in the absence ofp19ARF, 
mdm2 is able unapposed to inhibit the function ofp53. Mutation ofp53 during 
immortalisation was demonstrated by Rittling and Deinhardt, 1992. This study showed 
that two independently derived colonies of immortalised MEFs expressed mutant p53, with 
the mutations being evident in the DNA binding domain. The cells were derived using a 
3T12 protocol, where four times as many cells are re-plated at each sub-culture compared 
to the 3T3 protocol described in Section 2.1.9. A more recent report analysing the p53 
d .. "')/3 status of immortalised MEFs generated by a 3T3 protocol demonstrate a mutatIOn III -' 
independent colonies (Kim el al., 2001). One mutation was a missense mutation. resulting 
in a Pro to Arg change at anlino acid 275 (very close to the site of mutations detected in 
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this thesis, amino acid 278). The other mutation was a nonsense mutation at amino acid 
173, changing Cys to a stop codon. Interestingly, the third group of immortalised \1EFs. 
with wild type p53, did not produce detectable levels of p53 mRNA or protein, as 
measured by Northern blot and immunoprecipitation. This observation was due to a 
destabilisation ofp53 mRNA and protein in these cells, by an unknown mechanism. but 
with the result of losing the p53 expression. 
From the data summarised above, it is perhaps not surprising that the two immortalised 
PARP-I +1+ MEF cell lines derived in this thesis possess p53 mutations. In addition. the 
fact that immortalisation is an essential step in tumour formation and that over 50% of 
tumours possess p53 mutations, perhaps make the observation not entirely unexpected. 
However, it was interesting to find that two immortalised P ARP-I-1- MEF cell lines both 
expressed wild type p53. It should be noted that loss ofp53 function is not an essential 
step in immortalisation and also that several other cellular changes are required for cells to 
become immortal. For example, rodent cells can be immortalised by the introduction of 
cellular oncogenes such as c-myc and c-Ha-Ras, suggesting that the activation of certain 
oncogenes can result in or contribute to immortalisation. It may be that cells can become 
immortalised by undergoing a certain set of mutations, with one mutational event 
triggering another. In the PARP-I-1- MEFs, a set of genes may be mutated, which do not 
include p53. As stated earlier, p19ARF is frequently found to be mutated, deleted or 
epigenetically inactivated by methylation in immortalised cells expressing wild-type p53. 
It may be that the immortalised P ARP-I-1- MEFs lost p 19ARF function rather than p53 
during immortalisation. It would be interesting to measure the expression levels of various 
genes or proteins implicated in immortalisation in both the PARP-l +/+ and -/- MEFs. 
This could be achieved by cDNA microarray analysis and Western blotting and any 
interesting findings investigated further by sequencing of the particular gene. As Jescribed 
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earlier, this type of analysis may reveal that different 'sets' of genes were involved in the 
immortalisation process in the PARP-l +1+ and PARP-I-I- MEFs and hence may suggest a 
role for P ARP-l in a particular immortalisation pathway. 
6.3.3 The growth rates of primary PARP-l MEFs 
The observation that immortalised PARP-l +1+ MEFs tend to undergo p53 mutations during 
immortalisation whereas PARP-I-I- MEFs do not was investigated further by attempting to 
isolate several independent immortalised colonies of P ARP-l MEFs. As described in 
Section 2.1.9, five plates of PARP-l +1+ MEFs, five plates ofPARP-I-I- MEFs and five 
plates of PARP-l +1+ MEFs grown in the presence of 1 J..lM AG 14361 were set up for long 
term growth according to the 3T3 protocol. Unfortunately, all cells were lost due to 
infection before any immortalised colonies were derived. Despite this, several interesting 
observations were made regarding the growth rates and time to reach senescence of the 
primary MEFs. As can be seen in figure 6.4, the growth rates of the PARP-rl- MEFs were 
massively slower than the P ARP-I +1+ MEFs. Interestingly, treatment of the P ARP-l +1+ 
MEFs with 1 J..lM AG 14361 slowed growth to a similar extent to that observed in the 
P ARP-I-I- MEFs. This effect was not due to the DMSO content of the medium as a control 
plate of PARP-l +1+ MEFs grown in the presence of 0.010/0 DMSO grew with the same rate 
as the untreated P ARP-I +1+ MEFs. Interestingly, the inhibition of P ARP-I and knocking 
out of P ARP-I in primary MEFs appeared to bring about a premature senescence. as 
observed by the morpholological changes described in the previous section. 
There are several possible explanations for the different gro\\th rates in the presence and 
absence of PARP-I. Before discussing these possibilities, it should be noted that all of the 
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cells were plated out at the same initial cell number and grown under identical growth 
conditions. In addition, all cells were grown at the same time and were split at the same 
time until the cells reached senescence. 
One characteristic of primary MEFs is an inability to proliferate when plated at low 
densities. Therefore, it could be argued that the P ARP-I-1- MEFs have simply been plated 
out at too Iowa density and, as such, have ceased proliferating. However, PARP-l +1+ 
MEFs were plated out at the same initial cell number and yet were able to grow much 
faster than the PARP-I-1- MEFs. The fact that AG 14361 significantly retarded the growth 
rate of the P ARP-I +1+ MEFs may suggest that the absence of P ARP-l function decreases 
the plating efficiency of primary MEFs. In this situation, despite plating out identical cell 
numbers of PARP-l +1+ and P ARP-I-I- MEFs, fewer of the latter cells would adhere to the 
plate and hence the effective cell density would be lower. If a particular cell density 
threshold had not been met then the P ARP-I-I- MEFs may enter a premature senescence. A 
similar situation would arise in the PARP-l +1+ MEFs treated with AG 14361. This 
hypothesis could be tested by plating at a range of initial densities up to 500/0 confluence. 
A different study has previously described a slower growth rate in primary P ARP-I-I-
MEFs (disrupted in exon 2) than PARP-l+1+ MEFs (Wang et al., 1995), although the 
difference reported was not as great as that in this thesis. For two days in culture. the 
growth rates of the primary P ARP-l +1+ and P ARP- r l- MEFS were significantly di fferent. 
However, after 14 days in culture, the cumulative cell number ofPARP-I-I- tv1EFs was 
approximately 500/0 of the PARP-l +1+ MEFs, consistent with a decreased grov,th rate in the 
PARP-I-1- cells. Wang et ai, 1995, used slightly different conditions for the analysis of 
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growth rates, with 1 x 105 cells/well in a 6-well plate. However, this does not represent a 
greater cell density than that used in this thesis and therefore cannot be used as an 
explanation for the greater decrease in proliferation in the PARP-I-I- MEFs observed in this 
study. Wang et ai, 1995, also makes no mention of a premature senescence in PARP-l-
'
-
MEFs, again at odds with observations made in this thesis. 
It was described in Section 6.3.2 that primary MEFs may enter senescence as a result of 
'culture shock', caused by persistent DNA damage brought about by the non-physiological 
environment that the cells are grown in. F or example, the hyperoxic conditions could lead 
to oxidative damage to DNA, such as is inflicted by IR under oxic conditions. With 
reference to this hypothesis, it is interesting to note that primary A TM-1- MEFs, that are 
defective in the repair of DNA damage, grow more slowly than their A TM+1+ counterparts. 
Xu and Baltimore, 1996, generated A TM-1- mice by homologous recombination. These 
mice and also cells derived from them were shown to be hypersensitive to the effects of JR, 
indicating a role for ATM in the response to this type of DNA damage. In addition, this 
study showed a 60-800/0 decrease in cellular proliferation and a premature entry into 
senescence in ATM-1- MEFs compared to ATM+1+ MEFs. A similar premature senescence 
has also been observed in fibroblasts derived from AT patients (Shiloh et aI., 1985). The 
characteristics of the A TM-1- MEFs may be particularly relevant to this chapter, bearing in 
mind the similar putative role of PARP-l in the response to DNA damage. For example, 
ATM-1- and PARP-I-I- mice and cells have both been shown to be hypersensitive to IR (Xu 
and Baltimore, 1996; de Murcia et aI., 1997). As described previously, cells grov.n in 
culture are subject to constant DNA damage. Under normal circumstances, this damage is 
repaired and cells continue to proliferate. However, in the absence of A TM or PARP-I, 
this damage is likely to persist due to defective DNA repair pathways. This may result in a 
slowing of the cell cycle hence the reduced proliferation of PARP- r -and A TM- - M EFs. 
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Interestingly, Xu and Baltimore showed that ATM-I- MEFs progress more slowly throuuh 
• e 
the G 1 /S phase border than ATM+I+ MEFs. This was demonstrated by synchronizing A Tivl 
MEFs by serum starvation before release into medium containing 100/0 FBS for 24 hours. 
FACS analysis revealed that 74% of AT~/+ MEFs were in S-phase compared to 51 % of 
A TM-I- MEFs. This observation may also be in agreement with the culture shock 
hypothesis, whereby A TM-I- MEFs are less proficient in repairing the DNA damage during 
cell culture, resulting in a higher proportion of cells in G 1, possibly mediated by p53 
activation. With reference to a putative role of p53, it is interesting to note that the growth 
retardation observed in ATM-I- MEFs is abolished by additionally knocking out p53 to 
produce ATM-1- p53-1- MEFs (Westphal et aI., 1997). 
Importantly, other studies have shown a reduced growth rate in cells lacking other proteins 
involved in genetic stability. For example, Deans et aI., 2000 showed that XrccT I- mice 
were embryonic lethal (Xrcc2 has been implicated in homologous recombination repair). 
This same study went on to generate embryonic stem cells disrupted in Xrcc2 and showed 
that these cells entered a premature senescence, with complete growth arrest at or before 
passage 4 in culture. Similar findings have been observed for disruptions of both Rad5 J 
(Lim and Hasty, 1996) and Brca2 (Sharan et aI., 1997). The observed phenotype in all of 
these cell types could be explained by the accumulation of DNA damage caused by the 
stressful conditions of cell culture (and inefficient repair due to lack of important repair 
proteins) leading to the induction of cellular checkpoints causing a slowing or halting of 
the cell cycle. 
1'5 
--' 
Chapter 6 - Results -I 
Although a lot of data discussed in this section has involved ATM it is likely to be , . 
relevant to this study due to certain similarities between A TM-I- and P ARP -1-1- MEF s. For 
example, both sets of MEFs are hypersensitive to IR due to defective repair pathways. The 
culture shock hypothesis ofMEF senescence would suggest greater endogenous DNA 
damage in A TM-I- MEFs. This in tum would be in agreement with the observed build up 
of cells in G I in the absence of ATM, possibly due to a p53-mediated cell cycle arrest. 
This would obviously slow the growth rate of ATM-I- MEFs. It would be interesting to 
analyse the DNA content of PARP-I +1+ and PARP-I-1- by F ACS analysis to see whether 
results were similar to A TM+1+ and A TM-1- MEFs. Finally, although the principle aim of 
this chapter, to analyse the p53 status of immortalised MEFs, was not achieved, interesting 
data was derived suggesting a potential role of PARP-I in the proliferation of primary 
MEFs. Due to time restrictions involved in the completion of a PhD only tentative 
conclusions can be made. However, future work involving FACS analysis will provide 
greater detail on the nature of the growth retardation in the PARP-l"/- MEFs. In addition, it 
would be interesting to analyse the expression levels of several genes involved in cellular 
proliferation by cDNA microarray analysis to try and identify differences between the 
P ARP-l +1+ and P ARP-I-1- MEFs. Any differences could be confirmed by treatment of 
primary PARP-I +1+ MEFs with I J.!M AG 14361, and may provide a definitive link between 
P ARP-I and the control of cellular proliferation. 
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CHAPTER 7 
GENERAL SUMMARY AND FUTURE OBJECTIVES 
7.1 Summary 
The aim of this chapter is to summarise this entire thesis, from the initial introductory 
chapter through to the final results chapter. By doing this it is hoped that the reasons for 
proposing the original hypothesis are clear and also by summarising relevant results 
sections, to highlight the stepwise nature in which experiments were performed. 
This thesis has been structured to initially emphasise the central role of p53 in the cellular 
response to DNA damage. There are two major responses to DNA damage. cell cycle 
arrest and apoptosis, the aims of which are to either halt the cell cycle to allow efficient 
repair of the DNA damage, or, in the presence of high levels of damage, the cell is 
programmed to die via the apoptotic pathway. Both of these responses can be mediated by 
p53, and function to prevent the propagation of DNA damage during cellular replication. 
Loss of control over cell cycle arrest or apoptosis ultimately leads to the formation of a 
cancerous celL where DNA damage is propagated and mutations to essential regulatory 
genes occur. In this situation, the tumour cells are able to continually evolve and acquire 
new mutations, resulting in metastasis and the likely death of the organism harbouring the 
tumour. With this in mind, it is therefore essential to understand the mechanisms involved 
in the regulation of the tumour suppressor protein, p53. 
Data has been summarised showing the negative regulation ofp53 by mdm2. Mdm2 binds 
to the N-terminal transcriptional transactivation domain of p53. blocking the interaction of 
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p53 with components of the transcriptional machinery. This prevents the transcription of 
several p53-target genes, including Mdm2 itself and p21 waf-I. In addition, mdm2 targets 
p53 for proteasomal degradation via a ubiquitin-mediated pathway. The result of this is 
that a negative feedback loop exists, whereby p53 induces the expression of mdm2. then 
mdm2 blocks p53 function and down-regulates p53 protein levels. It is therefore 
hypothesised that activation of p53 in response to DNA damage requires the alleviation of 
the inhibition imposed by mdm2. 
In addition, data has been summarised showing the putative regulation of p53 by 
phosphorylation. The use of phospho-specific antibodies and site directed mutagenesis has 
identified more than 20 phosphorylation sites on p53, with the majority being mapped to 
the N-terminus. It is believed that Serl5 and Ser20 are particularly important in the 
activation ofp53, with DNA damage activated kinases targeting these residues with the 
result of disrupting the p53-mdm2 complex. 
P53 has also been shown to be post-translationally modified by acetylation. In response to 
DNA damage, an acetyl-transferase, p300, binds the N-terminal of p53 and targets residues 
within the C-terminal for acetylation. This results in an increased DNA binding activity of 
p53 and hence increased transcription of p53 target genes. 
The roles of mdm2. phosphorylation and acetylation in the regulation of p53 have been 
fairly well studied. However, there are a variety of other post-translational modifications 
that putatively occur, including sumoylation and, with particular respect to this thesis. 
poly(ADP-ribosylation), performed by the enzyme PARP-l. 
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PARP-I is activated rapidly in response to DNA damage and is invohed in the BER 
pathway to repair damage to DNA brought about principally by alkylating agents. In 
addition, PARP-I is thought to playa role in the repair of IR-induced damage, with 
animals lacking PARP-I being hypersensitive to the effects of this type of DNA damage. 
It is not known whether P ARP-I is involved in the repair of the major cytotoxic lesion of 
IR, DSBs, or whether a different subset of lesions induced by IR are involved (for 
example, thymine glycols and 8-hydroxyguanine). Several studies analysing the DNA 
damage response in the absence of P ARP-I have implicated this enzyme as an upstream 
regulator of p53. However, as has been stressed throughout this thesis, the nature of any 
regulation remains controversial. For example, studies have been published showing a 
decreased p53 response in the absence of P ARP-I, whereas others have shown an 
enhanced p53 response. In addition, there are also studies showing no difference in the 
p53 response in the presence and absence of PARP-l. It should be noted that a lot of these 
studies have analysed the response to different DNA damaging agents. In addition, several 
studies have utilised different methods to remove PARP-I from cells. For example three 
independent colonies of P ARP-I-1- mice have been generated, disrupted in exons 1, 2 or -+ 
of PARP-I. Also, a dominant-negative strategy, involving the overexpression of the 
PARP-I DBD, chemical inhibition of PARP-I and antisense RNA strategies have all bl:l?n 
used to remove P ARP-I activity from cells. With particular relevance to this thesis. the 
most commonly used PARP-l inhibitor in the literature, 3-AB is approximately lOOO-fold 
less potent than the PARP-I inhibitor used in this study, AG14361. Therefore. AGl4361 
may be expected to be more specific and. as such, any effects on p53 induction that \\I:re 
observed in this thesis could more confidently be attributed to PARP-l inhibition. 
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Therefore, the principal aim of this thesis was to clarify some of the conflicting data that 
exists in the literature regarding the potential regulation of p53 by PARP-I. This was to be 
achieved using a combination of PARP-I-1- MEFs and a noveL potent P ARP-l inhibitor. 
As well as analysing the p53 response by Western blot analysis, a p53-responsive 
luciferase reporter gene assay was validated to measure the transcriptional transactivation 
activity ofp53. Finally, the response to a variety of DNA damaging agents was analysed. 
to investigate whether P ARP-l regulated p53 in a DNA damage-specific manner. 
The initial experiments in this thesis aimed to characterise the PARP-I-1- MEFs and the 
PARP-I inhibitor, AG 14361. The MEFs were characterised using a combination of 
Southern blotting, Western blotting and an enzymatic assay measuring PARP-I activity. 
The generation of the P ARP-I-1- mice involved the insertion of a neomycin resistance 
cassette into exon 4 of P ARP-I using homologous recombination. In the wild type P ARP-
1 locus, there are two EcoRI sites, separated by 9.6kb. Therefore, upon EcoRI digestion of 
purified genomic DNA, a fragment of9.6kb was produced. This fragment was separated 
from the other DNA fragments by agarose gel electrophoresis. In the PARP-I-1- MEFs, 
disruption of the P ARP-I locus introduced an extra EcoRI site, with the result that 
restriction enzyme digestion produces a smaller, 3.3kb fragment. After agarose gel 
electrophoresis, the DNA was transferred to a nylon membrane before incubation of the 
membrane with a radiolabelled probe. This probe binds the N-terrninal of the PARP-l 
locus, which is present in both the PARP-l +1+ and PARP-I-1- MEFs, therefore subsequent 
autoradiography revealed bands of9.6kb and 3.3kb, respectively, confirming the disruption 
of the PARP-l locus in the PARP- r l - MEFs. 
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The MEFs were further characterised by Western blot analysis with a PARP-l specific 
antibody clearly showing the presence of a band corresponding to P ARP-l in the P ARP-
1 +1+ MEFs and the absence of a similar band in the P ARP-I-I- MEFs. 
The final step in the characterisation of the PARP-l MEFs was to assay PARP-l actiyit)' in 
the cells. A PARP-l permeabilised cell assay measuring the incorporation of radio labelled 
NAD+ into acid-precipitable material confirmed PARP-l activity in the PARP-l +1+ MEFs. 
This activity was stimulated by DNA ends, included in the assay as a short double-stranded 
oligonucleotide, and was abolished by treatment of the cells with 1 JlM AG 1436l. The 
PARP-I-I- MEFs possessed < 5% PARP activity compared to the PARP-l +1+ MEFs. In 
addition, this activity was not stimulated by DNA ends but was abolished by 1 JlM 
AG 14361. From this assay, it was concluded that the PARP-r l - MEFs possessed an 
alternative PARP activity that cannot be attributed to PARP-l and is likely due to one or 
more other PARP family member (e.g. PARP-2, tankyrase and sPARP-I). It has therefore 
been shown that AGI436I is also able to inhibit the activity of this other PARP activity. 
To further confirm that the activity measured by the radio labelled NAD+ method was 
indeed due to synthesis of ADP-ribose polymer, a modified assay was developed and 
validated. This assay did not involve the use of radiolabelled NAD+ and could be 
performed on a much smaller cell number than the previous assay. After PARP-l 
stimulation, the permeabilised cells were bound to a nylon membrane using a dot-blot 
apparatus and polymer detected using an ADP-ribose polymer-specific monoclonal 
antibody. This assay was shown to detect purified polymer. In addition, AG14361 was 
shown to virtually abolish polymer formation in PARP-l proficient cells and PARP- r
/
-
MEFs gave rise to only minimal amounts of ADP-ribose polymer. 
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The PARP permeabilised cell assay (both the radiolabelled NAD+ and immuno dot-blot 
method) demonstrated the effectiveness of AG14361 at removing PARP-l activity from 
PARP-l proficient cells. However, before using AG14361 in DNA damage response 
experiments, it was essential to show that the P ARP-l inhibitor itself was not grov~1h 
inhibitory during the time course of experiments. Therefore, SRB assays were performed 
in PARP-l +1+ and PARP-rl- MEFs, as well as human HCT-116 cells. No growth 
inhibition was observed up to 72h after treatment with 1 JlM AG 14361 in all celllint:s, 
compared to a DMSO-treated control. It was also important to show that AG 14361 does 
not stress the cells in such a way that a p53 response is induced. Therefore, Western blot 
analysis of p53 levels in HCT -116 cells treated with 1 JlM AG 14361 was performed, with 
no change in p53 levels observed over the course of a 24-hour treatment period. 
Having characterised the P ARP-l MEFs and AG 14361, the next aim was to treat P ARP-
1 +1+ and PARP- r l- MEFs with DNA damaging agents (such as IR and UV) and analyse 
p53 levels using Western blotting. These experiments were performed on immortalised 
MEFs, with subsequent Western blot analysis revealing very high p53 levels in PARP-I + + 
cells, which were not induced by DNA damage. In addition, there was virtually 
undetectable levels of Mdm2 in these cells. These characteristics were indicative of 
mutant p53, with subsequent cDNA sequencing confirming this belief. The PARP-I-1-
MEFs showed both a p53 and Mdm2 induction after IR or UV treatment and were shown 
to express wild type p53 by cDNA sequencing. Obviously, it was futile to analys~ p53 
responses in cells expressing mutant p53, therefore, the DNA damage experiments were 
repeated in a second independently derived pair of immortal ised P ARP-I MEF s. 
Interestingly, Western blot and cDNA analysis again re\"t:aled a mutant p53 in the PARP-
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1+1+ MEFs and wild type p53 in the PARP-I-1- MEFs. The mutations detected in the two 
colonies of PARP-l +1+ MEFs were in the same amino acid (278), but at a different site in 
the codon. The primary PARP-l MEFs from which these cells were derived were shO\\TI 
to express wild type p53; therefore the p53 mutation has developed during cell culture and 
was a likely consequence of the immortalisation procedure. This set of data led to the 
hypothesis that the absence of PARP-l bypasses the requirement to mutate p53 during the 
immortalisation of MEFs, a hypothesis that was tested in chapter 6. 
In order to produce a PARP-l proficient MEF cell line expressing wild type p53, it was 
decided to stably transfect immortalised PARP-rl- MEFs with a plasmid construct 
expressing P ARP-l. The stable transfection procedure resulted in the isolation of one 
P ARP-l positive colony, which was bulked up and aliquots frozen. This stable 
transfectant, termed clone 23, was shown to express P ARP-l protein and possess PARP-l 
activity that was stimulated by DNA ends, using the immuno dot-blot technique. 
It was now possible to perform DNA damage experiments on clone 23 and PARP-I-
1
-
MEFs and analyse the p53 response to a variety of DNA damaging agents. In addition, the 
effect of AG 14361 on the p53 response in these cells was analysed, as was the p53 
response in human HCT-116 cells. Firstly, cells were treated with 5Gy IR, with no 
difference in p53 or mdm2 induction observed between clone 23 and PARP-I-
1
- MEF s. 
Analysis of the luciferase assay results in these cells revealed that the PARP-I-
I
- MEFs had 
significantly lower luciferase and ~-galactosidase values than the clone 23 !\1EFs. The 
ratio of these values, which was used to estimate p53 activity, was also lower in the PARP-
1-1- cells, with no induction over time. This apparent lack of p53 activation was in contrast 
to the clear mdm2 induction observed in Western blots. This pattern was also observed in 
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response to two other DNA damaging agents and suggests that PARP-l may be required 
for the efficient transfection and/or transcription of exogenous plasmids. As an alternati \'e 
method to remove PARP-l activity, cells were treated with IIlM AG14361. Again no 
difference was observed in p53 induction or activity in all cell lines in the presence or 
absence of AG14361. Interestingly, PARP-l inhibition in clone 23 MEFs did not alter the 
expression of the luciferase or J3-galactosidase plasmids suggesting that PARP-l protein 
rather than activity is involved in the efficient expression of exogenous plasmids. 
The second type of DNA damage used was UV. Cells were treated with 50J/m2 UV and 
analysed by Western blot and luciferase analysis. As for JR, no difference in p53 induction 
or activity was observed between clone 23 and PARP-I-I- MEFs. Furthermore, treatment 
of all cells (PARP-l MEFs and HCT-116 cells) with IIlM AG14361 did not alter the 
observed p53 response to UV. 
The final type of DNA damaging agent used was temozolomide, a monofunctional 
alkylating agent. The induction ofp53 in clone 23 MEFs was slightly potentiated by 
treatment with 1 J.lM AG 14361. Similar results have been described in the literature using 
different alkylating agents and PARP-l inhibitors. This effect was attributed to the 
persistence of strand breaks in the absence of P ARP-l activity and hence increased 
signalling to p53. However, the altered p53 induction observed in this thesis was not 
evident in the PARP-I-I- MEFs, perhaps suggesting a distinction between PARP-I 
inhibition and knocking out PARP-l in cells. In addition, AG 14361 did not alter the p53 
activity after temozolomide treatment, as measured by mdm2 \\'estern blot and luciferase 
assay. Finally, HCT -116 cells showed identical p53 induction and acti \'ity after 
temozolomide treatment in the presence and absence of PARP-I activity. 
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The final results chapter aimed to analyse the p53 status of independently deri\ed colonies 
of immortalised PARP-l +/+ and PARP-l-/- MEFs. This was to be achieved by isolating 5 
independent immortalised colonies of both MEF cell lines according to the 3 T3 protocol. 
In addition, five plates of primary P ARP-l +/+ MEFs were grown in the presence of IJ..lM 
AG 14361 to see whether P ARP-l inhibition would mimic results obtained with P ARP-I 
knockout MEFs. Unfortunately all cells were lost due to infection before any p53 
sequence analysis could be performed. However. interesting data was obtained regarding 
the growth rate of primary MEFs in the presence and absence of PARP-l. 
Primary PARP-l +/+ MEFs grew with a constant growth rate for approximately 20 days in 
culture (doubling time of 40 hours), before reaching senescence. when cellular propagation 
slowed dramatically. In contrast, PARP-r/- MEFs grew much more slowly (doubling time 
of around 200 hours), with cells appearing to enter a premature senescence after only 5-7 
days in cell culture. Interestingly, similar observations were made in primary PARP-I +/+ 
MEFs grown in the presence of IJ..lM AG 14361. with cells growing with a doubling time of 
approximately 180 hours, and appearing to enter senescence after only 5-7 days in cell 
culture. These results may suggest a role for PARP-l in maintaining the normal growth of 
primary MEFs. Alternatively, the reduced growth rate may be due to the slowing of the 
cell cycle in response to increased levels of endogenous DNA damage in the absence of 
PARP-l. Interestingly, immortalised PARP-l +/+ and PARP- r i - MEFs show similar growth 
rates and AG 14361 has no effect on the growth of immortalised PARP-I proficient \tEFs. 
Immortalised cells, by definition. have lost control oyer some aspect of normal cellular 
growth. Perhaps the normal cellular response to endogcnous DNA damage has been lost. 
such that the absence of PARP-I no longer triggers the slowing of ccllular gro\\th. :\ 
similar effect on cell growth and senescence has been observed in A TM-
1
- MEFs. Like 
') t -
.. ~) 
PARP-l, A TM is a DNA damage responsive enzyme, perhaps supporting a model where 
increased endogenous DNA damage in the absence of P ARP -I (or A TM) leads to a 
slowing of cellular growth. 
Taken together, this thesis contains a comprehensive set of data investigating the potential 
role of PARP-l in the regulation of p53. Importantly, sequencing data has been presented 
showing that the immortalised PARP-l MEFs used in DNA damage experiments were 
expressing wild-type p53. Some of the studies in the literature have described altered p53 
responses in the absence of PARP-l in immortalised MEFs, without presenting sequencing 
data showing the status of the p53 gene. Given the tendency ofMEFs to develop p53 
mutations during immortalisation (see Chapter 6), such results should be interpreted with 
care. In addition, the production of a P ARP-l stably transfected MEF cell line has ensured 
that the comparison between the presence and absence of P ARP-l on p53 responses has 
been made in cell lines with identical genetic backgrounds. Data obtained in P ARP-I-I-
MEFs has also been supported by the use ofa potent PARP-l inhibitor. AG14361. As 
described several times during this thesis, AG 14361 is approximately IOOO-fold more 
potent than the most commonly used PARP-I inhibitor in the literature, 3-AB. Therefore 
AG 14361 is likely to be more specific and the responses observed using this inhibitor can 
more confidently be attributed to an inhibition of P ARP-l, rather than some of the other 
enzymes that have been shown to be inhibited by 3-AB. 
Having used well-characterised cell lines and a potent PARP-l inhibitor, the primary 
conclusion from this thesis is that PARP-l does not have a major direct causal link with 
DNA damage induced signalling to p53. in response to IR, UV or the monofunctional 
alkylating agent, temozolomide. A slight dlect was observcd in clone 23 MEFs treated 
246 
with AG 14361 but the enhanced p53 induction is likely to be due to a persistence of strand 
breaks and increased signalling (e.g. by ATM) to p53. 
7.2 Future objectives 
If time had pennitted, the main area of this thesis that warranted further investigation was 
the immortalisation of PARP-l MEFs. The interesting observation that two independent 
colonies of immortalised P ARP-l +1+ MEFs expressed mutant p53 whereas the P ARP-I--
MEFs expressed wild type p53 led to the hypothesis that the absence of PARP-I bypasses 
the requirement to mutate p53 during immortalisation ofMEFs. However, due to the loss 
of cells to infection, this hypothesis was not tested. Because of the long-term nature of 
immortalisation, this experiment could not be repeated during the time-scale of a PhD. 
In addition, the interesting observations on the growth rates of primary P ARP-I MEFs 
could be investigated further. For instance, if the proposed model of increased endogenous 
DNA damage in the absence of PARP-l is correct, it might be expected that PARP-I-1-
MEFs will contain higher levels ofp53. This could be tested by Western blot analysis of 
p53 levels throughout the immortalisation experiment. In addition, increased levels of 
endogenous DNA damage in PARP-I-I- MEFs may lead to a checkpoint response and the 
build up of cells in G 1 or G2 phases of the cell cycle. This hypothesis could be tested by 
comparing the cell cycle profile of P ARP-I +1+ and PARP- r l- MEFs using F ACS analysis. 
Finally, eDNA microarray ~malysis of primary PARP-I +/+ and P ARP-l"/- MEFs might 
reveal altered expression of certain genes involved in the regulation of cell gro\\th. Any 
findings from such an experiment could be investigated further by \\'estern blot analysis of 
protein levels within cells. 
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Appendix A 
Buffers and reagents 
Reagents for Western blot analysis 
a) Electrode buffer 
Tris 
Glycine 
SDS 
25mM 
200mM 
0.1% 
b ) Western blotting buffer 
Tris 25mM 
Glycine 200mM 
Methanol 20% 
c) TBS-Tween 
Tris 50mM 
0.15M 
0.1% 
d) 
NaCI 
Tween20 
SDS lysis buffer 
Tris 
SDS 
Glycerol 
Distilled water 
62.5mM (pH 6.8 with Hel) 
2% 
100/0 
15.5ml 
Reagents for agarose gel electrophoresis 
a) Tris-borate EDT A (TBE) 
Tris-borate 45mM 
EDTA ImM 
b) Loading buffer 
Glycerol 
0.5M EDTA 
Distilled water 
800fll 
40fll 
1160fll 
Reagents for Southern blotting 
a) 20 X sse 
NaCI 
b) 
Na citrate 
Distilled H:,O 
Gilbert s solution 
1 M 1'\a:,HP04 
175.3g 
88.~g 
800ml- pH to 7 with '\a()} I and make tp I 000m1 with I k:) 
15~.5ml (pH "7.0) 
1M NaH2P04 97.5ml (PH 7.0) 
0.5M EDT A 1ml (pH 8.0) 
dH20 74ml 
BSA 5g 
Filter sterilise then add 175ml of20% SDS 
Reagents for P ARP permeabilised cell assay measuring the incorporation of IJ2 PJ-
NAD+ 
a) Isotonic buffer 
HEPES 
KCI 
Dextran 
EGTA 
MgCh 
Sucrose 
DTT 
40mM 
130mM 
4%w/v 
2mM 
2.3mM 
225mM 
2.5mM 
adjusted to pH 7.8 with NaOH Hel 
Reagents for P ARP permeabilised cell assay by antibody recognition 
a) Permeabilisation buffer 
Tris.HCL 10mM 
EDTA ImM 
MgCh 4mM 
2-mercaptoethanol 30mM 
pH to 7.8 
supplemented with 0.015% digitonin 
b) Reaction buffer 
Tris.Hc1 
NAD+ 
MgCh 
pH to 7.8 
100mM 
ImM 
120mM 
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Appendix B 
Publications & presentations 
Jowsey et al., (2002). Proc Amer Assoc Cancer Res. p53 accumulation and p53-mediated 
transcriptional transactivation in response to ionizing radiation is independent ofpo~r(ADP­
ribose) polymerase-i. Vol 43, Poster 5640 
Jowsey et al., (2001). Proc Amer Assoc Cancer Res. Poly(ADP-ribose) po~rmerasc as all 
upstream regulator ofp53 and mdm2. Vol 42, Poster 1161 
Jowsey et aI., (2001). Br J Cancer. The dependence of p53 induction and activity on 
poly(ADP-ribose) polymerase-i. Vol 85, Poster 183 
British Institute of Radiology: DNA damage & response meeting; March 1 st 2002 
A fifteen minute oral communication entitled "p53 accumulation and p53 mediated 
transcriptional transacfivation in response to ionizing radiation is independcnt oj poZ\,(.lDP-
ribose) polymerase-i " 
